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Cigarette smoke induces inflammation, in part, by activation of Toll like receptor (TLR) 2 
and TLR4. TLRs are present on most cells and recognize pathogen associated molecular 
patterns (PAMPs) and non-pathogenic molecules, known as danger associated molecular 
patterns (DAMPs). Activation of TLRs results in the propagation of a signalling pathway 
leading to the de novo synthesis of pro-inflammatory mediators that include CXCL8 and 
IL-1β. TLRs initiate inflammation and are involved in tissue repair processes in a number 
of diseases such as chronic obstructive pulmonary disease (COPD) and cancer. 
Therefore, it is the aim of this thesis to explore the contribution of TLRs in inflammation 
and cellular proliferation, as these processes are integral to the pathology in inflammatory 
lung disease and cancer. 
 Activation of IL-1β is a two-step process. The first step synthesises pro-IL-1β and 
can be activated by TLR ligands. The second induces inflammasome complex assembly 
and results in the cleavage of pro-IL-1β to mature IL-1β by caspase-1. IL-1β is implicated 
in the inflammation caused by bacteria during exacerbations in lung disease. Interestingly, 
we found a difference in the activation and release of IL-1β from monocytes activated with 
the TLR2 ligand, Pam3CSK4 and the TLR4 ligand, LPS. The difference was seen at the 
level of inflammasome assembly, where, unlike TLR4, TLR2-induced IL-1β release was 
reliant on the hemichannel protein, pannexin-1.  
 We have previously found that cigarette smoke causes sensitisation of the blood of 
smokers to bacterial and viral PAMPs. Cigarette smoke is the major contributing factor in 
COPD and it is known that bacterial and viral induced exacerbations play a major role in 
the deterioration of lung function in these patients. COPD patients are also more prone to 
lung infections than their healthy age-matched equivalents. We therefore hypothesised 




PAMPs than blood from age-matched controls. COPD patient’s blood had an increased 
sensitivity to challenge with TLR2/1 and TLR3 ligands with respect to IL-1β release. 
Regarding CXCL8 release in this system, a greater response to stimulation with TLR2/1, 
TLR3, TLR4 agonists and IL-1β was observed in blood from COPD patients. There was a 
negative correlation between CXCL8 levels and COPD GOLD staging in response to 
TLR4 agonism.  
 TLR2 has been implicated in the proliferation of cancer cells. There is an emerging 
interest in the link between chronic inflammation and cancer. It is well documented that 
COPD patients have an increased risk of developing lung cancer, which has poor 
prognosis. Our aim was to investigate whether TLRs are a novel drug target for inhibiting 
the proliferation of lung cancer cells. TLR2, 3, 4 and 7 agonists had no effect on lung 
cancer cell proliferation; however, activation of TLR8 induced apoptosis in these cells. 
 In conclusion, my thesis shows that TLRs are important receptors involved in the 
initiation of inflammation and inhibition of cellular proliferation. We show, for the first time, 
that TLR4-induced CXCL8 release in COPD patients may be a good biomarker of disease 
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LRR leucine-rich repeat 
LTA lipoteichoic acid 
M mitosis 
MAL MyD88 adaptor-like protein 
MALP-2 macrophage-activating lipopeptide 
MAPK mitogen-activated protein kinase 
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MC medium-age control 
MCP-1 monocyte chemoattractant protein-1 
MHC major histocompatibility complex 
MIP-1 macrophage inflammatory protein 1 
MMPs matrix metalloproteinase 
mRNA messenger RNA 
MSU monosodium urate 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
MyD88 myeloid differentiation primary response protein 88 
NACHT  
NADP nicotinamide adenine dinucleotide phosphate 
NALP NACHT domain, leucine-rich-repeat and PYD-containing protein 
NCoR nuclear co-repressor 
NF-κB nuclear factor κB 
ND not detected 
NK natural killer 
NLR NOD-like receptors 
NLRC4 NLR family CARD domain-containing protein 4  
NLRP3 NOD-like receptor family, pyrin domain containing 3 
NO nitric oxide 
NOD nucleotide-binding and oligomerisation domain 
NOS nitric oxide synthase 
NS not significant 
NYHA New York Heart Association 
OC older control 
ODN oligodeoxynucleotides 
OSCC oral squamous cell carcinoma 
P2X7R purinoreceptor 7 
PI3K phosphoinositide 3-kinase 
PAH pulmonary arterial hypertension 
PAMP pathogen-associated molecular pattern 
Panx-1 pannexin-1 
PAT pulmonary artery thrombosis 
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PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 




PI Propidium iodide 
PIN1 peptidyl-prolyl cis/trans isomerase 
PNM polymorphonuclear 
Poly I:C polyinosine-polycytidylic acid 
PPAR peroxisome proliferator-activated receptor 
PRR pattern recognition receptor 
PYD pyrin domain 
QOL quality of life 
qPCR quantitative polymerase chain reaction 
RA rheumatoid arthritis 
RAC1 Ras-related C3 botulinum toxin substrate 
RANTES regulated on activation, normal T cell expressed and secreted 
REDOX reduction-oxidation 
RIP receptor-interacting protein 
ROS reactive oxygen species 
RNA ribonucleic acid  
RP105 radioprotective protein 105 
RPMI Roswell Park Memorial Institute medium 
RT reverse transcriptase 
RVSP right ventricle systolic pressure 
S synthesis 
SARM sterile α and HEAT–Armadillo motifs 
S.E.M. standard error of the mean 
siRNA small interfering RNA 
SMC smooth muscle cells 
SNP single-nucleotide polymorphism 
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SOCS-1 suppressor of cytokine signalling 1 
Src non-receptor tyrosine kinase 
ssRNA single-stranded RNA 
STAT-1 signal transducer and activator of transcription 
TAB TAK1-binding protein 
TAK TGFβ-activated kinase 
TAM tumor-associated macrophage 
Tc T cytotoxic cell 
TGF transforming growth factor 
TIR Toll/IL-1R 
TLR Toll-like receptor 
Th T helper cell 
TIRAP TIR-domain-containing adaptor protein 
TNF tumor necrosis factor 
TNFR tumor necrosis factor receptor 
TOLLIP Toll interacting protein 
TRAF tumor necrosis factor-associated factor 
TRAIL TNF-related apoptosis-inducing ligand  
TRAM TRIF-related adaptor molecule 
TReg T-regulatory cell 
TRIAD3A Triad domain-containing protein 3 
TRIF TIR-domain-containing adaptor protein inducing IFN-β 
TRIM30α  tripartite-motif protein 
TYK tyrosine kinase 
VCAM-1 vascular cell adhesion molecule-1 
VEGF vascular endothelial growth factor 
VSMC vascular smooth muscle cell 
xIAP X-linked inhibitor of apoptosis 
YC young control 
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1.1. Inflammation: a historical perspective. (Reviewed by Spector and Willougby, 1968) 
Inflammation is a localised response to a tissue injury or infection. The processes involved 
in inflammatory response are necessary for the elimination of pathogens or other 
inflammatory factors, clearing the damage tissue components and initiating the repair 
process. During the process of inflammation, activated immune cells release factors 
leading to the well-know clinical symptoms of inflammation [1]. The term edema was 
introduced by Hippocrates in the 5th century BC. The main four signs of inflammation: 
redness, heat, swelling and pain, were first described by Celsus, a Roman writer who 
lived between 30BC and 45 AD. Eighteenth-century applications of the microscope lead to 
descriptions of blood flow changes in inflamed tissue and the proposal by Gaubius that 
inflammation can promote the “disposition to coagulation.” The term angiogenesis was 
first time introduced by John Hunter in 1794 to describe the development of growing 
vessels in healing wounds, followed by description of leukocyte rolling attributed to 
Wagner in 1839. The contemporary understanding of this process we owe to 19th-century 
milestone discoveries by Rudolph Virchow, Julius Cohnheim and Elie Metchnikoff, who 
gave rise to cell-based definitions of inflammation [2, 3].  In the 20th century, the 
development of new technological tools allowed the rapid expansion of knowledge of the 
cells and mediators of inflammatory processes, as well as the molecular mechanisms of 
the microvascular responses to inflammation. Development of molecular biology and 
immunology, gene-targeted knock-out mice, discovery of cytokines, chemokines, and their 
receptors, as well as leukocyte and endothelial cell adhesion molecules, have proven to 
be immensely useful in the research of molecular mechanisms of inflammation in vivo.  
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1.2. The molecular basis of inflammation. 
In the acute phase, inflammation is characterized by increased blood flow and vascular 
permeability, accumulation of fluid, leukocytes, and inflammatory mediators such as 
cytokines and chemokines. The development of specific humoral and cellular immune 
responses to pathogens present at the site of tissue injury is seen in the chronic phase of 
inflammatory response. During both processes, a variety of soluble factors are released 
and involved in leukocyte recruitment through expression of cellular adhesion molecules 
and chemoattractants. Many of these soluble mediators regulate the activation of 
fibroblasts, endothelial cells, tissue macrophages, and mast cells. These newly recruited 
inflammatory cells such as monocytes, lymphocytes, neutrophils, and eosinophils and 
also some of mediators released by these cells, result in the systemic responses to the 
inflammatory process [4].   
1.2.1. Acute inflammation. 
Mast cells, tissue-resident macrophages, DCs, stromal cells, white blood cells and 
endothelial cells are responsible for the vascular and cellular changes necessary for the 
initiation of inflammation. After the injury or infection they are recruited to the inflammatory 
lesion and they release factors such as cytokines, chemokines, histamine and 
prostaglandins [5]. Histamine released from mast cells acts on target tissues to induce 
vasodilation, which elevates the regional blood flow to the affected area, and increases 
vascular permeability. It allows an extravasation of neutrophils, and leakage of plasma to 
the affected tissue. This results in an accumulation of fluid and plasma proteins into the 
inflamed tissue through large venular junction gaps. Cytokines released during the 
inflammatory process can also induce acute phase proteins such as C-reactive protein 
(CRP) and coagulation factor which in turn activate production of prostaglandins. PGE2 is 
a major proinflammatory prostaglandin which promotes so-called sickness behaviour: 
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fever, anorexia, fatigue and sleepiness [6]. Some prostaglandins affect the aggregation of 
platelets, which is a part of the clotting process, preventing the spread of infectious 
agents. Activated immune cells release more chemical substances recruiting dendritic 
cells, macrophages and neutrophils to remove foreign debris by phagocytosis, antigen 
processing and secretion of cytokines which play a role in slower lymphocyte-mediated 
adaptive immune response [7].  
The adaptive immune system does not form the major part of this thesis, it is described 
only briefly. The adaptive immune system is comprised of T and B lymphocytes which act 
as a host surveillance mechanism against invading pathogens [8]. The innate immune 
responses can activate adaptive immunity by increasing the flow of lymph containing 
antigens and antigen presenting cells (APC). The peptide fragments are then carried to 
the surface of the presenting cell on special molecules called major histocompatibility 
complex (MHC) proteins, which present the fragments to T cells [9]. B lymphocytes 
mediate antibody responses and are activated to secrete immunoglobulins. These 
antibodies can circulate in bloodstream and recognize foreign antigen that stimulated their 
production. T cells are responsible for the cell-mediated immune response. They react 
directly against a foreign antigen that is presented to them on the surface of a host cell, 
eliminating the infected cells before they had a chance to replicate. T cells can also 
produce signals to activate macrophages to destroy the microbes that have been 
phagocytosed [9]. There are two main classes of T cells—cytotoxic T cells (Tc) and helper 
T cells (Th). Effector Tc cells directly kill cells that are infected with a virus or some other 
intracellular pathogen. Effector Th cells, by contrast, help stimulate the responses of other 
cells—mainly macrophages, B cells, and Tc cells. Components on the surfaces of the 
microbes can also induce changes in phagocytic cells to synergize with lymphocytes 
whose receptors bind to specific microbial agents. Dendritic cell upon activation matures 
into a highly effective antigen-presenting cell, and undergoes changes that enable it to 
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activate pathogen-specific lymphocytes. Macrophages and DCs can also activate T 
lymphocytes and initiate adaptive immune response [10].  
The cross-talk between innate and adaptive immunity can be bidirectional. Atherosclerosis 
is a disease where major cytokines are produced by both, innate and adaptive immunity 
acting upon one another. Interferon (IFN) γ produced by effector Th1 cells activates 
macrophages and interleukin (IL)-4 and IL-5 produced by Th2 cells may stimulate 
macrophage and DC subsets [11]. On the other hand, IL-12, IL-18, and type I IFNs 
promote the differentiation of Th1 cells, and IL-12 can stimulate the production of IFNγ by 
natural killer (NK) cells [12, 13]. CXCL10, which is produced by T cells, dendritic cells, and 
macrophages, inhibits IL-12 production and Th1-mediated inflammation [14].  
1.2.2. Chronic inflammation. 
Acute inflammation is rapid in onset and lasts as long as a few days. Chronic inflammation 
is characterized by persistent inflammation and lasts from a few days to a few years. It 
can cause a considerable damage to the tissues and interferes with the function of various 
organs [15]. Pro-inflammatory signalling pathways have the capacity to induce the parallel 
expression of anti-inflammatory mediators, such as CXCL10. A deficiency in any of 
negative regulators may result in exaggerated inflammatory response to insult or injury 
that culminates in severe inflammation and damage to the host. Genetic studies in mice 
have shown that even the absence of one negative regulator is sufficient to result in 
serious inflammatory disorders [16]. Thus, aberrations in such negative regulatory 
pathways can contribute to the development of chronic inflammatory diseases. The 
phagocytosis of apoptotic cells plays an important role in the negative regulation of 
macrophage activation; apoptotic leucocytes may well fit into the category of endogenous 
anti-inflammatory mediators; therefore, the mechanisms of apoptosis and the clearance of 
apoptotic cells may be critical in the development of chronic inflammation [16]. 
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Proliferation of endothelial cells resulting in the formation of new capillaries (a process 
known as angiogenesis) leads to restoration of the vascular supply, and promotes the 
proliferation of fibroblasts which restores the connective tissue matrix. These important 
processes involved in the chronic inflammatory cycle are orchestrated by mediators 
secreted by resident cells, neutrophils, macrophages, T and B lymphocytes, plasma cells 
and platelets [17-20]. The spectrum of inflammatory conditions can shift from acute 
inflammatory reactions in response to wounds and infections to chronic inflammatory 
disease such as (COPD), atherosclerosis, asthma, type 2 diabetes and cancer [6].  In all 
these patients, systemic inflammation is considered a key factor in the pathogenesis of 
the multicomponent disease manifestations. Inflammation is not just isolated to the 
affected organ, but also results in an elevation of inflammatory mediators in the 
circulation, which is responsible for systemic effects observed in most inflammatory 
diseases [21]. 
1.3. Toll-like receptors.  
Toll-like receptors (TLRs) are type I transmembrane receptors that recognize structurally 
conserved pathogen associated molecular patterns (PAMPs). They participate in the first 
line of defence against invading pathogens and play a significant role in inflammation, 
immune cell regulation, survival and proliferation [22]. TLRs are human homologues of the 
Drosophila protein Toll. This protein controls the dorsal-ventral patterning in the 
developing fly embryo and is critical for the fly’s recognition of Gram-positive bacteria and 
fungi, and the production of anti-microbial peptides [23]. TLRs posses extracellular leucin-
rich repeat (LRR) domain which consist of varying numbers of repeats, each 24–29 amino 
acids in length, containing the motif XXLXLXX and other conserved leucines [24]. This 
domain is involved in the recognition of a variety of pathogens and is followed by a single 
transmembrane region. The carboxyterminal intracellular tail contains a conserved region 
of ∼200 amino acids called the Toll/interleukin-1 receptor (TIR) homology domain which is 
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also found in the IL-1 receptor (Fig. 1). TIR domain binds one or more of four adaptor 
proteins and mediates signal transduction [23, 24].  In 2001 a new adaptor was described; 
sterile α and HEAT–Armadillo motifs (SARM) [25] which it is a negative regulator of 
nuclear factor κB (NF-κB) and interferon regulatory factor (IRF) activation [26].  
 
 
Figure 1. Structure of Toll-like receptors. 
 
Apart from pathogenic ligands, TLR can also recognize non-pathogenic molecules; known 
as danger associated molecular patterns (DAMPs) which can contribute to sterile 
inflammation. Many studies showed that these endogenous molecules or alarmins 
released from necrotic cells, activate leukocytes and play a critical role in inflammation 
[27]. The first suggestion of DAMP recognition came from studies by Erridge et al. where 
heat shock proteins (HSPs) were recognized by TLRs [28]. After that, a number of other 
endogenous ligands including the extra domain A of fibronectin and hyaluronic acid were 
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also shown to activate these receptors [29, 30]. Recognition of DAMPs by TLRs may also 
contribute to the autoimmune responses. The high mobility group box protein 1 (HMGB1) 
which normally resides in the cell nucleus can activate TLR2 and induce symptoms of 
lupus-like disease when released from apoptotic cells [31, 32]. 
There are 10 Toll-like receptors discovered in humans and they can be found in different 
subcellular compartments depending on the nature of the molecule they recognize. 
Endogenous viral and bacterial ligands for human TLRs are shown in Table 1. TLR1, 
TLR2, TLR4, TLR5, TLR6, TLR10 recognize bacterial, fungal and protozoan cell wall 
components and are localized to the cell membrane. Activation of these receptors leads to 
NF-κB activation and an innate immune response. TLRs that detect viral or microbial 
nucleic acids (TLR3, TLR7, TLR8, TLR9) are localized to intracellular membranes and are 
thought to encounter their ligands in phagosomes or endosomes. TLRs are expressed on 
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lipoproteins/lipopetides, peptodoglycan, lipoteichoic acid, glycolipids, zymosan, porins, atypical LPS, 

































triacyl lipopeptides and a wide variety of other microbial-derived agonists shared by TLR1, but not 
TLR6 
 
Table 1. Toll-like receptors ligands. Adapted from Gay and Gangloff, 2007 [33].  
 
Respiratory epithelium is the first line of defence against invasion of microorganisms, 
therefore it is not surprising that TLRs are also expressed on epithelial cells and play 
crucial role in innate immunity of the lung. Respiratory epithelium is continuously exposed 
to microbial challenges and environmental stress as a result of breathing, and 
constitutively express TLRs in alveolar and bronchial epithelial cells [34].  
1.3.1. TLR1/2/6/10. 
TLR2 is involved in recognition of broad range of products including peptidoglycan from 
Gram-positive bacteria, lipoteichoic acid (LTA) bacterial lipoproteins, zymosan, 
mycobacterial cell-wall components and yeast cell walls. [35]. TLR2 ligand recognition 
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involves the co-operation with other TLR family members, TLR1 and TLR6, but it is 
unknown whether dimerization of TLR2 with other TLRs occurs constitutively or if it is 
induced in response to ligand stimulation. TLR1 is highly homologous to TLR6 and both 
are able to heterodimer with TLR2. TLR2/1 heterodimer recognizes of triacyl peptides and 
lipoprotein from mycobacteria as macrophages from TLR1 deficient mice showed 
impaired production of inflammatory cytokines in response to these ligands. TLR1 is also 
responsible for recognizing the differences between lipid moieties of lipoproteins [36]. 
TLR2 co-operates with TLR6 in recognition of macrophage-activating lipopeptide-2 
(MALP-2) and other diacetylated lipoproteins. TLR2-deficient macrophages are 
unresponsive to bacterial and mycoplasmal lipoproteins, whereas TLR6-deficient cells are 
unresponsive to MALP-2, but respond normally to bacterial lipoproteins [37]. A study by 
Hoebe et al. using forward-genetic mutagenesis demonstrated that TLR2/6 heterodimers 
also require CD36 to sense diacylated lipoproteins, whereas TLR2/1 heterodimers do not 
[38]. TLR1/2 heterodimers induce also a different immune response against pathogens as 
compared to TLR2/6 heterodimers. When TLR1/2 heterodimers were absent from cells, 
there was a reduction of early cytokine release. In contrast, TLR2/6 heterodimeric 
receptors played a role in modulating the balance between a Th1/Th2 immune response 
[39].  
Recent studies showed that generation and analysis of chimeric receptors containing the 
extracellular recognition domain of TLR10 and the intracellular signalling domain of TLR1, 
senses triacylated lipopeptides and a wide variety of other microbial-derived agonists 
shared by TLR1, but not TLR6. TLR10 requires TLR2 for innate immune recognition, and 
these receptors colocalize in the phagosome and physically interact in an agonist-
dependent fashion [40].  One major hindrance to TLR10 studies is that it lacks a rodent 
homologue [41]. This has hampered the assignation of a natural or synthetic ligand to 
TLR10 because the majority of TLR ligands have been defined using mutant or genetically 
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deficient mouse models. Thus, it has been speculated that TLR10 could potentially act as 
a TLR2 coreceptor [42, 43]. Polymorphisms in TLR10 have conferred increased 
susceptibility to a number of chronic inflammatory diseases, which include prostate and 
urothelial cancer (rs4129009) [44], asthma and atopy (1031G->A and 2322A->G) [45] 
1.3.2. TLR3. 
TLR3 recognizes double-stranded RNA (dsRNA) and has been studied in the context of 
immediate innate responses to virus infections [46]. It is a potent inducer of type I IFNs 
and it is expresses in conventional DCs (cDCs) and in a epithelial cells found in the 
airways, uterine and intestine. It can also been found in the brain, specifically in astrocytes 
and glioblastoma cells [47]. TLR3 uses the TIR domain containing adaptor inducing 
interferon-beta (TRIF) adaptor protein to activate IRF3, NF-κB and activating protein 1 
(AP-1) transcription factors. Activation of these molecules leads to the release of 
hundreds of cellular genes including IFN genes [48]. TLR3 lacks the proline residue that is 
conserved among other TLRs [36]. This is particularly important for the immune 
responses to viruses that do not directly infect dendritic cells, as TLR3 was demonstrated 
to promote crosspriming of CD8 T cells in response to dsRNA [49]. 
1.3.3. TLR4. 
TLR4 recognizes lipopolysaccharides (LPS) from Gram-negative bacteria, LTA and heat-
sensitive cell-associated factor derived from Mycobacterium Tuberculosis and many non-
pathogenic molecules such as HSP60 [35], fibrinogen and surfactant protein A (SP-A). It 
was the first functional TLR to be identified. There are two mouse stains, C3H/HeJ and 
C57BL10/ScCr that were known to be hyperresponsive to LPS. It was shown by two 
independent groups that a mutation in TLR4 gene was responsible for LPS resistance 
[36]. Recognition of LPS also requires another co-receptor, CD14, which is preferentially 
expressed in monocytes, macrophages and neutrophils, and which helps maneuver the 
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LPS-LPS-binding protein complex to TLR4 [50].  MD-2 is another molecule that is 
associated with the extracellular portion of TLR4 and enhances LPS responsiveness [51]. 
MD-2 associated TLR4 homodimers do not bind LPS directly, LPS must be first bound by 
soluble LPS binding protein (LBP) in a complex that then recruits CD14. The exact 
mechanism of this binding is not clear but it is suggested that LBP might transfer LPS to 
CD14 thereby facilitating the activation of TLR4 [52]. TLR4 possesses two options for 
signal transduction, either to signal via MyD88 or through TRIF. MyD88-dependent and 
MyD88-independent pathways utilize distinct adapter proteins but both pathways involve 
the activation and nuclear translocation of NF-κB which leads to the expression of 
numerous proinflammatory cytokines [53]. TLR4 is expressed in 
monocytes/macrophages, DCs, mast cells, B lymphocytes and also epithelial and 
endothelial cells [54].   
1.3.4. TLR5. 
Flagellin is a primary component of flagella, a structure that extends from the outer 
membrane of Gram-negative bacteria and is recognized by TLR5. Flagellin-induced 
immune responses are mediated by Myd88, which results in the activation of NF-κB [36]. 
It is the only TLR that is conserved in vertebrataes from fish to mammals and it is 
expressed in epithelial cells, monocytes and dendritic cells [55]. Gut epithelial cells are 
hyporesponsive to LPS, but respond well to flagellin, which induces a robust 
proinflammatory response. Flagellin has been suggested to be a major target of innate 
and adaptive immunity in Crohn’s disease and, in certain ethnicities, heterozygous 




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  






TLR7 and TLR8 show a high degree of homology to each other and recognize single-
stranded RNA (ssRNA).  Similarly to TLR3 and TLR9 they are expressed within 
endosomal membranes where they will encounter enveloped viruses [47]. Both TLR7 and 
TLR8 have been shown to be stimulated by sequences containing GU- or poly-U. 
Activation of these receptors results in NF-κB activation and induction of cytokines, 
chemokines, adhesion molecules and apoptosis-related proteins. Synthetic 
imidazoquinolines which are recognized by TLR7 are potent antiviral and antitumor agents 
and have the ability to induce type I IFNs such as IFN-α [36]. Moreover, TLR7 and TLR8 
activation can induce IFNs in a NF-κB independent fashion [57]. TLR7 and TLR8 are 
expressed in DCs and epithelial cells. The strongest TLR8 mRNA expression was found 
in monocytes, monocytes derived DCs, macrophages and Langerans cells. TLR7 is 
strongly expresses in plasmacytoid DCs (pDCs) and human B cells. T cells also express 
TLR7 and TLR8 [58, 59].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
1.3.6. TLR9. 
Viral DNA is recognized by TLR9. The immune stimulatory activity of bacterial DNA is 
attributed to the unmethyleated CpG motifs which are not present in mammalian genome. 
Some studies have reported that CpG recognition occurs in the endosome and activation 
of signalling pathways such as c-Jun N-terminal kinase (JNK) and NF-κB is delayed 
compared with LPS-induced activation of macrophages [60, 61]. Upon TLR9 stimulation 
mediated by distinct classes of CpG oligonucleotides (ODNs), pDCs are activated to 
produce IFN-α/β and various chemokines. B lymphocytes are also induced to proliferate 
and secrete IgM and IL-6 [62]. There is variation in the results of studies investigating the 
subcellular location of TLR9.  In dendritic cells and macrophages, TLR9 is located in the 
endoplasmic reticulum of resting cells but upon stimulation with CpG DNA is endocytosed 
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and moves to the lysosomal compartment and subsequently binds directly to TLR9.  
Surface expression of TLR9 has also been found to occur in human embryonic kidney 293 
cells (HEK293) cells transfected with TLR9-containing vectors in gastric and intestinal 
epithelial cells, and in some peripheral blood mononuclear cells (PBMCs). Recently, a 
cytosolic innate immune response to DNA has been identified, which triggers a potent 
type I IFN response. It remains unknown whether expression or localization of TLR9 
changes in response to native bacterial DNA [63].  
1.4. TLR signalling.  
Pathogen recognition by TLRs causes rapid activation of innate immunity by inducing the 
production of proinflammatory cytokines and the upregulation of costimulatory molecules 
[64]. Once TLRs are activated they recruit adaptor molecules that facilitate a signalling 
cascade, which results in the initiation of the innate immune response by the cell. There 
are five known adaptor proteins, four of which positively regulate signalling: MyD88, 
MyD88-adaptor-like (Mal), TRIF and TRAM, and sterile-alpha and Armadillo motif 
containing protein (SARM) that acts as a negative regulator of TLR activation [65]. TLR 
signalling pathways consist of a Myd88-dependent pathway that is common for all TLRs 
except TLR3, and an alternative pathway, Myd88-independent that is activated only by 
TLR4 and TLR3 [66].  
1.4.1. Myd88-dependent signalling pathway. 
Once the adaptor proteins are associated with the TLR complex, the IL-1 receptor-
associated kinase (IRAK) family is recruited through interaction of the death domains of 
both molecules. IRAK1 and IRAK4 are activated by phosphorylation, and then actively 
associate with the ubiquitin E ligase TNF receptor associated factor 6 (TRAF6). TRAF6 
becomes auto-ubiquitinated and forms a complex with TGFβ-activated kinase (TAK1)-
binding protein (TAB2)/TAB3/TAK1, which in turn results in the activation of the MAP 
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kinase (MAP3K) and TAK-1.  TAK-1 phosphorylates the kinases upstream of p38, MAPKs 
and JNK. In addition, TAK-1 can also activate the inhibitor of nuclear factor kappa-B (IKK) 
complex, which consists of IKKα and IKKβ and scaffolding protein IKKγ. Phosphorylation 
of the IκBα inhibitory unit leads to its degradation and the release of NF-κB that mediate 
the de novo synthesis of a number of proinflammatory cytokines. Moreover, TLR 
signalling pathway can activate other transcription factors such as AP-1 also leading to 
the release of proinflammatory cytokines (Fig. 2). TLR7/8/9 stimulation activate IRF5 and 
IRF7, which are transcription factors playing a role in antiviral defence, cell growth and 
immune regulation, and are transducers of virus-mediated TLR signalling [67, 68].  
1.4.2. Myd88-independent pathway. 
This pathway was first described when the study by Kawai el al. showed that Myd88 
knockout mice responded to LPS stimulation and activated NF-κB and JNK with delayed 
kinetics [69]. TRIF interacts with receptor-interacting protein 1 (RIP1), TRAF6 and TRAF3 
[67]. TRAF6 activation leads to the same signalling pathway as Myd88 activation, but 
TRAF3 associates with TRIF and two non-canonical IKKs, TBK1 and IKKε. These kinases 
preferentially phosphorylate the transcription factors IRF3 and IRF7. IRF3 translocates to 
the nucleus as a homodimer and induces the expression of IFNβ, which in turns activates 
the receptor for IFNα/β and the JAK/STAT pathway leading to the phosphorylation of 
IRF7. IRF7 is activated by TBK1/IKKε and induces the expression of IFNα/β, forming a 
positive feedback loop for the release of large amounts of type I IFNs [70]. 
1.4.3. Negative regulators of TLR signalling. 
Excessive activation of TLR pathways can contribute to the pathogenesis of many human 
diseases, thus their regulation needs to be tightly controlled. There are several negative 
regulators of TLR pathways that have been described. The best-known example is the 
ubiquitin-modifying enzyme, Triad domain-containing protein 3 (triad3A), which can 
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degrade TLR3/4/5/9 using ubiquitin/proteasome machinery. Another example is 
suppressor of cytokine signalling-1 (SOCS-1), which interacts with the adaptor protein 
Mal, a key mediator of TLR4 and TLR2 signalling. SOCS-1 upregulation results in Mal 
degradation, thereby inhibiting Mal-mediated phosphorylation of the p65 subunit of NF-κB 
and thus the expression of NF-κB–dependent genes [71, 72]. Prolyl isomerase (Pin)1 
suppresses TLR3 mediated and IRF3-dependent transcriptional activation. Tripartite-motif 
protein (TRIM30α) is another protein which stimulates degradation of TAB2 and TAB3 [73, 
74]. Recent research provides increasing numbers of examples proving the importance of 
de-ubiquitinating enzymes in regulation of TLR signalling pathways. De-ubiquitinating 
enzyme A (DUBA) interacts with TRAF3 and inhibits the its self-ubiquitination. 
Cylindromatosis protein (CYLD) negatively regulated TLR-mediated immune and 
inflammatory responses by inhibiting activation of TRAF6 and TRAF7 [75, 76]. SARM was 
also shown to be a negative regulator of TRIF-dependent signalling [26]. Another example 
is IRF-4 which interacts with MyD88 and competes with IRF-5, but not with IRF-7, for 
MyD88 interaction [77]. Radioprotective 105 (RP105) and its helper molecule, MD-1, have 
a physical association with TLR4/MD2, and this association inhibits LPS–TLR4/MD2 
complex formation [78]. TLR pathways can also be negatively regulated by IRAK-M, which 
associates with IRAK-1 and inhibits its signalling [79]. Recent research also demonstrated 
activating transcription factor-3 (ATF3) as a negative regulator not only in the TLR4-
stimulated inflammatory response, but also in TLR2/6 heterodimer, TLR3, TLR5, TLR7, 
and TLR9 pathways [80]. Another example is Tollip which associates directly with TLR2 
and TLR4 and inhibits TLR-mediated cell activation [81] [82].  
TLRs have also been shown to regulate cell death. Activation of PI3K-Akt signalling 
pathway promotes cell survival and TLR-mediated increased expression of anti-apoptotic 
proteins Bcl-2-related protein A (BCL2A1), inhibitor of apoptosis 1 (cIAP1), cIAP2, X-
linked inhibitor of apoptosis protein (XIAP) and other Bcl-2 family members [83].  
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1.5. The role of TLRs in inflammasome activation. 
It was described previously that recognition of PAMPs and DAMPs by the TLRs triggers a 
series of events that lead to the expression of many immune and inflammatory genes (Fig. 
3). Activation of TLRs by various ligands leads to NF-κB activation which is needed to 
induce the expression of cytokines such as CXCL8 and IL-1β [84]. The release of IL-1β 
has to be tightly controlled, as excess levels of this cytokine not only causes fever, 
anorexia, and other constitutional symptoms but also triggers tissue damage and 
remodelling. IL-1β itself can drive the activity of cryopyrin, thereby inducing its own 
secretion leading to autoinflammatory diseases such as Muckle–Wells syndrome. It 
requires processing by the enzyme, caspase-1, which cleaves the inactive precursor, pro-
IL-1β, to its mature form. Activation of caspase-1 takes place via a protein complex called 
the inflammasome [85]. Several protein platforms/inflammasomes have been described 
for the activation of caspase-1, each of them include members of the NOD-like receptor 
(NLR) family of proteins [86]. The NLR family is characterized by the presence of a central 
nucleotide-binding and oligomerization (NACHT) domain, which is involved in the 
regulation of homo-oligomerization or hetero-oligomerization and inflammasome 
assembly. It is flanked by C-terminal LRRs and N-terminal caspase recruitment (CARD) or 
pyrin (PYD) domains. LRRs function in ligand sensing and autoregulation, whereas CARD 
and PYD domains mediate homotypic protein-protein interactions for downstream 
signalling [87]. The most studied inflammasome, NACHT, LRR and PYD domains-
containing protein 3 (NLRP3) can be activated by a variety of both, exogenous and 
endogenous signals. Activation of inflammasome requires two signals. A “priming” signal 
that results in transcription of pro-IL-1β, and a second signal that promotes inflammasome 
assembly, activation of caspase-1, followed by the maturation and secretion of IL-1β. The 
first signal is under NF-κB activation and can be achieved by TLRs stimulation, whereas 
numerous molecules can provide second signal including various pore-forming toxins, 
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amyloid-β, reactive oxygen species (ROS), adenosine triphosphate (ATP), K+ efflux, as 
well as silica and uric acid crystals [88-90], however, the underlying mechanism of 
activation is poorly understood.  The first danger-associated signal described was ATP 
that activates P2X7 ion channel receptors [91]. P2X7 receptors belong to a family of ion 
channel receptors activated by extracellular ATP [85]. ATP has a high intracellular 
concentration and is kept low in the extracellular space by the activity of ATPases. It is 
released from dying cells and activated platelets, and it is usually present locally in 
stressed tissues. Binding of extracellular ATP to the P2X purinoceptor 7 (P2X7R) leads to 
IL-1β maturation via the effects of purinergic stimulation of the hemichannel pannexin-1 
(panx1), which forms large pores in the plasma membrane and acidifies endosomal 
compartments [1]. The hemichannel protein pannx1 was suggested to form large, 
nonselective pores after ATP stimulation of P2X7R, thereby allowing DAMPs and PAMPs 
access to cytosolic	  NLRP3 [92]. Inflammasomes have been extensively studied in recent 
years but more research is needed to investigate the role of various inflammasomes in 
human inflammatory diseases and infections.  
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Figure 3. Activation of the inflammasome. 
1.6. Smoking and inflammation. 
Cigarette smoking is the major risk factor in many inflammatory diseases such as 
cardiovascular disease, COPD and a number of malignancies including lung 
adenocarcinoma. Cigarette smoke (CS) contains more than 4500 components in its 
gaseous and particulate phases including direct carcinogens (methylcholanthrene, benzo-
α-pyrenes and acrolein); toxins (carbon monoxide, ammonia, acetone, nicotine and 
hydroquinone) and oxidants (superoxide and nitrogen oxides). It is chemically a highly 
reactive condensate that contains billions of oxidative moieties. Furthermore, CS affects 
the immune system by chemically modifying signalling pathways and the extracellular 
matrix through acetylation, nitrosylation, carbonylation and oxidation which can have an 
effect on cell survival, activation and differentiation. Cigarette smoke has been shown to 
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have both stimulatory and inhibitory effects on immune cell activation. These findings 
have made the interpretation of the literature related to animal models difficult to translate 
to the human situation [93]. In the innate immune system cigarette smoke increases the 
number of alveolar macrophages (AM) which upon activation release lysosomal enzymes 
and elastases. These enzymes contribute to the damage of connective tissue and 
parenchyma of the lung. In addition, AM from smokers produce more oxygen radicals and 
have higher myeloperoxidase activity and a reduced ability to phagocytose and kill 
bacteria [94, 95]. It was also shown that NK cells activity against cultured cancer cells was 
reduced in smokers and animal models [96, 97]. Moreover, cigarette smoking in humans 
can cause leukocytosis and greatly reduce the function of these cells [97]. Some studies 
also demonstrated that long-term smoking reduces serum levels of immunoglobulins, 
confirmed in animal models, as well as increasing susceptible to influenza and sarcoma 
viruses [97, 98]. T cells from smokers and animals that were exposed to CS have a 
decreased ability to proliferate in response to T cell mitogens, which indicates a deficient 
cell-mediated immune response [98, 99]. 
1.7. The role of TLRs in sensing oxidants. 
Oxidants which can be found in CS play a part in damage caused by inflammation but it is 
not fully understood how exactly oxidants are sensed and propagate the inflammatory 
reaction. A specific function for TLR2 as a ‘receptor’ for oxidants was first suggested by 
Frantz et al. using cardiac myocytes or fibroblasts stimulated with H2O2, where it was 
shown that activation of NF-κB by H2O2 was only seen in TLR2-expressing cells and was 
prevented after blocking of TLR2 with antibody against this receptor [100]. After this study, 
many other papers showed that inflammatory responses after cigarette smoke exposure 
were mediated by TLRs. A study by Karimi et al. showed that human monocytes and 
monocyte-derived macrophages produced high amounts of CXCL8 after cigarette smoke 
stimulation. CXCL8 production was dependent on TLR4 activation where LPS was not 
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present. Moreover, neutralization of TLR4 but not TLR2 inhibited CS medium-induced 
CXCL8 secretion by human macrophages [101]. Another study demonstrated that CS 
increased the expression of TLR4 and NF-κB activation from the bronchial epithelial cell 
line (16-HBE) [102]. A number of studies from our group, using animal models, showed 
that oxidant-induced inflammation associated with cigarette smoke extract or ozone was 
absent in TLR2 or TLR4 knockout animals, suggesting that both TLR2 or TLR4 could act 
as sensors for oxidants [103-106]. In 2009, study from our group showed that oxidants 
evoked the release of CXCL8 from monocytes/macrophages which was abrogated by 
pretreatment with N-acetylcysteine or binding antibodies to TLR2. Oxidative activation of 
TLRs was associated with a rapid phosphorylation of IRAK1. Oxidants added to HEK293 
cells transfected with TLR2, TLR1/2, or TLR2/6 but not TLR4/MD2-CD14 or control HEK 
nulls also resulted in the release of CXCL8. These findings clearly substantiate the 
hypothesis that TLRs are the sensors of early oxidant-induced inflammation. The 
involvement of TLR4 in oxidant-induced inflammation in vivo, was shown at later time 
points (≥6h), and it may be due to a secondary inflammatory insult mediated by bacterial 
leakage from the gut or the lungs [64]. TLR9 has also been implicated in TLR-mediated 
inflammatory responses after CS exposure. It was demonstrated using neutrophils and 
HEK293 cells, that CS induced CXCL8 release via TLR9. It also increased expression of 
TLR9 and this upregulation was suppressed by N-acetylcysteine [107].  These results 
were confirmed by Nadigel et al. where CD8+ T cells exposed to CS had increased TLR4 
and TLR9 levels and increased cytokine production [108]. Cigarette smoke also induces 
the release of ATP and activates P2X7 receptor signal transduction pathways of human 
neutrophils [109]. A study by Mortaz et al. demonstrated that the inflammasome activator 
monosodium urate crystals (MSU) induced the release of CXCL8 and IL-1β from HBE-14o 
and that the caspase-1 inhibitor, Z-VADDCB, suppressed the CS-induced release of 
CXCL8. In addition, CS, CpG ODN, LPS and monosodium urate crystals (MSU) all 
increased the expression of caspase-1 and IL-1β suggesting that CS releases CXCL8 
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from HBE-14o cells via TLR4, TLR9 and inflammasome activation [110]. Similar results 
were obtained by Eltom et al. where mice were exposed to CS twice a day to induce 
COPD-like inflammation and the role of the P2X7 receptor was investigated. CS-induced 
neutrophilia in a pre-clinical model was temporally associated with increased caspase-1 
activity and the release of IL-1β/IL-18 in the lungs. A selective P2X7 receptor antagonist 
and P2X7 knockout mice, attenuated caspase-1 activation, IL-1β release and airway 
neutrophilia in response to CS. This pathway was not restricted to early stages of disease 
development by showing increased caspase-1 activation in lungs from a more chronic 
exposure to CS and from patients with COPD. These results demonstrated the critical role 
of the P2X7/caspase-1 and inflammasome in CS-induced inflammation [111] [112]. 
Cigarette smoke has also been shown to induce COX-2 in lung epithelial cells in vitro in a 
TLR4-dependent manner [113].  
1.8. The role of TLRs in smoking related disease. 
The role of TLRs has been implicated in many diseases induced by cigarette smoking. 
This may be through the involvement of TLRs in innate and adaptive immunity. Here, I 
describe two diseases, which are relevant to my thesis, where TLRs may play a role in 
disease pathogenesis and may therefore provide an attractive therapeutic target for drug 
development. 
1.8.1. Chronic obstructive pulmonary disease (COPD). 
It is well known that cigarette smoking is a major risk for developing COPD. COPD is a 
chronic inflammatory disease which includes chronic obstructive bronchitis with fibrosis 
and obstruction of small airways, emphysema with enlargement of airspaces, destruction 
of lung parenchyma, loss of lung elasticity, and closure of small airways. It is 
characterized by the presence of CD8+ cytotoxic T cells and Th1 cells [114]. Upon 
stimulation of epithelial cells and macrophages by noxious particles, these cells release 
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high levels of pro-inflammatory cytokines such as CXCL8, IL-6, TNF-α and monocyte 
chemoattractant protein-1 (CCL2) that recruit neutrophilic granulocytes and macrophages 
[115]. Activated neutrophils release inflammatory mediators such as serine proteases 
contributing to tissue destruction [116].  
Exacerbations of COPD are episodes of worsening of symptoms, accompanied by a 
reduction in FEV1, which impose a substantial burden on health-care systems worldwide; 
they are a major cause of morbidity, mortality, and reduced health status. They are now 
the most common cause of medical hospital admission in the UK, at a cost to the National 
Health System of over £253 million a year. COPD exacerbations are heterogeneous 
events that are now thought to be caused by complex interactions between the host, 
respiratory viruses, airway bacteria, and environmental pollution, leading to an increase in 
the inflammatory burden [117]. The first step in COPD management is the reduction of 
risk factors. Smoking cessation is currently the only effective therapy for a decline of 
COPD progression. Inhaled long acting bronchodilators in combination with 
glucocorticosteroids form the basis of symptomatic treatment in COPD but a lot of patients 
show insensitivity to these drugs [116]. Pulmonary hypertension (PH) is a common 
complication of COPD. The increase in pulmonary artery pressures is often mild to 
moderate. However, 5–10% of patients with advanced COPD may suffer from severe 
pulmonary hypertension and present with a progressively downhill clinical status because 
of right heart failure added to ventilatory handicap [118].  Since TLRs play a role in the 
defence against pathogens and other danger molecules, they might be important in 
pathogenesis of COPD as infections in airways worsen the disease process. This is 
normally associated with a clinical worsening of FEV1. TLR2 downregulation was found in 
alveolar macrophages from COPD patients and smokers [119]. However, another study 
showed increased expression of TLR2 in peripheral blood monocytes from COPD 
patients, suggesting a difference between alveolar and systemic effects in terms of TLR 
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expression [119, 120]. TLR4 gene expression was reduced in nasal epithelium of COPD 
patients and smokers [121]. However, in airway epithelium TLR4 expression was 
increased in subjects with mild-moderate COPD compared to normal controls, while with 
increasing severity of disease and fall in FEV1, TLR4 expression was reduced [122]. A 
recent study by Wang et al. demonstrated that TLR5 was downregulated at mRNA, 
protein and functional levels in airway epithelium in healthy smokers and in smokers with 
COPD [123]. COPD is also characterized by progressive and irreversible airway 
obstruction [124]. Small airway remodelling includes adventitial fibrosis and mucus 
hyperplasia and may involve increased airway smooth muscle cells mass [125]. It is also 
possible that the destruction of the epithelial cells and the release of growth factors cause 
thickening of the reticular basement membrane and proliferation of smooth muscle cells 
[126]. In addition to initiating inflammatory responses, TLRs have been shown to regulate 
cell proliferation and survival in a variety of biological settings. Most of the evidence for 
TLRs and proliferation in non-cancerous cells has been shown in vascular smooth muscle 
cells (VSMC) and in cardiovascular models. TLRs can regulate the compensatory 
proliferative responses and suppression of apoptosis [64]. The mechanisms responsible 
for the control of these outcomes are poorly defined. In 2007, Schultz and collaborators 
revealed that IL-1R signalling promotes basal and TLR agonist-stimulated CCL2 release, 
as well as TLR-induced proliferation of VSMCs. They demonstrated that IL-1α is a key 
mediator of the phenotypic responses of human VSMC to TLR agonist and that it also 
contributes to growth factor-induced proliferation in human vascular disorders [127].  
Another study revealed that early aortic lipid accumulation and expression of 
proinflammatory mediators markedly dependend on TLR4, and to a lesser extent TLR2, at 
lesion prone sites in apolipoprotein E (ApoE)–deficient mice. Furthermore, VSMCs 
incubated in cholesterol-enriched media in vitro expressed CCL2 and the cholesterol-
esterifying enzyme acyl-coenzyme A: cholesterol acyltransferase (ACAT1). VSMCs were 
also shown to accumulate intracellular cholesteryl ester in a TLR4-dependent fashion, 
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which suggests that TLR4 contributes to proinflammatory events and foam cell formation 
in early atherogenesis. A study by Pera et al. demonstrated that CSE and LPS, both of 
which can act via TLRs, induced a profound increase in DNA synthesis in bovine tracheal 
smooth muscle cells (BTSM) [125]. Since TLR4 is responsible for sensing LPS and CS 
they may contribute to airway remodelling in COPD through direct effects on airway 
smooth muscle (ASM) cells causing a proliferative phenotype that may be involved in 
increased ASM mass in this disease. There is a lot of evidence that TLRs provide a 
fascinating and rapidly expanding area of research; it is likely that therapies that target 
these receptors and their signalling could be of use in COPD [112]. 
1.8.2. Lung cancer. 
Chronic infection and inflammation are widely known to be risk factors for tumorigenesis. 
Infiltrating host leukocytes, such as neutrophils, tumor-associated macrophages (TAMs), 
dendritic cells (DC), mast cells and lymphocytes are known to be present at tumor sites 
and in the surrounding stroma. The damage caused by invading pathogens induces 
destructive cycles that are initiated within tissues and result in excessive tissue 
remodeling, loss of function and in some cases DNA mutations. In this way chronic 
infection and inflammation are widely known to be risk factors for tumorigenesis  [128]. 
Activated TLRs on cancer cells may promote cancer progression, anti-apoptotic activity 
and resistance to host immune response. Ligation of TLRs increases production of 
proinflammatory mediators like TNFα, IL-1α, IL-6, intercellular adhesion molecule 1 
(ICAM-1) and vascular endothelial growth factor (VEGF). Their presence releases various 
factors that have multiple effects on tumor, immune and normal cells. An activated 
immune system can induce cytokine release that stimulates cancer associates fibroblasts 
(CAFs) and impairs the function of APCs, effector T cells and TAA-specific immunity 
[129]. Summary of these effects maintain tumor environment and promote further 
progression. Recently, the expression or up-regulation of TLRs has been detected in 
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many tumor cell lines or tumors, especially epithelial derived cancers. Several studies 
have shown a link between TLR activation and tumor growth. For example, Kim and 
collaborators demonstrated that the proteoglycan versican, which is upregulated in many 
human tumors, was produced by Lewis Lung Carcinoma (LLC) and strongly enhanced 
LLC metastatic growth through activation of TLR2/6 and the secretion of TNF-α [130].  
TLR2, TLR3, TLR6, and TLR9 were consistently expressed in the hepatocellular 
carcinoma cell line, Hep G2. mRNA for TLR4 was also detected in these cells. Breast 
cancer cell responsiveness to LPS suggests that functional TLR4 can be expressed in 
breast cancer cells [131-133]. 
Lung cancer is one of the leading cause of death worldwide and only 15% of patients 
survive longer than 5 years from the time of diagnosis [134]. It is a non-immunogenic 
cancer, resistant to the surveillance of immune system, which should recognize and 
eliminate transformed cells [135].  A study by He et al. demonstrated that TLR4 was 
expressed on human lung cancer cell lines. TLR4 ligation promoted production of 
immunosuppressive cytokines such as transforming growth factor beta (TGF-β), VEGF 
and CXCL8. In addition, TLR4 ligation induced resistance of human lung cancer cells to 
TNF-α or TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. p38 
activation was necessary for increased VEGF and CXCL8 secretion, and NF-κB activation 
contributed to apoptosis resistance of human lung cancer cells induced by LPS [136].  
Droemann and colleagues showed that TLR9 is expressed in the cytoplasm of tumor cells 
in the majority of lung cancer specimens as well as in all tested tumor cell lines. Non-
malignant lung tissues showed only sporadically weak expression. Stimulation of HeLa 
and A549 cells with CpG ODN induced secretion of CCL2 and reduction of spontaneous 
and TNF-α-induced apoptosis [137]. The induction of Th1-like and cytotoxic immunity by 
TLR signalling should lead to tumor regression or arrest. However, results obtained from 
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basic research and clinical trials have suggested that there is no antitumor activity seen 
when TLRs are activated [125]. 
1.9. Therapeutic potential of TLRs. 
TLRs play a key role in the detection of microbes and in sterile inflammation. Excessive 
TLR responses may have important consequences during infection, leading to 
exaggerated responses such as in chronic disease, as well as more acute settings such 
as severe sepsis. This knowledge has led to a great deal of research effort directed 
towards developing TLR agonists and antagonists as therapeutic targets for the 
prevention and treatment of diseases. Inappropriate TLR responses may have important 
consequences during infection, leading to exaggerated responses such as in severe 
sepsis [138]. To reduce signal transduction through TLRs in sepsis, different strategies 
are being developed. Firstly, soluble TLRs that can bind and neutralize the microbial 
ligands; secondly, antibodies neutralizing TLRs blocking the binding of the ligands; thirdly, 
small molecular mass inhibitors blocking signalling pathways activated by TLRs [139].  
TLRs are also very attractive targets for the treatment of chronic inflammatory diseases 
that are caused by dysregulation of the immune system. TLR agonist or adjuvant therapy 
can be very successful, especially during episodes of exacerbations. Activation of TLRs 
can boost the protective inflammatory response that destroys pathogens and protects the 
host [116]. Certain TLR activators have also the potential to reverse Th2-type responses 
to allergens and thus, restore the balance of the immune system [140]. However, these 
two approaches may be harmful for the host and might amplify unwanted tissue 
destructive inflammation. TLR inhibitors are currently being developed for the treatment of 
inflammation. Antagonist therapies can downregulate inflammatory responses by blocking 
the interaction between TLRs and their ligands or by blocking the downstream signalling 
cascades. However, so far no studies have addressed a potential role for TLR antagonists 
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in the treatment of asthma or COPD specifically [116]. Better understanding of the 
pathways and mechanisms leading to inflammatory responses and chronic inflammation 
may lead to better therapeutic approaches for COPD.  Further studies of the inflammatory 
signalling networks and the cross talk between them are important to develop a greater 
understanding of the pathogenesis of COPD. It is still debatable whether COPD occurs as 
a result of excessive inflammatory drive or a lack of inhibitory feedback loops. However, it 
is clear that many of these pathways are abnormally activated in COPD and that 
interference with these signalling pathways could shed light on disease processes and 
provide novel therapeutic approaches [141].  
There is also a growing evidence to indicate therapeutic interest in TLR7/8 agonists for 
cancer treatment. In the 19th century William Coley observed that repeated injection with 
bacterial toxins from Staophylococcus pneumoniae and Serratia marcescens produced an 
efficient antitumor effect. It was discovered later that LPS from the Coley’s toxins 
stimulated TLR4 and resulted in anti-tumor activity [83]. Nowadays, clinical trials 
investigating novel anticancer therapies are based on TLR ligand delivery. A successful 
example is imiquimod. This TLR7 agonist is used extensively to treat actinic keratosis and 
basal cell carcinoma, and it is being studied as an adjuvant therapy for melanoma. 
Imiquimod induces IFNα, IFNγ and IL-12, which activate APC function and TAA-specific 
immunity, thereby correcting the aberrant conditions of the tumor microenvironment [142]. 
Another example is Bacillus Calmette-Guérin (BCG) which was originally developed as a 
tuberculosis vaccine, but was later discovered to be effective against superficial bladder 
tumors. BCG targets TLR2 and TLR4 and enhances immune responses [143]. Stimulation 
of TLR9 activates human pDCs and B cells, and induces potent innate immune responses 
in preclinical tumor models and in patients. As such, the TLR9 agonist, CpG ODN, has 
shown promising results as vaccine adjuvant and in the treatment of cancers, infections, 
asthma and allergy [144]. Vaccine adjuvants are perhaps the most extensively explored 
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applications for TLR agonists. The rational design of specific TLR agonists with reduced 
toxicity but increased potency, as compared to adjuvant candidates from only a decade 
ago, offers the opportunity to meet the stringent safety criteria required for prophylactic 
vaccines [145]. TLR stimulation can also have a negative role in tumorigenesis. It can 
increase proliferation, decrease rates of apoptosis and enhance the growth of adoptively 
transferred cells. TLRs are believed to be directed against tumor cells, but they also have 
been found to be involved in tumor development. It is crucial to develop further studies to 
establish the exact role of TLRs in human disease.  
TLRs offer a promising new therapeutic strategy for the treatment of human inflammatory 
diseases. However, the potential for adverse effects when targeting such fundamental 
pathways of the host defence mechanism needs to be carefully assessed, especially for 
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Hypothesis and aims of this thesis.  
 
The overall hypothesis of this thesis is that TLR signalling is central to inflammation and 
cellular proliferation in lung pathologies, and that understanding how specific functions of 
TLRs mediate responses at the cellular level and in tissue from patients will be of value in 
the search for new biomarkers and drug therapies. 
 
The specific aims are as follows: 
1) To investigate the signalling mechanisms involved in inflammasome activation and IL-
1β release from human monocytes after activation with TLR2 and TLR4 ligands. 
2) To assess the sensitivity of the blood of COPD patients to produce CXCL8 and IL-1β 
after challenge with bacterial and viral TLR ligands. 
3) To study the role of TLRs in proliferation and death of human lung cancer cells.
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2.1. Cell culture. 
Type II pneumocyte-delivered human lung cancer cell line A549 (ECACC) was cultured in 
T175cm2 culture flasks (Nunc) and incubated at 37oC containing 5% CO2. A culture 
medium of Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% filtered 
heat-inactivated Foetal Calf Serum (FCS), 2mM glutamine and100U/ml 
penicillin/streptomycin was used to sustain the cells. Cells were observed to be confluent 
after approximately 3 days. For T175cm2 flasks cells were seeded at 2mln cells/flask, for 6 
well plates cells were seeded at 3x105cells/well, for 96 well plates cells were seeded and 
1x104 or 2.4x104 cells/well. 
Human acute monocytic leukemia cell line THP-1 (ECACC) and freshly isolated PBMCs 
were cultured in T175cm2 culture flasks and incubated at 37oC containing 5% CO2. A 
culture medium of RPMI 1640 supplemented with 10% filtered heat-inactivated Foetal Calf 
Serum (FCS), 2mM glutamine and 100U/ml penicillin/streptomycin was used to sustain 
the cells. Cells were observed to be confluent after approximately 3 days. For T175mm2 
flask cells were seeded at 2mln cells/flask and for 96 well plates cells were seeded at 
1x105 cells/well.  
2.1.1. Cell passage. 
For adherent cells, media was removed from the cells with an aspiration pipette and 
washed once with PBS at room temperature. 10 mls of trypsin solution made up with PBS 
was added to detach cells from the flask surface (5ml for T75cm2, 10ml for T175cm2). 
After 5min incubation at 37oC, equal volume of media was added to neutralize the trypsin. 
For non-adherent cells, cell suspension was simply transferred from the flask to a 
centrifuge tube. Both, adherent and non-adherent cell lines, were centrifuged at 190xg for 
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5min at room temperature. The cell supernatant was removed and 1ml of media was 
added. Cells were counted and either used for experiments or frozen into aliquots for 
long-term storage.  
2.1.2. Cell counting. 
10µl of cell suspension was added to 90µl Turk’s solution (0.01% crystal violet, 3% acetic 
acid in H2O). 10µl of the suspension was added onto haemocytometer (Neubauer) and 
observed under a bright-field microscope. The total number of cells was counted in 25 
0.004mm3 squares. 25 squares with combined volume of 25x(0.004)=0.1mm3. There are 
1000 cubic mm in one cubic cm, so the number of cells was multiply by 1000 and the 
dilution factor (10x). The concentration of cells in the original suspension (cell/ml) is 
represented by: 
 
2.1.3. Cell freezing/storage/thawing. 
Cells were resuspended to the concentration 1mln cells/ml. 10% of DMSO was added to 
the suspension and placed in the cryotubes. The cryotubes were then placed in a storage 
device containing isopropanol and placed in the -80ºC freezer. This ensured freezing at 
no more that 1ºC per min. After 24h cryotubes were transferred to the liquid nitrogen 
container for long-term storage. To thaw cells, cryotube was placed in the 37 ºC water 
bath until cells had just started to thaw. Cells were carefully resuspended and added to 
the flask with complete media.  
                         
                              Cell/ml = number of cells in 25 squares /0.1 x 1000 x 10 
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2.2 Pharmacology of TLR2 and TLR4 agonists on IL-1β and CXCL8 release by 
human monocytes and peripheral blood mononuclear cells. 
2.2.1. Isolation and culture of human peripheral blood mononuclear cells. 
Blood samples were collected from healthy volunteers (ethics number: 08/H0708/69). 
Informed consent was obtained from all subjects. Prior to blood collection 3ml of 
Histopaque 1077 was added to the 15ml centrifuge tubes. Peripheral blood samples were 
taken from healthy volunteers. For each donor 20 ml of blood was collected into 50ml 
centrifuge tube containing sodium citrate (ratio of sodium citrate:blood was 1:9). Citrated 
blood was diluted with RPMI media which had been warmed to 37ºC. 6ml of diluted blood 
was layered on top of 3ml Histopaque (prepared earlier) and centrifuged at 400xg (with a 
very low brake) for 30min at room temperature. Layer of PBMCs, which at this point was 
between the Histopaque and the serum, was carefully removed from each tube using 
Pasteur pipette. PBMCs were transferred into 15ml centrifuged tubes (up to 7ml per tube) 
and made up to 14ml with warm RPMI media. Tubes were centrifuges at 200xg for 15min 
at room temperature to remove any remaining Histopaque. After spinning, supernatants 
were discarded from each tube. Cell pellets were pooled into 50ml falcon tubes with 20ml 
of fresh media and centrifuged again at the same conditions for a final wash. After final 
wash, supernatant was removed and cell pellet was resuspended in 1ml of media and 
counted using haemocytometer. PBMC were seeded in 96 well plates at 1x105 cells per 
well.  
2.2.2. Measurement of cytokine release (ELISA). 
Levels of cytokines (IL-1β, CXCL8 and CXCL10) in the cell culture supernatants and 
plasma were measured by enzyme-linked immunosorbent assay (ELISA) using 
commercially available kits (R&D Systems, UK) following the manufacturer’s instruction.  
Briefly, 96 well plates were coated overnight with capture antibody specific for the cytokine 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





being measured. Plates were washed 3 times with PBS/Tween (Sigma) and blocking 
buffer was added to block any remaining spaces on the well. After an hour, plates were 
washed three times with PBS/Tween and incubated with samples (diluted it reagent 
specified in protocol if necessary) and standard solution of the cytokine being measured. 
After 2h plates were washed 3 times in PBS/Tween and incubated with biotinylated 
detection antibody specific for the cytokine being measured. After 2h plates were washed 
3 times in PBS/Tween and incubated with a streptavidin/horseradish peroxidise conjugate 
solution. After 20 min plates were washed 3 times with PBS/Tween and then incubated 
with substrate solution, a mix of H2O and tetramethylbenzidine (BD Bioscience, UK). 
Reaction was stopped with addition of 2N H2SO4. Optical density of each well was 
obtained by reading the plate at 450nm with wavelength correction at 570nm using 
microplate reader. Levels of cytokine in samples were calculated by interpolation from the 
standard curve, which is generated from optical density reading for the wells containing 
standards.  
The sensitivities of the assays used: 
• IL-1β - 3.91-250 pg/ml 
• CXCL8 – 31.2-2000 pg/ml 
• CXCL10 – 31.2-2000 pg/ml 
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Figure 4. Example of the results of human IL-1β ELISA standard curve. Absorbance 
read at 450nm with wavelength correction at 570nm. 
.  
Figure 5. Example of the results of human CXCL8 ELISA standard curve. 
Absorbance read at 450nm with wavelength correction at 570 nm. 
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Figure 6. Example of the results of human CXCL10 ELISA standard curve. 
Absorbance read at 450nm with wavelength correction at 570 nm. 
 
2.2.3. Cell treatment. 
THP-1 cells  
THP-1 cells were seeded at 1x105 cells/well in 96 well plates in complete media and 
treated with the following inhibitors: 
• Steroid- Prednisone (0.1-10 µg/ml) 
• IKK inhibitor- SC-514 (0.1-10 µg/ml) 
• TAK1 inhibitor- 5Z-7 (0.1-10 µg/ml) 
• p38 inhibitor- BIRB (0.001-10 µg/ml) 
• Caspase inhibitor- Z-VAD-FMK (0.001-10 µg/ml) 
• Panx1 inhibitor- Carbenoxolone (0.001-10 µg/ml) 
• P2X7R inhibitor- AZ (0.001-10 µg/ml) 
• Media with 0.01% DMSO (control) 
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After 30min LPS (0.1µg/ml) and Pam3CSK4 (0.1µg/ml) were added for 24h. Cells were 
centrifuged at 400xg for 5min at room temperature. Supernatants were collected and 
stored at -20ºC for cytokines measurement by ELISA (as described in section 2.2.2). Cells 
were kept for AlamarBlue cell viability assay (section 2.4.2). 
Experiments that included an ATP pulse were performed as follows: THP-1 monocytes 
were plated and treated with PAMPs for 24 hours as described above. After 24 hours, 
cells were centrifuged (190xg, 5min) and supernatants collected. Media was then 
replaced with media alone or media containing 5mM ATP for 30min. Cells were then 
centrifuged (190xg, 5min) and supernatants collected for ELISA.  
PBMCs  
PBMCs were seeded at 1x105 in 96 well plates in 100µl of media and treated with the 
following inhibitors: 
• p38 inhibitor- BIRB (0.001-10 µg/ml) 
• Caspase inhibitor- Z-VAD-FMK (0.001-10 µg/ml) 
• Pannexin-1 inhibitor- Carbenoxolone (0.001-10µ g/ml) 
• P2X7R inhibitor- AZ (0.001-10µg/ml) 
• Media with 0.01% DMSO (control) 
After 30min LPS (1µg/ml) and Pam3CSK4 (1µg/ml) were added for 24h. Cells were 
centrifuged at 400xg for 5min at room temperature. Supernatants were collected and 
stored at -20ºC for cytokines measurement by ELISA (as described in section 2.2.2). Cells 
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2.2.4. Cytokine release after activation of Myd88 and TRIF signalling pathways. 
Freshly isolated PBMCs were seeded at density 1x105 cells/well. On the next day cells 
were treated with: 
• TLR2/1 agonist- Pam3CSK4 (0.01-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.01-1 µg/ml) 
• TLR3 agonist- Poly I:C (0.1-10 µg/ml) 
• TLR4 agonist- LPS (0.001-1 µg/ml) 
• Media (control) 
After 24h IL-1β and CXCL8 levels were measured by ELISA as described in section 2.2.2. 
2.2.5. Cytokine release after inhibition of Myd88 and TRIF adaptor proteins. 
2.2.6. Preparation of cigarette smoke extract (CSE). 
CSE was produced as described previously [146].	   Briefly, CSE was prepared by 
combusting four full-strength Marlboro cigarettes (filters removed) using a 60ml syringe 
apparatus. Cigarette smoke was passed through 100ml of RPMI media, supplemented 
with 10% foetal calf serum, Penicillin Streptomycin (100U/ml), and L-Glutamine (200 mM). 
Each full draw of the syringe took approximately 10s to complete, yielding approximately 
5-6 draws in total. CSE was then filtered using a 0.25-µ to sterilise and remove large 
particulates. At this point CSE is considered to be at 100% and was used immediately, 
unless otherwise stated. 
2.2.7. Cell treatment. 
Freshly isolated PBMCs were seeded at density 1x105 cells/well. On the next day cells 
were treated with: 
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• TLR2/1 agonist- Pam3CSK4 (1 µg/ml) 
• TLR3 agonist- Poly I:C (10 µg/ml) 
• TLR4 agonist- LPS (1 µg/ml) 
• CSE (10%) 
• Media (control) 
After 6h, 10µM or 50µM of inhibitors was added to the cells. 
IL-1β, CXCL8 and CXCL10 levels were measured by ELISA as described in section 2.2.2. 
2.2.8. Transfection of THP-1 cells using siRNA. 
THP-1 cells were maintained as described in section 2.1 and harvested by centrifufation  
(200xg, 21°C, 5min). Media was removed and cells were resuspended in solution V 
(Lonza cat no VCA–1003). For each nucleofection, siRNA was added (20nM-100nM) per 
sample and transferred to a new electroporation cuvette (Lonza). Cuvette was inserted to 
Amaxa Nucleofector transfection system and electroporated using program V-001. 
Immediately after the pulse, pre-warmed media was added to the cuvette and aspirated to 
a new eppendorf tube using the supplied pipettes. After 10min incubation at 37°C, cells 
were transferred onto the 96 well plate. After 48h, cells were treated with: 
• TLR2/1 agonist Pam3CSK4 (1 µg/ml) 
• TLR4 agonist- LPS (1 µg/ml) 
• Media (control)  
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AllStars Negative Control siRNA (Qiagen) 










2.2.9. RNA extraction (Macherey-Nagel). 
RNA was extracted by Macherey-Nagel kit according to the manufacturer instruction. 
Briefly, cells were lysed by adding 350µl of RA1 buffer (containing 10µl β-mercaptoethanol 
per ml of RA1) and pipetting up and down 5 times. Viscosity of the lysate was reduced by 
filtration through Nucleospin Filter and centrifuged at 11,000xg for 1min.  350µl of 70% 
Ethanol (Sigma) was added to the homogenized lysate and transferred to a Nucleospin 
RNA II Column. After centrifugation, membrane was desalted by adding 350µl of MDB 
buffer and spun at the same conditions. 10µl of DNase was added to 90µl Reaction Buffer 
for DNase in a clean Eppendorf tube and added directly to the membrane. Column was 
incubated at room temperature for 15min. 200µl Buffer RA2 was added directly to the 
column and spun for 30s at 11,000xg.  To wash the column, 600µl of buffer RA3 was 
added and after centrifugation additional 250µl of the same buffer was added. After 
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spinning at the same conditions RNA was eluted with 60µl of DNase/RNase free water. 
Concentration of the RNA was measured at 260/280nm using a UV spectrophotometer 
(Nanodrop ND-1000, Thermo). 
2.2.10. RT-PCR. 
RNA (stored at -80°C) was thawed at room temperature. 250ng of RNA was used to make 
up the first strand reaction as outlined below.  
RNA 200ng 
Oligo (dT)12-18  (Invitrogen) 1µl 
10mM dNTP Mix (Fisher Scientific) 1µl 
DNase / RNAse Free Water (Qiagen) Make up to 20µl 
	  
After 5min incubation at 65°C, tube was placed on ice for 1min. Then following reagents 
were added: 
Reagent Volume(µl) 
Reverse Transcriptase (Fermenetas) 1 
RT Buffer (Fermentas) 4 
	  
Tubes were placed in Techne Cycler and incubated at 25°C for 10min, 42°C for 60min 
and 70°C for 10min.  
Master mix for the PCR reaction was made up using following instruction:  
Reagent Volume per well (µl) 
SyBr Green Mastermix (Sabiosciences) 12.5 
Primer Mix (Sigma) 1 
cDNA from first strand reaction   1 
Dnase / RNAse Free Water (Qiagen) 10.5 
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25µl per well was loaded and run on the ABI7500 qPCR machine with the following cycle: 
Cycles Duration Temperature 
1 10 minutes 95°C 
40 15 Seconds 95°C 




Forward 5’ GAAGGTGAAGGTCGGAGTC 
Reverse 5’ GAAGATGGTGATGGGATTTC 
P2X7 
Forward 5’ TCCTACGTTTGCTTTGCTCTGG 
Reverse 5’ ATTCCTTTGCTCTGCGGGTC 
Panx1 
Forward 5’ TCACGTGCATTGCGGTGGGG 
Reverse 5’ GCGAAACGCCAAGAACAGCGG 
2.3 COPD and PAH study – cytokine release measurement from whole blood. 
2.3.1. Whole blood culture – Ethics statement. 
Patients with COPD from Greater London area, who were attending respiratory clinics at 
the Royal Brompton Hospital, were invited to participate. The study was approved by the 
Royal Brompton, Harefield and National Heart and Lung Institute Research Ethics 
Committee (ethics number 07/Q0404/17; the study was adopted by UK Clinical Research 
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Network; http://www.crncc.nihr.ac.uk/). Signed informed consent was obtained from all 
subjects. The diagnosis of COPD was made when the FEV1/FVC ratio was less than 
70%. Patients were diagnosed according to the GOLD guidelines 
(http://www.goldcopd.org/gold-around-the-world.html). COPD severity was classified as 
mild (stage I – FEV1 ≥ 80%), moderate (stage II – FEV1 50-79%) and severe (stage III – 
FEV1 30-49%) or very severe (stage IV – FEV1 <30%). Smoking history and pack years 
smoked were also recorded.  
Patients with idiopathic pulmonary hypertension (PAH) were invited to participate. The 
study was approved by the Royal Brompton Hospital Cardiovascular Biomedical Research 
Unit Tissue Bank Ethics Committee, reference 09/H0504/104. Signed informed consent 
was obtained from all patients. Disease severity was based on NHYA score (from I-IV); 
where higher RVSP (right ventricular systolic pressure from echo); lower PAT (pulmonary 
arterial acceleration time) and lower 6MW (6-minute walk) value all indicated worse PH.  
2.3.2. Study Design. 
We calculated the mean age of COPD patients and chose the volunteers for the control 
group to give us as similar an age range as possible. We also divided our control subjects 
into three groups:  
• Young controls (<30yrs) 
• Medium-age controls (30-50yrs) 
• Older controls (>50yrs) 
to investigate whether any changes in cytokines release were caused by disease or were 
associated with aging. 12ml of whole blood from volunteers was collected into 2.7ml 
vacutainers (BD Bioscience) containing sodium citrate (3.2%). 190µl of blood was 
aliquoted onto 96 well plate and treated with 10µl of the following agonists: 
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• TLR2/1 agonist- Pam3CSK4 (0.001-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.001-1 µg/ml) 
• TLR3 agonist- Poly I:C (0.01-10 µg/ml) 
• TLR4 agonist- LPS (0.001-1 µg/ml) 
• NOD1 agonist- C12-iE-DAP (0.001-1 µg/ml) 
• IL-1β (0.001-1 ng/ml) 
• Media (control) 
Cells were incubated at 37oC containing 5% CO2 for 24h. Plates were centrifuged at 
1000xg at room temperature for 5min with very low breaking. Serum was carefully 
transferred to the dummy plate and frozen at -20ºC for future analysis of IL-1β and CXCL8 
release by ELISA (as described in section 2.2.2). 
2.4 The Role of TLRs in lung cancer cells proliferation and survival. 
2.4.1. Cytokine release measurement from A549 cells. 
A549 cells were seeded at 1x104 cells/well in 96 well plates in media (with 10% FCS and 
0% FCS) and treated with: 
• TLR2/1 agonist- Pam3CSK4 (0.1-1 µg/ml) 
• TLR2/6 agonist FSL-1 (0.1-1 µg/ml) 
• TLR3 agonist- Poly I:C (0.1-10 µg/ml) 
• TLR4 agonist- LPS (0.01-1 µg/ml) 
• TLR7 agonist- Imiquimod (0.1-10 µg/ml) 
• TLR8 agonist- ssRNA40/Lyovec (0.1-10 µg/ml) 
• Media (control) 
After 24h, 48h, 78 and 144h supernatants were collected and frozen at -20ºC. ELISA was 
performed on the following day (section 2.2.2).  
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2.4.2. AlamarBlue assay. 
A549 cells were seeded in complete media at density 1x104 cells/per in 96 well plates and 
left overnight to become adherent. The next day, cell supernatant was aspirated and new 
culture medium containing stated concentrations of FCS (0-10%) was added. Cells were 
treated with the following agonists: 
• TLR2/1 agonist- Pam3CSK4 (0.01-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.01-1 µg/ml) 
• TLR3 agonist- Poly I:C (0.1-10 µg/ml) 
• TLR4 agonist- LPS (0.01-1 µg/ml) 
• TLR7 agonist- Imiquimod (0.1-10 µg/ml) 
• TLR8 agonist- ssRNA40/Lyovec (0.1-10 µg/ml) 
• Media (control) 
After 24h AlamarBlue reagent (Invitrogen) was added to each well (1/10th of the total 
volume in the well). Plate was incubated in the dark at 37ºC for 4h and cell viability was 
measured by reduction assay. This assay incorporates a specially selected oxidation-
reduction (REDOX) indicator that both fluoresces and undergoes colorimetric change in 
response to cellular metabolic reduction. The active ingredient of AlamarBlue (resazurin) 
is a nontoxic, cell permeable compound that is blue and nonfluorescent.  Upon entering 
cells, resazurin is reduced to resorufin, which produces very bright red fluorescence. 
Hence, cell viability can be monitored as reduction is accompanied by a measurable shift 
in color (blue to pink).  
2.4.3. Cell Cycle BioApplication (Cellomics). 
A549 cells were seeded in complete media at density 1x104 cells/per in 96 well plates and 
left overnight to become adherent. The next day, cell supernatant was aspirated and new 
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culture medium containing stated concentrations of FCS (0-10%) was added. Cells were 
treated with the following agonists: 
• TLR2/1 agonist- Pam3CSK4 (0.01-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.01-1 µg/ml) 
• Media (control) 
After, 24h, 48h and 72h cells were washed once in PBS and fixed immediately in 4% 
para-formaldehyde (PFA) for 10min at room temperature. PFA was removed and plates 
were then washed again in PBS and left for 5min. This step was repeated 3 times. Cell 
nuclei were stained with DAPI. Plates were then stored in PBS at  4°C prior to imaging 
using a Cellomics VTi HTS Arrayscanner (Thermo Fisher, Pittsburgh, US). This 
BioApplication is designed to classify cells and define cell cycle stage by measuring the 
nuclear DNA content using the total intensity of a DNA binding dye (DAPI) for each 
individual cell. Correspondingly, the cells are classified into one of five classes (Fig. 7): 
less than 2N (apoptotic/damaged), 2N (G1), 2N-4N (S), 4N (G2/M), and >4N (polyploid or 
necrotic). Cellomics arrayscanner is an automated fluorescence microscope that provides 
comprehensive data on the spatial and temporal distribution of fluorescence intensities in 
96-well plates. In these experiments the system scanned 49 fields per well. After adjusting 
the parameters for our cell type so that the camera was able to pick up individual cells and 
their nuclei distinctly, DNA content was measured using fluorescent intensity recorded on 
a camera. This fluorescence was characteristically bimodal and corresponded to the cell 
cycle position for individual cells. To corroborate findings of this system, individual capture 
frames were looked at by eye and compared with the automated readouts. 
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Figure 7. Schematic of the total fluorescence intensity distribution from the DNA 
binding dye and the corresponding populations of cells in the different cell cycle 
phases. 
2.4.4. CyQuant Assay. 
A549 cells were seeded in complete media at density 1x104 cells/per in 96 well plates and 
left overnight to become adherent. On the following day media from half of the plate was 
removed and replaced with media without FCS. Cells were treated with the following 
agonists: 
• TLR2/1 agonist- Pam3CSK4 (0.01-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.01-1 µg/ml) 
• TLR4 agonist- LPS (0.01-1 µg/ml) 
• TLR8 agonist- ssRNA40/Lyovec (0.1-10 µg/ml) 
• Media (control) 
After, 24h, 48h and 72h CyQuant cell proliferation assay (Invitrogen, San Diego, USA) 
was performed following the instruction provided by the manufacturer. A solution of 
CyQuant GR dye, which exhibits strong fluorescence enhancement when bound to 
cellular nucleic acids, was made in cell lysis buffer prior to each experiment. Cells were 
lysed using a freeze-thaw cycle, frozen at -80oC and thawed at room temperature. 200µl 
of Cyquant GR dye/lysis buffer was added to each well. The samples were incubated in 
darkness for 2 to 5min. The fluorescence of each sample was at 485nm excitation and 
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530nm emission filters. For each experiment, a DNA standard curve was prepared from 
bacteriophage λ DNA that was provided with the assay. The DNA content of samples was 
calculated using the standard curve generated each time. 
 
 
Figure 8. Example of standard curve used for CyQuant proliferation assay. 
Fluorescence was read at 485nm excitation and 530nm emission filters. 
2.4.5. Cell viability assay. 
A549 cells were seeded in complete media at density 1x104 cells/per in 96 well plates and 
left overnight to become adherent. The next day, cell supernatant was aspirated and new 
culture medium containing stated concentrations of FCS (0-10%) was added. Cells were 
treated with the following agonists: 
• TLR2/1 agonist- Pam3CSK4 (0.01-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.01-1 µg/ml) 
• TLR4 agonist- LPS (0.01-1 µg/ml) 
• Media (control) 
After 4h cells were treated with apoptotic agents: 
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• Cycloheximide (3µg/ml) 
• TNF-α (3ng/ml)  
• H2O2 (0.6 mM)  
• TNF-α+CHX  (3ng/ml+3µg/ml) 
• Media (control) 
Alamar Blue assay was performed 24h later as described in the section 2.4.2. 
2.4.6. Flow Cytometry. 
Annexin V and propidium iodide (PI) can be used to quantitatively determine the 
percentage of cells that undergo apoptosis within a population. During the apoptosis, the 
membrane phospholips phosphatidylserine (PS) is translocated to the outer leafleat 
exposing PS to external environment. Annexin V is a phospholipid-binding protein that has 
high affinity to PS and PI can bind nucleic acid therefore, these two markers can be used 
to distinguish viable cells from apoptotic/dead ones. Cells that stain positive for both 
annexin V and PI are apoptotic or dead and cells that stain negative for both annexin V 
and PI are alive and not undergoing measurable apoptosis. For FACS analysis A549 cells 
were harvested after treatment and washed twice with media containing 10% FCS. After 
final wash with cold PBS and centrifuging at 200xg for 5min at room temperature, cells 
were resuspended in the binding buffer and 100µl of cells at density 105 cells/tube were 
transferred to a 5ml FACS tube. Cells were filtered through a mesh cloth to discriminate 
doublets and 5µl of annexin V and PI were added to the each tube. After 15min incubation 
in the dark at room temperature, 400µl of binding buffer was added to each tube and cells 
were analysed on FACS Canto II machine.  The emission/excitation wavelengths were 
530/488 nm for annexin V FITC and 650nm/488nm for PI, according to the manufacturer’s 
specifications of wavelength combinations. Data were analysed by FACS Diva software. 
Cells were classified as: annexin V and PI negative (viable, with no measurable 
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apoptosis), annexin V positive and PI negative (early apoptosis, membrane integrity is 
present), annexin V and PI positive (late apoptosis and death). 
2.4.7. Apoptotic agents concentration curves. 
A549 cells were seeded in complete media at density 3x105 cells/well in 6 well plates and 
left overnight to become adherent. The next day, cells were treated with the following 
apoptotic agents: 
• TRAIL (50-1000 ng/ml) 
• Cycloheximide (1-100 µg/ml) 
• TNF-α (15ng/ml) + Cycloheximide (1-100 µg/ml) 
• Cycloheximide (1µg/ml) + TNF- α (1-20 ng/ml) 
• Media (control) 
After 24h cells were harvested and stained with annexin V and PI and subjected to FACS 
analysis.  
2.4.8. Stimulation of TLRs and apoptosis 
A549 cells were seeded in complete media at density 3x105 cells/per in 6 well plates and 
left overnight to become adherent. The next day, cells were treated with the following 
agonists: 
• TLR2/1 agonist- Pam3CSK4 (0.01-1 µg/ml) 
• TLR2/6 agonist- FSL-1 (0.01-1 µg/ml) 
• TLR4 agonist- LPS (0.01-1 µg/ml) 
• TLR3 agonist- Poly I:C (0.1-10 µg/ml) 
• TLR7 agonist- Imiquimod (0.1-10 µg/ml) 
• TLR8 agonist ssRNA40\Lyovec (0.1-10 µg/ml) 
After 4h the following apoptotic agents were added: 
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• TRAIL (1000ng/ml) 
• TNF-α (15ng/ml) + Cycloheximide (1µg/ml) 
• Media (control) 
After 24h cells were harvested and stained with annexin V and PI and subjected to FACS 
analysis.  
2.5. Statistical analysis. 
All statistical tests were performed using GraphPad Prism 4 software. Results are 
expressed as the mean ± standard error (S.E.M). We used one-way ANOVA to compare 
the means of several different groups with one independent variable, and the two-way 
ANOVA to compare the means of two or more different groups with more than one 
independent variable. Dunnett's post-test was used when all groups were compared 
against one control group and Bonferroni’s post-test was used when multiple comparisons 
were made between selected columns. We also used column analysis with one-sample t-
test for normalized data. Differences at a probability value (P) of ≤0.05 were considered 
as significant. 
2.6. Reagents. 
All cell culture plastics, general disposables and enzyme linked immunosorbent assay 
(ELISA) plates were obtained from Fisher Scientific. Unless stated otherwise, all cell 
culture reagents were supplied by Invitrogen. General laboratory reagents were purchase 
from Sigma-Aldrich. Agonists for TLRs were obtained from Sigma and Invivogen unless 
stated otherwise. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  























	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





Pharmacology of TLR2 and TLR4 agonists on IL-1β and CXCL8 
release by human monocytes and peripheral blood mononuclear 
cells. 
Rationale 
IL-1β and CXCL8 are pro-inflammatory cytokines that play a critical role in innate and 
adaptive immunity. CXCL8  is a major chemoattractant for the recruitment of neutrophilic 
granulocytes and is secreted by endothelial cells, fibroblasts and local immune cells [147].  
IL-β is a pro-inflammatory cytokine and its secretion is tightly controlled [148]. The release 
of IL-1β requires two well-defined signals: a “priming signal” to induce pro-IL-1β synthesis, 
and a second signal to trigger assembly of the inflammasome. The induction of pro-IL-1β 
is under regulation of NF-κB and it occurs upon activation of TLRs, whilst inflammasome 
assembly is associated with a number of highly varying stimuli, including ATP [1]. The 
P2X7 receptor is an ion channel gated by high concentrations of extracellular ATP, and it 
has been demonstrated to be responsible for ATP-mediated processing and the release of 
IL-1β from LPS primed cells [149]. Panx1 exists as a transmembrane channel allowing the 
passage of ions and small molecules. It is upregulated by LPS stimulation and it co-
immunoprecipitates with P2X7R. Inhibition of panx1 with siRNA blocked caspase-1 
cleavage as well as IL-1β processing and release from a repertoire of LPS-primed mouse 
and human macrophages in response to P2X7R activation [150]. Recently, a role for 
TLRs in inflammasome activation and IL-1β release has been identified. For example, 
stimulation of TLR4 on monocytes or macrophages by LPS results in the induction of pro-
IL-1β synthesis. The second step of activation of the inflammasome and subsequent 
release of bioactive IL-1β is governed by other factors as previously mentioned. Less is 
known regarding the effect of TLR2 ligands on the release of IL-1β. Thus in the present 
study we hypothesised that there are differences in TLR2 and TLR4-induced 
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inflammasome activation and subsequent release mature IL-1β release. Since TLRs and 
the inflammasome are now highly implicated in respiratory disease, such as COPD [111], 
we performed a study where we have directly characterized the signalling pathways in 
TLR4 versus TLR2 induced release of IL-1β. In the present study we stimulated THP-1 
cells and PBMCs with TLR ligands and measured the levels of CXCL8 and IL-1β. We also 
inhibited components of TLR and inflammasome signalling pathways and knocked-down 
panx1 and P2X7R genes using siRNA to investigate whether there are any differences 
between TLR2 and TLR4-induced release of CXCL8 and IL-1β. TIR domains of TLRs are 
composed of five β-strands alternating with five α-helices. A functionally important proline-
glycine combination that is highly conserved among TIR domains is located in the loop 
connecting the second β-strand with the second helix, the “BB loop”. In our study we used 
Myd88 and TRIF BB loop inhibitory peptides which block MyD88 signalling by inhibiting its 
homodimerization through binding, and which block TRIF signalling by interfering with 
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For the experiments in this chapter, THP-1 cells and PBMCs were cultured in 96 well 
plates as described in chapter 2.1. Cells were treated in sterile conditions with: 
• TLR agonists (LPS, Pam3CSK4, FSL-1, Poly I:C) with or without ATP pulse. 
• TLR signalling and inflammasome inhibitors 30min prior to TLR2 and TLR4 
activation with Pam3CSK4, FSL-1 and LPS. 
• siRNA to knock-down P2X7R and panx1 48h prior to TLR activation with LPS and 
Pam3CSK4. 
• Myd88, TRIF and Myd88/TRIF inhibitory peptides 6h prior treatment with LPS, 
Pam3CSK4, FSL-1 and CSE. 
Cells were incubated for 24h after which media was removed and stored at -20°C for 
future analysis. IL-1β, CXCL8 and CXCL10 levels were measured by ELISA as described 
in chapter 2.2.2. 100µl of fresh media and 10µl of AlamarBlue solution was added to the 
cells to measure cell viability/respiration (see chapter 2.4.2. for further details of methods) 
For the knock-down experiments, THP-1 cells were cultured in 96 well plates. P2X7R, 
pannexin-1 or control siRNA were added to the media and cells were transfected using 
the Amaxa Nucleofector system (Lonza), according to the manufacturer’s protocol. 
Transfection efficiency was analysed by PCR. IL-β and CXCL8 levels were measured by 
ELISA according to the protocol furnished by the manufacturer. More details of the 
methods are described in materials and methods chapter and in figure legends in the 
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3.1. Effect of TLR stimulation on IL-1β and CXCL8 release from THP-1 cells.	   
THP-1 monocytes upon stimulation with TLR2/1 agonist Pam3CSK4, TLR2/6 agonist FSL-
1 and TLR4 agonist LPS produced measurable quantities of IL-1β after either 3h or 24h 
(Fig. 9A,B). In contrast, TLR3 agonist Poly I:C failed to result in the release of significant 
levels of IL-1β from THP-1 cells. These agonists also caused a concentration-dependent 
increase in CXCL8 levels after 24h (Fig. 10A), it is worth noting that non of the TLR 
ligands tested release CXCL8 at 3h (data not shown). This is not surprising as in previous 





















































Figure 9. Mature IL-1β release from THP-1 cells in response to LPS, Pam3CSK4 and 
FSL-1. THP-1 monocytes were seeded in a 96 well plates at 1 x 105 cells per well in RPMI 
with 10% FCS and allowed to equilibrate for 12h. After this time period cells were treated 
with media, Pam3CSK4, FSL-1 and Poly I:C for 3h (A) and 24h (B). IL-1β was measured 
in the supernatants by ELISA. Data represented are the mean ± SEM of a total of n=9 
replicates from 3 experimental days. *denotes p≤ 0.05 as assessed using a one-way 
ANOVA followed by a Dunnett’s multiple comparison post-hoc test.  
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3.2. Role of ATP in IL-1β release from human monocytes stimulated with TLR2 and 
TLR4 ligands. 
It has recently been documented that monocytes, unlike macrophages, are capable of 
releasing IL-1β in response to TLR activation alone, as they release sufficient endogenous 
ATP to stimulate NLRP3 inflammasome assembly [151]. ATP, via P2X7 receptors, opens 
a pannexin pore, which leads to assembly and activation of the inflammasome. For this 
reason ATP was added in selected protocols. Cells were stimulated with PAMPs followed 
by a 30min pulse with exogenous ATP. When THP-1 monocytes were pre-stimulated for 
3h and 24h with Pam3CSK4, FSL-1 or LPS, followed by 30 min ATP pulse (1mM or 5mM), 
we observed a significant increase in IL-1β release compared with media pulsed cells 
(Fig. 11).  




























Figure 10. CXCL8 release from THP-1 cells in response to LPS, Pam3CSK4 and FSL-
1. THP-1 monocytes were seeded in a 96 well plates at 1 x 105 cells per well in RPMI with 
10% FCS and allowed to equilibrate for 12h. After this time period cells were treated with 
media, Pam3CSK4, FSL-1 and Poly I:C for 24h. CXCL8 release was measured in the 
supernatants by ELISA. Data represented are the mean ± SEM of n=9 replicates from 3 
experimental days. *denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a 
Dunnett’s multiple comparison post-hoc test.  
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Figure 11. The effect of ATP pulse on the release of IL-1β in human monocytes after 
PAMP stimulation. THP-1 monocytes were seeded in a 96 well plates at 1 x 105 cells per 
well in RPMI with 10% FCS and allowed to equilibrate for 12h. After this time period cells 
were treated with media, LPS (1 µg/ml), FSL-1 (1 µg/ml) and Pam3CSK4 (1 µg/ml) for 24h 
after which media was removed and cells were pulsed for 30 min with either ATP or fresh 
media. IL-1β release was measured by ELISA after 3h (A) and 24h (B). Data represented 
are the mean ± SEM of a total of n=9 replicates from 3 experimental days. *denotes p≤ 
0.05 as assessed using a one-way ANOVA followed by a Bonferroni’s multiple 
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3.3. Effect of signalling inhibitors on TLR2 and TLR4-induced IL-1β release by THP-
1 monocytes.  
To investigate whether there is any difference between TLR2 and TLR4-induced IL-1β 
release, we treated THP-1 cells with increasing concentrations of TLR signalling inhibitors, 
30min prior to activation with LPS, Pam3CSK4 and FSL-1. All of the inhibitors that we 
used (Prednisone, p38, IKK and TAK-1 inhibitors) significantly reduced cytokine release 
with no difference observed between TLR4 and TLR2 signalling pathway (Fig. 12). The 
only difference that we noted was the potency and efficacy of the drugs to reduce IL-1β 
release. To determine whether inhibition of cytokine release was caused by the toxicity of 
the drug and/or cell death, we performed an AlamarBlue assay to measure cell 
respiration/viability. Our results showed that using the top concentration of TAK-1 inhibitor 
5Z-7, caused a significant reduction in THP-1 respiration/viability and it might have been 
the cause of IL-1β reduction (Tab. 2). 
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Figure 12. Effect of signalling inhibitors on TLR2 and TLR4 induced IL-1β release from 
THP-1 cells. THP-1 cells were seeded in a 96 well plates at 1 x 105 cells per well in RPMI 
with 10% FCS and allowed to equilibrate for 12h. After this time period cells were treated 
with increasing concentration of Prednisone (A-C), SC-514 (D-F), 5Z-7 (G-I) and BIRB (J-L). 
After 0.5h, LPS (0.1µg/ml), Pam3CSK4 (0.1µg/ml) and FSL-1 (0.1µg/ml) were added. IL-1β 
release was measured by ELISA after 24h. Data represented are the mean ± SEM of n=9 
replicates measured over 3 separate experimental days. *denotes p≤ 0.05 as assessed 
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3.4. Effect of inflammasome inhibitors on TLR2 and TLR4-induced IL-1β release by 
THP-1 monocytes.  
TLR ligands induce activation of NF-κB and trigger the gene expression and synthesis of 
pro-IL-1β. Conversion of pro-IL-1β to its active form requires activation of caspase-1 and a 
second stimulus to induce the formation of the inflammasome. Inflammasome assembly is 
associated with a number of highly varying stimuli which include ATP.  To determine 
whether there are any differences between TLR2 and TLR4-induced IL-1β release, we 
used three inhibitors of inflammasome activation. Caspase-1 inhibition reduced IL-1β 
release after TLR2 and TLR4 stimulation with no differences seen between the two 
pathways (Fig. 13A,B, C). P2X7 inhibition (Fig. 13D,E,F) caused a decrease in cytokine 
secretion in TLR2 stimulated cells. After LPS stimulation there was a reduction in IL-1β 
only when the highest concentration of the inhibitor was used. Interestingly, pannexin-1 
inhibition (Fig.13G,H,I) reduced IL-1β production only after TLR2 stimulation showing that 
TLR4 pathway does not require pannexin-1 in the absence of exogenous ATP (Fig. 13G). 
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Figure 13. Effect of inflammasome inhibitors on TLR2 and TLR4 induced IL-1β release 
from THP-1 cells. THP-1 cells were seeded in a 96 well plates at 1 x 105 cells per well in 
RPMI with 10% FCS and allowed to equilibrate for 12h. After this time period cells were 
treated with increasing concentration of Z-VAD-FMK (A-C), AZ 11645373 (D-F) and 
Carbenoxolone (G-I). After 0.5h, LPS (0.1µg/ml), Pam3CSK4 (0.1µg/ml) and FSL-1 
(0.1µg/ml) were added. IL-1β release was measured by ELISA after 24h. Data represented 
are the mean ± SEM of n=9 replicates measured over 3 separate experimental days. 
*denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s multiple 
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3.5. Effect of signalling inhibitors on TLR2 and TLR4-induced CXCL8 release by 
THP-1 monocytes.  
We performed the same experiments as previously, but we measured CXCL8 release 
instead of IL-1β. All inhibitors that we used caused significant reduction of CXCL8 
production by THP-1 monocytes (Fig. 14A–L). Although there were some differences in 
the potency and efficacy of the drugs, we did not observe any difference in activation 
between the TLR2 and TLR4 pathways. The top concentration of TAK-1 inhibitor again 
caused a significant reduction in cell viability/respiration (Tab. 2).  
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Figure 14. Effect of signalling inhibitors on TLR2 and TLR4 induced CXCL8 release 
from THP-1 cells. THP-1 cells were seeded in a 96 well plates at 1 x 105 cells per well in 
RPMI with 10% FCS and allowed to equilibrate for 12h. After this time period cells were 
treated with increasing concentration of Prednisone (A-C), SC-514 (D-F), 5Z-7 (G-I) and 
BIRB (J-L). After 0.5h, LPS (0.1µg/ml), Pam3CSK4 (0.1µg/ml) and FSL-1 (0.1µg/ml) were 
added. CXCL8 release was measured by ELISA after 24h. Data represented are the mean ± 
SEM of n=9 replicates measured over 3 separate experimental days. *denotes p≤ 0.05 as 
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3.6. Effect of inflammasome inhibitors on TLR2 and TLR4-induced CXCL8 release 
by THP-1 monocytes.  
CXCL8 release was slightly reduced after treating THP-1 monocytes with caspase-1 and 
P2X7 inhibitors but we did not observed a concentration dependent inhibition (Fig. 15B,F). 
CXCL8 release was slightly increased after pre-incubation with the P2X7 receptor inhibitor 
in LPS-primed monocytes and it showed as statistical significant but we think that this may 
be due to off target effects of AZ11645373 (Fig. 15A,D,H). Our results indicated that 
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Figure 15. Effect of inflammasome inhibitors on TLR2 and TLR4 induced CXCL8 
release from THP-1 cells. THP-1 cells were seeded in a 96 well plates at 1 x 105 cells per 
well in RPMI with 10% FCS and allowed to equilibrate for 12h. After this time period cells 
were treated with increasing concentration of Z-VAD-FMK (A-C), AZ 11645373 (D-F) and 
Carbenoxolone (G-I). After 0.5h, LPS (0.1µg/ml), Pam3CSK4 (0.1µg/ml) and FSL-1 
(0.1µg/ml) were added. CXCL8 release was measured by ELISA after 24h. Data 
represented are the mean ± SEM of n=9 replicates measured over 3 separate experimental 
days. *denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s 
multiple comparison post-hoc test.  
	  
A                                           B                                                          C 
D                                           
5E                                            
5F 
E                                           
5E                                              
5F 
F                                           
5E                                              
5F 
G                                           H                                                          I 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





3.7. Effect of signalling inhibitors on TLR2 and TLR4-induced IL-1β release by 
PBMCs.  
To give clinical relevance and to assess our model, experiments in THP-1 cells were 
repeated in freshly isolated PBMCs. We chose inhibitors where differences were found 
between TLR2 and TLR4-mediated cytokines release. We stimulated cells only with LPS 
and Pam3CSK4, but not FSL-1, as there was no difference between TLR2/1 and TLR2/6-
mediated responses in THP-1 cells. PBMCs were less sensitive to TLR stimulation than 
THP-1 cells and the response to LPS was much greater than to Pam3CSK4. We observed 
a reduction in IL-1β release after inhibition of p38 (Fig. 16A,B), caspase-1 (Fig. 16E,F) 
and P2X7 (Fig. 16G,H) with no difference between TLR2 and TLR4. Similarly to THP-1 
cells there was significant inhibition after pre-incubation with inhibitors of pannexin-1 (Fig. 
16I,J), where we observed a reduction in TLR2 but not TLR4-induced IL-1β release. The 
same effect was seen after inhibition of IKK (Fig. 16C,D) which is probably associated 
with late NF-κB activation after LPS stimulation and recruitment of TRAM protein. We also 
observed a very small decrease in cell viability induced by the highest concentration of Z-
VAD-FMK and AZ. However, unlike the effects on CXCL8, this effect was not 
concentration dependent and therefore unlikely to account for the inhibitory effects of 
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Figure 16. Effect of signalling inhibitors on TLR2 and TLR4 induced IL-1β  release from 
PBMCs. Freshly isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in 
RPMI with 10% FCS and allowed to equilibrate for 12h. After this time period cells were 
treated with increasing concentration of BIRB (A,B), SC-514 (C,D), Z-VAD-FMK (E,F), AZ 
11645373 (G,H) and Carbenoxolone (I,J). After 0.5h, LPS (1µg/ml) or Pam3CSK4 (1µg/ml) 
were added. IL-1β release was measured by ELISA after 24h. Data represented are the 
mean ± SEM of n=12 replicates from 6 separate donors. *denotes p≤ 0.05 as assessed 
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3.8. Effect of signalling inhibitors on TLR2 and TLR4-induced CXCL8 release by 
PBMCs.  
CXCL8 release was decreased only after p38 inhibition (Fig. 17A,B). Surprisingly, we did 
not observe any reduction after pre-incubation with the IKK inhibitor (Fig. 17C,D). All other 
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Figure 17. Effect of signalling inhibitors on TLR2 and TLR4 induced CXCL8 release 
from PBMCs. Freshly isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per 
well in RPMI with 10% FCS and allowed to equilibrate for 12h. After this time period cells 
were treated with increasing concentration of BIRB (A,B), SC-514 (C,D), Z-VAD-FMK (E,F), 
AZ 11645373 (G,H) and Carbenoxolone (I,J). After 0.5h, LPS (1µg/ml) or Pam3CSK4 
(1µg/ml) were added. CXCL8 release was measured by ELISA after 24h. Data represented 
are the mean ± SEM of n=12 replicates from 6 separate donors. *denotes p≤ 0.05 as 
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3.9. IL-1β release after P2X7 and pannexin-1 knock down in THP-1 cells.  
	  Previous experiments showed that there is a difference between TLR2 and TLR4-induced 
IL-1β release, where the TLR2 but not the TLR4 pathway involved panx1. To verify our 
results we knocked down panx1 and P2X7 genes using siRNA. After 48h, Pam3CSK4 and 
LPS were added to THP-1 cells, Il-1β levels were measured after 24h incubation. Gene 
knock down was confirmed using RT-PCR (Fig. 19A) and cell viability was measured using 
trypan blue exclusion (Fig. 19B). Our results were consistent with results we obtained using 
P2X7 and pannexin-1 inhibitors in PBMCs and THP-1 cells. We demonstrated that when we 
knock down panx1 gene, levels of IL-1β decreased after TLR2 but not TLR4 stimulation, 
suggesting that TLR2-induced IL-1β release requires panx1 (Fig. 18B). IL-1β levels were 
reduced by 50%, which corresponded with a decrease in panx1 mRNA levels (Fig. 19A). 





































Figure 18. Effect of P2X7 and pannexin-1 knock down on TLR2 and TLR4 induced IL-
1β release from THP-1 cells. THP-1 cells were transfected with 100µM of siRNA using 
Amaxa Nucleofector system. Cells were seeded in 96 well plates at 1 x 105 cells per well in 
RPMI with 10% FCS. After 48h LPS (A) and Pam3CSK4 (B) were added to the cells. ELISA 
was performed after 24h incubation. Data represented are the mean ± SEM of n=15 
replicates over 3 experimental days. *denotes p≤ 0.05 as assessed using a one-way 
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Figure 19. Cell viability and gene expression after siRNA transfection. THP-1 cells 
were transfected with 100µM of siRNA using Amaxa Nucleofector system. Cells were 
seeded in 96 well plates at 1 x 105 cells per well in RPMI with 10% FCS. After 48h cell 
viability was measured by the AlamarBlue assay (A) and RNA was extracted for future 
analysis. Gene expression was measured by RT-PCR (B). Data represented are the mean 
± SEM of n=3 replicates over 3 experimental days. *denotes p≤ 0.05 as assessed using a 
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3.10. IL-β release after activation of adaptor proteins in response to PAMPs. 
TLR4 unlike TLR2 upon stimulation with PAMPs was shown to activate Myd88-dependent 
and TRIF-dependent signalling pathways. Stimulation of PBMCs with LPS (Fig. 20A) 
induced much higher response in IL-1β release than with Pam3CSK4 (Fig. 20B). To 
investigate whether activation of TRIF can induce inflammasome assembly, we decided to 
stimulate Myd88, TRIF and both pathways together to measure IL-1β levels in 
supernatants. LPS (Fig. 20A) was the best agonist to induce IL-1β release, but 
Pam3CSK4 (Fig. 20B), Poly I:C (Fig. 20C) and FSL-1 (Fig. 20D) activation also produced 
significant amounts of IL-1β when stimulated with the highest concentration of ligands. 
When we treated PBMCs with Pam3CSK4 (activates Myd88) or FSL-1 (activates Myd88) 
together with Poly I:C (activates TRIF), we observed a significant increase in IL-1β 
production but the release was not as high as after stimulation with LPS alone (Fig. 20 
E,F). My data suggests that in the presence of Poly I:C, LPS is a more potent activator of 
IL-1β release than either Pam3CSK4 or FSL-1. This could be due to differences in the 
signalling between TLR adaptor protein pathways for TLR4 and TLR2. For example, 
TLR4, but not TLR2, signalling is associated with TRAM. 
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Figure 20. IL-β release after activation of Myd88 and TRIF in response to PAMPs. 
Freshly isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in RPMI 
with 10% FCS and allowed to equilibrate for 12h. After this time period cells were treated 
with LPS alone (A), Pam3CSK4 alone (B), Poly I:C alone (C), FSL-1 alone (D), 
Pam3CSK4+Poly I:C (E) and FSL-1+Poly I:C (F). IL-1β release was measured by ELISA 
after 24h. Data represented are the mean ± SEM of n=6 replicates from 3 separate donors. 
*denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s multiple 
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3.11. CXCL8 release after activation of adaptor proteins, Myd88 and TRIF in 
response to PAMPs. 
We also measured CXCL8 release and we observed significant increase after stimulation 
with LPS, Pam3CSK4, FSL-1 and Poly I:C. Activation of Myd88 and TRIF pathways 
simultaneously by TLR2 and TLR3 agonists did not cause an additive or synergistic effect 
in CXCL8 release (Fig. 21). 
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Figure 21. CXCL8 release after activation of Myd88 and TRIF in response to PAMPs. 
Freshly isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in RPMI 
with 10% FCS and allowed to equilibrate for 12h. After this time period cells were treated 
with LPS alone (A), Pam3CSK4 alone (B), Poly I:C alone (C), FSL-1 alone (D), 
Pam3CSK4+Poly I:C (E) and FSL-1+Poly I:C (F). CXCL8 release was measured by ELISA 
after 24h. Data represented are the mean ± SEM of n=6 replicates from 3 separate donors. 
*denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s multiple 
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3.12. IL-1β release after inhibition of Myd88 and TRIF adaptor proteins.  
To investigate further the role of adaptor proteins in inflammasome activation and IL-1β 
release, we used bb loop inhibitory peptides to block Myd88 and TRIF adaptor proteins. 
TIR domains of TLRs are composed of five β-strands alternating with five α-helices. A 
functionally important proline-glycine combination that is highly conserved among TIR 
domains is located in the loop connecting the second β-strand with the second helix, the 
“BB loop”. In our study we used Myd88 and TRIF BB loop inhibitory peptides which block 
MyD88 signalling by inhibiting its homodimerization through binding, and blocks TRIF 
signalling by interfering with TLR-TRIF interaction. 
After 6 hours we treated PBMCs with LPS, Pam3CSK4, Poly I:C and cigarette smoke 
extract (CSE) and we measured IL-1β, CXCL8 and CXCL10 release 24h later. We 
observed a significant increase in IL-1β release after treatment with LPS and Pam3CSK4. 
Poly I:C and CSE did not have any effect on cytokine production (Fig. 22A). Pre-treatment 
of cells with 10µM of Myd88, TRIF and both inhibitors together reduced LPS-induced IL-
1β production (Fig. 22C). When we treated PBMCs with Pam3CSK4 after pre-incubation 
with inhibitors, we observed a reduction in IL-1β production only when we used Myd88 
and TRIF peptides together (Fig. 22D). Pre-treatment of PBMCs did not have any effect 
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    A                                                  B 
Figure 22. IL-1β release after inhibition of Myd88 and TRIF adaptor proteins. Freshly 
isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in RPMI with 10% 
FCS and allowed to equilibrate for 12h. After this time period cells were treated with 10µM of 
inhibitors. After 6h LPS (C), Pam3CSK4 (D), Poly I:C (E) and CSE (F) were added. IL-1β 
release was measured by ELISA after 24h. Data represented are the mean ± SEM of n=6 
replicates from 3 separate donors. *denotes p≤ 0.05 as assessed using a one-way ANOVA 
followed by a Dunnett’s multiple comparison post-hoc test. (A) treatment with TLR agonists 
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Similar to IL-1β release only LPS and Pam3CSK4 significantly induced CXCL8 production 
while Poly I:C and CSE did not cause any effect (Fig. 23A). When we treated cells with 
LPS after pre-incubation with inhibitors we detected a decrease in CXCL8 production 
under all conditions used (Fig. 23E,C). Surprisingly, Pam3CSK4-induced CXCL8 release, 
which is not TRIF dependent, was reduced after pre-incubation with TRIF inhibitory 
peptide, suggesting that these inhibitors might be non-selective (Fig. 23D). These 
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  A                                                         B 
Figure 23. CXCL8 release after inhibition of Myd88 and TRIF adaptor proteins. Freshly 
isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in RPMI with 10% 
FCS and allowed to equilibrate for 12h. After this time period cells were treated with 10µM of 
inhibitors. After 6h LPS (C), Pam3CSK4 (D), Poly I:C (E) and CSE (F) were added. CXCL8 
release was measured by ELISA after 24h. Data represented are the mean ± SEM of n=6 
replicates from 3 separate donors. *denotes p≤ 0.05 as assessed using a one-way ANOVA 
followed by a Dunnett’s multiple comparison post-hoc test.  (A) treatment with TLR agonists 
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3.14. CXCL10 release after inhibition of Myd88 and TRIF adaptor proteins. 
Only Poly I:C induced significant release of CXCL10 (Fig. 24A) but pre-incubation with 
inhibitory peptides did not have any effect on this cytokine production. We observed an 
increase in CXCL10 after pre-incubation with Myd88 inhibitor after LPS and CSE 
treatment (Fig. 24C,D). 
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• THP-1 monocytes 
Figure 24. CXCL10 release after inhibition of Myd88 and TRIF adaptor proteins. Freshly 
isolated PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in RPMI with 10% 
FCS and allowed to equilibrate for 12h. After this time period cells were treated with 10µM of 
inhibitors. After 6h LPS (C), Pam3CSK4 (D), Poly I:C (E) and CSE (F) were added. CXCL10 
release was measured by ELISA after 24h. Data represented are the mean ± SEM of n=6 
replicates from 3 separate donors. *denotes p≤ 0.05 as assessed using a one-way ANOVA 
followed by a Dunnett’s multiple comparison post-hoc test. (A) treatment with TLR agonists 
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Table 2. Effect of signalling inhibitors on cell viability/respiration. THP-1 cells were 
seeded in a 96 well plates at 1 x 105 cells per well in RPMI with 10% FCS and allowed to 
equilibrate for 12h. After this time period cells were treated with increasing concentration 
of inhibitors. Cell viability was measured by the AlamarBlue assay after 24h. Data 
represented are the mean ± SEM of n=6 replicates from 3 separate experiments *denotes 
p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s multiple 
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Table 3. Effect of signalling inhibitors on cell viability/respiration. Freshly isolated 
PBMCs were seeded in a 96 well plates at 1 x 105 cells per well in RPMI with 10% FCS 
and allowed to equilibrate for 12h. After this time period cells were treated with increasing 
concentration of inhibitors. Cell viability was measured by the AlamarBlue assay after 24h. 
Data represented are the mean ± SEM of n=6 replicates from 3 separate experiments. 
*denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s multiple 
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Aberrant inflammasome activation has been linked to a number of hereditary 
cryopyrinopathies such as familial cold autoinflammatory syndrome, Muckle-Wells 
syndrome and chronic infantile neurologic cutaneous articular syndrome. Blood 
monocytes from patients with these disorders release more IL-1β than monocytes from 
unaffected controls and mutation of NLRP3 gene has also been found [152]. Recent study 
by Eltom et al. using either a selective P2X7 inhibitor or P2X7 knockout mice has also 
shown a temporal correlation between markers of the P2X7/inflammasome pathway 
activation and airway inflammation [111]. Thus, there is an increased interest in the 
biology of IL-1β as a potential target for inflammatory disease. The role of TLR receptors 
in inflammasome activation has been described previously (Chapter 1, section 1.5) but the 
exact mechanism of inflammasome activation is not fully understood. A number of 
questions remain surrounding the events that occur upstream of NLRP activation and it is 
important to answer them for future development of drugs that will make them more 
effective and specific for the treatment of inflammation. In the current study we have 
confirmed the work of others by demonstrating that LPS, Pam3CSK4 and FSL-1 activate 
human THP-1 monocytes to release IL-1β. IL-1β release by these agonists occurred 
independently of additional ATP. However, IL-1β levels could be elevated further when 
ATP was added exogenously. This is wholly consistent with what is known for LPS-
induced IL-1β release from these cells [151]. As with other cytokines, including CXCL8 
[153] we show here that TLR2 and TLR4 signalling also induce CXCL8 release over 24h. 
We also found that activation of TLR3 with Poly I:C did not induce IL-1β and CXCL8 
release from THP-1 monocytes.  
To investigate TLR2 vs TLR4-induced IL-1β and CXCL8 release, we used TLR signalling 
pathway inhibitors and measured cytokine release after 24h. We observed a decrease in 
CXCL8 levels after inhibition of IKK, TAK-1 and p38, suggesting that all these proteins are 
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involved in the release of this cytokine. Prednisone which inhibits transcription of 
inflammatory mediators also reduced CXCL8 release form THP-1 cells. However, there 
was no difference between TLR2 and TLR4 pathways. Inflammasomes are not involved in 
CXCL8 production and it was not surprising that we did not observed any decrease after 
treatment of THP-1 cells with inhibitors of components of the inflammasome (caspase-1, 
P2X7 and pannexin-1). We obtained different results after IL-1β measurements. Again 
there was a decrease in IL-1β release after inhibition of TLR signalling pathway (IKK, 
TAK-1, p38) and after steroid treatment and there was no difference between TLR2 and 
TLR4. IL-1β levels were reduced after caspase-1 inhibition, which is responsible for the 
cleavage of pro-IL-1β to mature IL-1β. P2X7 receptor inhibition also caused a decrease 
after TLR2 stimulation, whereas only the highest dose of this inhibitor reduced TLR4 
stimulation with LPS. The most interesting results we obtained after inhibition of pannexin-
1, where there was a reduction of IL-1β levels after TLR2 but not after TLR4 activation. 
We decided to perform the same experiment on primary mononuclerar cells freshly 
isolated from blood as there are sometimes differences in the responses from cell lines 
and primary cells. In terms of CXCL8 release, we obtained the same results as was seen 
in THP-1 cells after stimulation with TLR2 and TLR4 agonist followed by inhibition with 
components of the TLR signalling pathway. The only difference seen was after IKK 
inhibition where we did not observe a reduction in CXCL8 release. One possible reason 
for this might be that the release of CXCL8 is also under the regulation of the transcription 
factor AP-1. It is interesting to note that the signalling pathways leading to NF-κB and AP-
1 activation overlap and both are involved in the induction and regulation of cytokines 
[154]. NF-κB and AP-1 transcription factors binding sites have been identified in the 
promoter region of CXCL8 [155] and the effect we have seen in PBMCs might be due to 
the activation of AP-1 [146]. As with THP-1 cells there was no reduction in levels of 
CXCL8 after inhibition of inflammasome assembly components in PBMCs. Regarding IL-
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1β release, we observed a reduction after p38 inhibition, however no differences between 
TLR2 and TLR4 activation were observed. However, when we blocked IKK with SC-514, 
we observed a decrease after TLR2 but not TLR4 stimulation. In comparison to early 
activation, late activation of NF-κB and the induction of type I IFNs following TLR4 
activation with LPS, have been demonstrated to utilize different adaptor proteins. TRIF 
was identified to be the adaptor protein responsible for MyD88-independent pathway 
activation by TLR4 [24]. Importantly TRIF also has the ability to activate NF-kB and the 
IFNβ promoter. The difference between TLR2 and TLR4-induced IL-1β release might be 
explained by late NF-κB activation after TRIF recruitment by TLR4 [156]. After inhibition of 
inflammasome activation pathway components, a decrease in IL-1β release was observed 
after caspase-1 and P2X7R blockage. Once again the most interesting effect was seen 
after pannexin-1 inhibition with carbenoxolone. Our results showed that similarly to THP-1 
cells, there was a reduction in IL-1β levels after TLR2 but not TLR4 activation. To confirm 
our results by a different approach we used siRNA to knock down P2X7R and panx1 
genes in THP-1 cells. This also resulted in a reduction in IL-1β release after TLR2 but not 
TLR4 activation. P2X7 receptor is an ion channel gated by high concentrations of 
extracellular ATP which are known to be present at sites of injury and inflammation.  Its 
activation not only opens a ‘typical' ion channel selective for small cations but also leads 
to the gradual opening of a larger pore that allows passage of molecules up to 900 Da 
[149]. Pannexin-1 is one of three vertebrate pannexins that show homology to gap 
junction-forming invertebrate innexins [157]. Pannexin-1 is expressed broadly, whereas 
pannexin-2 is expressed largely in brain, and pannexin-3 is in skin and connective tissues 
[158]. A study by Pelegrin et al. showed that panx1 was highly expressed in human and 
mouse macropgahes and it was upregulated by LPS. It also co-immunoprecipitated with 
P2X7 protein. Inhibition of panx1 by siRNA and inhibitory peptide, reduced P2X7R-
mediated dye uptake without altering P2X7 protein expression. It also blocked caspase-1 
cleavage as well as IL-1β processing and release from LPS-primed mouse and human 
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macrophages [150]. Pannexin-1 dependent pore formation has been suggested as a 
mechanism for IL-1β secretion after cleavage of pro-IL-1β by caspase [150, 159], as IL-1β 
lacks signal sequences for export via the classical endoplasmic reticulum/Golgi dependent 
secretory pathway [160]. It should be noted that most of the investigators studying the 
inflammasome accelerate the cleavage of the IL-1β precursor by shocking cells with 
millimolar concentrations of ATP. Primary monocytes from patients with Still’s disease or 
neonatal onset multi-inflammatory disease secrete significantly more IL-1β whether in a 
resting state, or after endotoxin stimulation during a 24h culture without the addition of 
ATP [161, 162]. ATP can also accumulate in the extracellular space at sites of 
inflammation where it is thought to activate pannexin-1. The role of pannexin-1 in IL-1β 
release in the absence of exogenous ATP has yet to be established in primary human 
monocytes [163]. Our results showed that IL-1β release is enhanced by exogenous ATP, 
but ATP is not required in this system for IL-1β release. In the absence of exogenous 
ATP, TLR2 but not TLR4 pathways require pannexin-1 membrane protein for the release 
of mature IL-1β. Study by Qu et al. using murine bone marrow derived macrophages 
(BMDMs) lacking pannexin-1 demonstrated that neither caspase-1 activation nor IL-1β 
secretion mediated by either NLRC4 or NLRP3 was compromised by pannexin-1 loss 
after LPS stimulation [92]. This is in-line with our data, where we observed the same effect 
after TLR4 stimulation by LPS but not after TLR2/1 stimulation with Pam3CSK3 and 
TLR2/6 stimulation with FSL-1. The difference between TLR4 and TLR2 signalling 
pathway is that TLR4 can activate Myd88 dependent and Myd88-indepented signalling 
responses. The independent pathway is mediated by the TRIF adaptor protein and also 
leads to proinflammatory responses. To take our study further we decided to investigate 
the role of TRIF in inflammasome activation. Previous results by Saitoh et al. showed that 
TRIF was linked to NLRP3 signalling in situations in which the autophagy machinery was 
blocked or depleted [164]. Another study on Kupffer cells showed that despite their normal 
production of pro-IL-1β and pro-IL-18, Trif−/− Kupffer cells could not release IL-1β or IL-18 
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due to their inability to activate caspase-1 [165, 166]. To investigate the role of adaptor 
molecules in inflammasome activation and IL-1β release in our model, we activated 
adaptor proteins with different TLR ligands. Our previous results showed that LPS induced 
much higher IL-1β release in PBMCs than Pam3CSK4 and we wanted to investigate 
whether TRIF activation was responsible for this response. Since TLR4 activates TRIF 
and Myd88, TLR3 activates TRIF, and TLR2 activates Myd88 (Fig. 25), we treated 
PBMCs with different TLR ligands to investigate whether separate activation of TRIF and 
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Our results showed that when we treated cells with Poly I:C (activates TRIF) together with 
Pam3CSK4 (activates Myd88) or FSL-1 (activates Myd88), IL-1β levels were still much 
lower that after LPS treatment (activates TRIF and Myd88). CXCL8 levels were similar 
after all treatments. These results may be explained by the fact that the signalling 
mechanisms involved in TLR3 activation of TRIF are different than those of TLR4, where 
the additional adaptor TRAM is required. It was initially believed that TRAM acted as an 
Figure 25. TLR adaptor proteins. Upon activation of TLRs, the adaptor proteins Mal, 
MyD88, TRIF and TRAM are differentially recruited to the various receptors. MyD88 is 
utilised by all the TLRs with the exception of TLR3. TRIF is activated downstream of TLR3 
and TLR4. Mal and TRAM act as bridging proteins, recruiting MyD88 and TRIF, 
respectively to TLR4. The recruitment of the adaptor proteins leads to the activation of 
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anchor protein for TRIF after activation of TLR4, however recent data shows that TRAM 
induces unique signalling events, which are specific to this adaptor protein [167]. 
To investigate further the role of adaptor proteins in inflammasome activation and IL-1β 
release, we used blocking peptides (BPs) comprised of 14 aa that correspond to the 
sequences of the BB loops of the two TIR domain-containing adaptor proteins, Mydd88 
and TRIF. After treating PBMCs with these inhibitors we stimulated cells with LPS, 
Pam3CSK4, FSL-1 and cigarette smoke extract (CSE), which has been shown to activate 
TLRs [64].  Our results showed that there was a decrease in IL-1β release in PBMCs 
stimulated with LPS after inhibition of Myd88, TRIF and both together. However, after 
Pam3CSK4 stimulation we saw a reduction only after Mydd88/TRIF inhibition. Similar 
results were obtained after CXCL8 measurement. Pam3CSK4 stimulation caused a 
decrease in cytokine levels only after TRIF inhibition even though TRIF does not take part 
in TLR2 signalling pathway. We expected a reduction in CXCL10 levels in cells stimulated 
with Poly I:C after inhibition of TRIF but surprisingly this inhibitor did not have any effect 
on CXCL10 release in these cells. A possible explanation for our results is described in a 
paper by Toshchakov et al. where BPs showed little specificity with respect to genes 
induced by LPS via Myd88-dependent and Myd88-indepentent pathways. For example, 
the Myd88 inhibitory peptide did not preferentially block IL-1β gene induction, an event 
that is reliant on Myd88 signalling. It was suggested that the stability of the TLR4 
signalling platform is disrupted or fails to assemble correctly as a consequence of BP-
target protein interactions. In addition, these BPs were much weaker inhibitors of TLR2-
mediated signalling and did not affect TLR2-induced activation of JNK and ERK, and had 
much weaker effect on IL-1β expression suggesting that that the architecture of receptor-
adaptor complexes differs between TLR2 and TLR4. The idea that adaptors shared by 
different TLRs can interact with individual receptors in a fundamentally different ways 
supports the existence of asymmetrical models of TIR-TIR complex formation [168]. A 
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recent study by Dunne et al. predicted that TLR4 and TLR2 bind Myd88 through different 
non-overlapping sites [169].  
While I was writing this thesis there was a paper published in August by Rathinam et al. 
demonstrating that in mouse model TRIF licensed caspase-11 dependent NLRP3 
activation by Gram-negative bacteria. In this study it was shown that TRIF activates 
caspase-11 via type I IFN signalling. Caspase-11 subsequently synergized with NLRP3 
inflammasome to regulate caspase-1 activation. These events occurred specifically during 
infection with Gram-negative but not Gram-positive bacteria [170]. In Our study LPS 
induced higher IL-1β release than Pam3CSK4, and it did not required pannexin-1 for IL-1β 
cleavage. TLR2-induced IL-1β release required second signal for the inflammasome 
assembly and it was under regulation of pannexin-1, which form large pores in the 
membrane allowing the passage of substances with a molecular weight of up to about 900 
Da. The last remaining question is what is the second signal required for the 
inflammasome activation after TLR2 stimulation and exactly how this stimulant causes 
assembly of the inflammasome. NLRP3 inflammasome is activated by a diverse series of 
endogenous and exogenous agonists but there is no evidence of direct ligand binding, 
thus challenging the concept that this is a receptor. However, it might be possible that 
after large pore formation by activated pannexin-1 there is an influx to the cytoplasm of 
pathogen-associated molecular patterns and other factors like ATP, uric acid, hyaluronan, 
and many more molecules that could  activate the inflammasome [91, 171, 172]. The 
possible explanation of our results is shown in Figure 26. 
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To summarize our results, we demonstrated that (i) THP-1 cells and PBMCs released IL-
1β and CXCL8 after stimulation with TLR4 and TLR2 ligands, (ii) ATP further enhanced 
IL-1β release, (iii) in the absence of exogenous ATP, TLR2 but not TLR4 pathways 
require pannexin-1 hemichannel protein. This data suggests an important dissociation in 
inflammasome activation induced by TLR4 versus TLR2 and could be important in our 
Figure 26. Mechanism of IL-1β release. Release of IL-1β requires two well-defined 
signals: a “priming” signal to induce pro-IL-1β synthesis, and a signal to trigger assembly 
of the NLRP3 inflammasome, which culminates in the processing and release of mature 
IL-1β. TLR2 and TLR4 activation leads to NF-kB activation and induction of pro-IL-1β via 
MyD88-dependent mechanism. TLR2-induced IL-1β release requires second signal like 
ATP which is believed to activate the inflammasome by binding to P2X7 receptors and 
opening a cation channel and a large pore through pannexin-1. Triggering K+ efflux and 
Ca2+ influx activates inflammasome assembly through as yet unconfirmed mechanisms. 
Moreover, TLR4 ligation also activates TRIF which licenses NLRP3 inflammasome 
activation via the type I IFN pathway. Type I IFNs upregulate caspase-11 expression, an 
event that is both necessary and sufficient to enable caspase-11 
autoactivation.  Caspase-11 activation via the TLR4-TRIF-IFNβ pathway synergizes with 
NF-κB activation to orchestrate caspase-1-dependent IL-1β processing and secretion 
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understanding of both bacterial and sterile inflammation in man. It also can help in the 
future to design more efficacious and more specific drugs to treat inflammatory 
conditions. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  












	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




The effect of TLR and NOD1 agonists on IL-1β and CXCL8 release in patients 
with respiratory disease. 
Rationale 
Chronic pulmonary obstructive disease (COPD) affects 200 million people worldwide and 
is currently the fourth leading cause of death in industrialized countries. The most 
important risk factor for COPD is smoking tobacco, although it is known that other 
environmental and genetic factors also contribute to the development of COPD. COPD is 
defined by a combination of three clinical manifestations; chronic bronchitis, small airways 
obstruction and emphysema, and is associated with a decrease in quality of life and 
premature death [173]. The lower airway inflammation present in COPD patients involves 
the recruitment and activation of inflammatory cells and results in changes in the structure 
of the lung. Increased secretion of cytokines, chemokines, growth factors and adhesion 
molecules is observed and in most cases increased expression of these molecules in 
associated with enhanced gene transcription [174]. Exacerbation of COPD is a sudden 
worsening of COPD symptoms. They are usually triggered by bacterial and viral infections 
and are a major cause of hospital admissions and mortality. As a results there is a need 
for developing effective treatment and vaccines to improve the health status of COPD 
patients [117]. Conserved germ-line pathogen associated molecular patterns (PAMPs) 
present on or within bacteria, viruses and fungi are recognised by numerous pathogen 
recognition receptors (PRRs), which include TLRs and NLRs [175]. In addition, recent 
evidence from our group and others have shown that these receptors also act as danger 
recognitions receptors (DRRs) and are activated by structural proteins, such as fibrinogen 
hyaluronan and oxidants [105]. These molecules are present only when cells are 
damaged and undergo necrosis during bouts of inflammation, infection or trauma. We 
therefore hypothesised that these PRRs may be dysregulated or sensitised during chronic 
inflammatory pathologies, thereby playing a major role in controlling inflammation 
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observed in COPD. In this chapter we hypothesised that the blood of COPD patients is 
more sensitive, than that of age matched control donors, to bacterial and viral TLR 
ligands. In this chapter we measured basal levels of IL-1β and CXCL8 levels in blood 
serum of COPD patients and healthy volunteers. To assess if COPD patients have a 
greater susceptibility to infection, we measured their innate immune response to IL-1R, 
TLR2/1, TLR2/6, TLR3, TLR4 and NOD1 agonists in serum and compared our data to that 
obtained from healthy controls. Since pulmonary hypertension (PAH) and pulmonary 
vascular remodelling is a common complication of COPD [176], we also measured 
cytokine release profile in patients with PAH and healthy controls to see whether any 
changes in sensitivity to agonists are specific for COPD and not just related to a general 
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Patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension 
(PAH) were invited to participate. 12mls of whole blood was collected into 2.7mls 
vacutainers containing sodium citrate. 190mls of blood was aliquoted onto 96 well plates 
and incubated with TLR (LPS, FSL-1, Pam3CSK4, Poly I:C), NOD1 (C12-IE-DAP) and IL-
1R (IL-1β) agonists (as described in chapter 2.3.2). Whole blood was incubated at 37°C 
containing 5% CO2 for 24h. Plates were centrifuged at 1000xg at room temperature for 5 
min with very low breaking. Serum was carefully transferred to the dummy plate and 














	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




ID No Age GOLD 
Stage 
FEV1% FEV1/FVC% Smoking 
Status 
Pack/Yrs Gender 
COPD1 84 I 81 60 ex 10 F 
COPD2 72 IV 24 21 ex 114 M 
COPD3 70 II 56.9 39.6 ex 26 F 
COPD4 74 II 60 48 ex 10 M 
COPD5 74 I 88 69 ex 63 M 
COPD6 68 III 47 51 ex 5 M 
AMC1 60 N/A N/A N/A non N/A F 
AMC2 63 N/A N/A N/A non N/A M 
AMC3 68 N/A N/A N/A non N/A M 
AMC4 60 N/A N/A N/A non N/A M 
AMC5 79 N/A N/A N/A ex 33 F 
AMC6 67 N/A N/A N/A non N/A F 
AMC7 76 N/A N/A N/A ex 2.5 F 
AMC8 73 N/A N/A N/A non N/A F 
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PH1 31   iPAH 
 
IV non N/A F 
PH2 69 CTD-PAH III non N/A F 
PH3 32 iPAH III non N/A F 
PH4 43 iPAH III non N/A M 
PH5 47 iPAH II non N/A F 
PH6 42 iPAH III non N/A M 
PH7 63 severe PAH no data ex 5 F 
PHC1 38 N/A N/A non N/A F 
PHC2 46 N/A N/A non N/A M 
PHC3 27 N/A N/A non N/A F 
PHC4 68 N/A N/A non N/A F 
PHC5 61 N/A N/A non N/A M 
PHC6 31 N/A N/A non N/A M 
PHC7 41 N/A N/A non N/A M 
Table 5. Clinical assessment of pulmonary hypertension patients (PAH) and age-
matched controls (PHC). iPAH-Idiopathic Pulmonary Arterial Hypertension, CTD-
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N 6 8 
Age, Years (mean+SEM) 73.6±2.2 68.2±2.5 
Gender F/M 2/4 5/3 
Smoking Status (non/ex/current) 0/6/0 6/2/0 
Pack/Years 38±17.5 4.4±4 
FEV1% (mean+SEM) 59.4±9.4 N/A 
FEV1/FVC% (mean+SEM) 53.1±8.4 N/A 





N 7 7 
Age, Years (mean+SEM) 46.71(5.4) 44.57 (5.7) 
Gender F/M 5/2 3/4 
Smoking Status (non/ex/current) 0/0/1 0/0/1 
Pack/Years 0.71±0.71 N/A 
FEV1% (mean+SEM) N/A N/A 
FEV1/FVC% (mean+SEM) N/A N/A 
Table 7. Clinical assessment PAH patients vs controls. 
Patient ID White Blood Cell Count  (x 109 cells/liter) Normal Range (4.8-10.8) 
COPD2 7.4 normal 
COPD3 7.7 normal 
COPD4 8.4 normal 
COPD6 7.1 normal 
Table 8. COPD patients’ white blood cell count 
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4.1. Assessment of control groups – IL-1β release. 
The aged immune system decreases its responsiveness to infections and increases the 
sensitivity to systemic inflammation and autoimmune disease [177]. As it was mentioned 
before, to investigate whether any changes in cytokines release were caused by disease 
or were associated with aging, we divided our control subjects into three groups:  
• Young controls (<30yrs) 
• Medium-age controls (30-50yrs) 
• Older controls (>50yrs) 
We found that each control group that we used demonstrated differences in sensitivity to 
TLR and NOD1 agonists. Looking at IL-1β release (Fig. 27), we observed that older 
control groups (43.7 yrs and 68.2 yrs) produced generally higher levels of the cytokine 
compared with younger group. Poly I:C induced higher levels of IL-1β in blood of younger 
versus older control volunteers.  
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Figure 27. IL-1β release from whole blood after TLR and NOD1 stimulation. Blood 
from participants was collected and treated with LPS (A), C12-IE-DAP (B), FSL-1 (C), 
Pam3CSK4 (D), Poly I:C (E) and IL-1β (F). After 24h, serum was separated from whole 
blood by centrifugation at 1000xg for 5min and stored at -20ºC. Levels of IL-1β were 
measured by ELISA. Data are the mean ± SEM of n=7 for YC (young controls), n=7 for 
MC (medium-age controls) and n=8 for OC (older controls). *denotes p<0.05 two-way 
ANOVA followed by Bonferroni post test.  
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4.2. Assessment of control groups – CXCL8 release. 
CXCL8 levels (Fig. 28) were higher in younger control group except for C12-IE-DAP 
treatment where medium-age control group released more cytokine. Control group (44 
yrs) had the lowest levels of CXCL8 after stimulation with all agonists. Thus, for the 
experiments in this chapter we calculated the mean age of COPD and PAH patients and 
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Figure 28. CXCL8 release from whole blood after TLR and NOD1 stimulation. Blood 
from participants was collected and treated with LPS (A), C12-IE-DAP (B), FSL-1 (C), 
Pam3CSK4 (D), Poly I:C (E) and IL-1β (F), After 24h, serum was separated from whole 
blood by centrifugation at 1000xg for 5min and stored at -20ºC. Levels of CXCL8 were 
measured by ELISA. Data are the mean ± SEM of n=7 for YC (young controls), n=7 for 
MC (medium-age controls) and n=8 for OC (older controls). *denotes p<0.05 two-way 
ANOVA followed by Bonferroni post test.  
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4.3. Basal levels of IL-1β and CXCL8 in whole blood. 
Basal levels of IL-1β (Fig. 29A) were higher in COPD patients than in age-matched 
controls but the difference did not reach significance. Only 2 out of 6 patients had 
significantly higher levels of IL-1β which was not associated with disease severity. Similar 
results were seen after CXCL8 measurement, where cytokine levels (Fig. 29B) were 
significantly increased in COPD patients compared with controls but there was also no 
correlation between plasma cytokine levels and disease severity according to GOLD 
status (Fig. 30A,B).  
In PAH patients, we did not observe any difference in basal IL-1β and CXCL8 levels 
compared to control group. (Fig. 29C,D). There was also no correlation between plasma 
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Figure 29. Basal levels of IL-1β and CXCL8 in blood plasma. Plasma was separated 
from whole blood by centrifugation at 1000xg for 5min and stored at -20ºC. Levels of IL-1β	  
(A,C) and CXCL8 (B,D) were measured by ELISA. Data are the mean ± SEM of n=6 for 
COPD patients and n=8 for age-matched controls (A,B), n=7 for PAH patients and their 
controls (C,D). *denotes p<0.05 one-way ANOVA followed by Bonferroni post test (3A and 
3B) and two-tailed t-test (3C and 3D). AMC – age-matched controls, COPD – COPD 
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Figure 30. Correlation between plasma levels of IL-1β (A,C) and CXCL8 (B,D) and 
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4.4. IL-1β and CXCL8 release in response to Gram-negative bacterial ligands in 
COPD and PAH patients. 
IL-1β release in response to the TLR4 agonist, LPS was similar in COPD patients (Fig. 
31A) and the age-matched healthy control group. In blood of PAH patients (Fig. 31B), we 
observed a significantly higher release of IL-1β at the top concentration of LPS used when 
compared with their age-matched controls.  
In contrast, CXCL8 levels were significantly higher in the COPD patient group than in age-
matched controls with no difference seen between PAH patients and their controls. 
Figure 31. IL-1β and CXCL8 release from whole blood after LPS stimulation. Blood 
from participants was collected and treated with LPS (0.001-1µg/ml). After 24h, 
plasmawas separated from whole blood by centrifugation at 1000xg for 5min and stored at 
-20ºC. Levels of IL-1β (A,B) and CXCL8 (C,D) were measured by ELISA. Data are the 
mean ± SEM of n=6 for COPD patients and n=8 for age-matched controls (A,C), n=7 for 
PAH patients and their controls (B,D). *denotes p<0.05 two-way ANOVA followed by 
Bonferroni post test. AMC – age-matched controls, COPD – COPD patients, PAH- 
pulmonary hypertension patients. 
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The NOD1 agonist, C12-IE-DAP induced very low levels of IL-1β (Fig 32A, B) with no 
difference observed between patient groups and their controls. 
 
Figure 32. IL-1β and CXCL8 release from whole blood after C12-IE-DAP stimulation. 
Blood from participants was collected and treated with C12-IE-DAP (0.001-1µg/ml). After 
24h plasma was separated from whole blood by centrifugation at 1000xg for 5min and 
stored at -20ºC. Levels of IL-1β (A,B) and CXCL8 (C,D) were measured by ELISA. Data 
are the mean ± SEM of n=6 for COPD patients and n=8 for age-matched controls (A,C), 
n=7 for PAH patients and their controls (B,D). *denotes p<0.05 two-way ANOVA followed 
by Bonferroni post test. AMC – age-matched controls, COPD – COPD patients, PAH- 
pulmonary hypertension patients. 
 
4.5. IL-1β and CXCL8 release in response to Gram-positive bacteria ligands in 
COPD and PAH patients. 
There was no significant difference in IL-1β	   levels between groups after FSL-1 (TLR2/6 
agonist) treatment (Fig. 33A,B).  
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CXCL8 secretion after FSL-1 stimulation (Fig. 33C,D) was slightly higher in COPD group 
than in age-matched control group but this did not reach significance.  Similarly, there was 
no difference between PAH patients and their controls.  
 
Figure 33. IL-1β and CXCL8 release from whole blood after FSL-1 stimulation. Blood 
from participants was collected and treated with FSL-1 (0.001-1µg/ml). After 24h 
incubation plasma was separated from whole blood by centrifugation at 1000xg for 5min 
and stored at -20ºC. Levels of IL-1β (A,B) and CXCL8 (C,D) were measured by ELISA. 
Data are the mean ± SEM of n=6 for COPD patients and n=8 for age-matched controls 
(A,C), and n=7 for PAH patients and their controls (B,D). *denotes p<0.05 two-way 
ANOVA followed by Bonferroni post test. AMC – age-matched controls, COPD – COPD 
patients, PAH- pulmonary hypertension patients. 
Pam3CSK4 (TLR2/1 agonist) in general released higher levels of IL-1β and CXCL8 than 
the TLR2/6 agonist, FSL-1. 
Levels of IL-1β after Pam3CSK4 stimulation (Fig. 34A) at the top concentration were 
significantly higher in blood of COPD patients than in the age-matched control subjects.  
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No difference in levels of IL-1β was seen between responses of blood from PAH patients 
and their controls (Fig. 34B).  
Similarly, COPD patients released higher levels of CXCL8 after TLR2/1 stimulation (Fig. 
34C) than their controls and they were significantly different compared with age-matched 
controls. Once again, there was no difference between PAH patients and age-matched 
controls (Fig. 34D). 
 
Figure 34. IL-1β and CXCL8 release from whole blood after Pam3CSK4 stimulation. 
Blood from participants was collected and treated with Pam3CSK4 (0.001-1µg/ml). After 
24h, plasma was separated from whole blood by centrifugation at 1000xg for 5min and 
stored at -20ºC. Levels of IL-1β (A,B) and CXCL8 (C,D) were measured by ELISA. Data 
are the mean ± SEM of n=6 for COPD patients and n=8 for age-matched controls (A,C), 
n=7 for PAH patients and their controls (B,D). *denotes p<0.05 two-way ANOVA followed 
by Bonferroni post test. AMC – age-matched controls, COPD – COPD patients, PAH- 
pulmonary hypertension patients. 
 







































































A                                                                            B 
C                                                                              D 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




4.6. IL-1β and CXCL8 release in response to viral ligand in COPD and PAH patients. 
Poly I:C induced significantly higher levels of IL-1β in COPD patients than in the age-
matched control group (Fig. 35A). Although, there was no significant difference between 
PAH patients and their controls. (Fig. 35B). After the measurement of CXCL8 secretion, 
we observed that COPD patients induced significantly higher levels of CXCL8 in response 
to viral ligands compared with their controls (Fig. 35C,D). By contrast, blood of PAH 
patients did not release IL-1β after stimulation with viral ligands. However, blood of aged 
matched control donors released IL-1β after stimulation with Poly I:C. This suggests that 
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Figure 35. IL-1β and CXCL8 release from whole blood after Poly I:C stimulation. 
Blood from participants was collected and treated with Poly I:C (0.01-10µg/ml). After 24h, 
plasma was separated from whole blood by centrifugation at 1000xg for 5min and stored 
at -20ºC. Levels of IL-1β (A,B) and CXCL8 (C,D) were measured by ELISA. Data are the 
mean ± SEM of n=6 for COPD patients and n=8 for age-matched controls (A,C), n=7 for 
PAH patients and their controls (B,D). *denotes p<0.05 two-way ANOVA followed by 
Bonferroni post test. AMC – age-matched controls, COPD – COPD patients, PAH- 
pulmonary hypertension patients. 
 
4.7. IL-1β and CXCL8 release in response to interleukin-1 receptor (IL-1R) agonist. 
TLRs and IL-1R-family members share the same adaptor and signalling components such 
as Myd88, IRAK and TRAF6 and both can activate NF-κB and MAP kinases. We used the 
IL-1R agonist, IL-1β to control for possible differences or perturbations in the TLR 
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signalling pathway. It was difficult to analyse the data from the IL-1β ELISA, where IL-1β 
was used as a stimulus due to reactivity with the IL-1β antibodies (data not shown). 
Looking at CXCL8 release there was significantly higher release in COPD patients that in 
age-matched controls (Fig. 36A) with no difference between PAH patients and their 
controls (Fig. 36B).   
Figure 36. CXCL8 release from whole blood after IL-1β stimulation. Blood from 
participants was collected and treated with IL-1β (0.001-1ng/ml). After 24h, plasma was 
separated from whole blood by centrifugation at 1000xg for 5min and stored at -20ºC. 
Levels of CXCL8 were measured by ELISA. Data are the mean ± SEM of n=6 for COPD 
patients and n=8 for age-matched controls (A), n=7 for PAH patients and their controls 
(B). *denotes p<0.05 two-way ANOVA followed by Bonferroni post test. AMC – age-
matched controls, COPD – COPD patients, PAH- pulmonary hypertension patients. 
 
4.8. Correlation between cytokines release and disease severity.  
To investigate whether there is any relationship between cytokine levels and disease 
severity, we performed correlation studies where we quantified the association between 
cytokine release and COPD GOLD stage for each patient. Our results demonstrated that 
there was negative correlation between CXCL8 levels and COPD GOLD stage after LPS 
treatment. We found that blood of patients with a lower GOLD status released higher 
amounts of CXCL8 after TLR4 stimulation (Fig. 37C). We did not find any correlation 
between cytokine levels and PAH severity. 
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Figure 37. Correlation between IL-1β levels and COPD severity after Pam3CSK4 (A) and 
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Figure 38. Correlation between CXCL8 levels and COPD severity  after LPS 
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Figure 39. Correlation between levels of cytokines and PAH severity after LPS (A) 
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In this study we assessed whether there was a dysfunction in the immune system of 
COPD patients making their blood more/less sensitive to bacterial and viral PAMPs. 
Responses of blood from patients with a different chronic lung condition, namely PAH, 
were compared. Since PAH is a disease of pulmonary vessels rather than airways, this 
comparison enabled us to expand our discussions into a clinical setting. 
COPD is a disease where chronic inflammation plays a central role. The predominant 
cause of COPD is cigarette smoking triggering an inflammatory response and alveolar 
destruction. Inflammation is further amplified by oxidative stress. Increased numbers of 
neutrophils and macrophages are found in the BAL fluid and sputum of COPD patients 
and in the small airways, where there are increased numbers of CD68+ macrophages and 
CD8+ T-cells [114]. Neutrophils have also been associated with tissue damage in COPD 
through the release of a number of enzymes such as elastases and matrix 
metalloproteinases (MMPs) [178]. Cytokines are known to orchestrate the inflammatory 
responses in COPD. Increased levels of IL-6, IL-1β, TNF-α and CXCL8 have been 
observed in sputum of COPD patients [179]. Release of CXCL8, IL-1β, TNF-α and 
CXCL10 from alveolar macrophages of COPD patients has also been observed [180]. Our 
results showed that basal levels of IL-1β were not significantly increased in the plasma of 
COPD patients as compared to controls. Only 2 of the 6 patients sampled had higher 
levels of IL-1β in plasma and there was no association with disease severity. However, 
CXCL8 levels were significantly higher in COPD patients than in controls. CXCL8 is a 
chemokine which acts as a neutrophil chemoattractant and activator. CXCL8 recruits 
PMNs to sites of inflammation, where they can have an anti-pathogenic effect via the 
release of free radicals and enzymes, which if persistent can initiate tissue damage.  
CXCL8 has been shown to play a central role in neutrophilic inflammation, mucus 
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hypersecretion and destruction of alveoli [181], and can be one of the many factors that 
contribute to the COPD pathogenesis.  
Bacterial and viral infections have been implicated in exacerbations of COPD. They are 
often associated with a decline in lung function and disease progression resulting in 
reduced physical activity, poorer quality of life and increased risk of death. Exacerbations 
are important outcomes in clinical trials and their prevention is a key component of COPD 
management strategies. However, little is known about their incidence, determinants and 
their effects in COPD at various levels of severity. COPD with frequent exacerbations is a 
distinct phenotype that is seen in moderate and severe stages of disease and that the 
incidence of frequent exacerbations increases with increasing disease severity [16]. It can 
therefore be hypothesised that TLRs are important in COPD because of their role in 
activating the immune system against bacterial and viral infections. TLRs can not only be 
found on immune cells as they are also expressed on epithelial and endothelial cells of 
the lung where their activation may play a pivotal role in disease pathology. [112]. A 
recent study by Nadigel et al. showed that COPD patients had increased expression of 
TLR4 and TLR9 on lung CD8+ cells. However, the overall expression of these receptors in 
the lung tissue and peripheral blood of COPD patients was not increased [182].  TLR2 has 
also been demonstrated to be up-regulated in peripheral blood monocytes [120] and 
peripheral blood neutrophils [183] but downregulated in alveolar macrophages [119]. A 
recent study by Wang et al. demonstrated that TLR5 at the level of mRNA, protein, and 
function levels was downregulated in airway epithelium of healthy smokers and in 
smokers with COPD. [123]. Moreover, single nucleotide polymorphisms (SNPs) in TLR 
genes have been previously described in COPD patients. Asp299Gly is a SNP in the 
TLR4 gene, which is associated with decreased LPS signalling and has been shown to 
have a lower prevalence in patients with COPD than in aged-matched controls [184, 185]. 
Another study by Budulac et al. showed that tagging SNP in TLR2 and TLR4 were 
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associated with the decline of lung function as well as with inflammatory cell numbers in 
induced sputum in COPD patients [186]. However, some other studies focusing 
on	  TLR2	  showed that Arg677Trp and Arg753Gln were not associated with either the onset 
or the course of COPD [187].  TLRs also recognize DAMPs such as heat shock proteins, 
hyaluronic acid, fibronectin and ROS. DAMPs are increased during inflammation and can 
propagate ‘sterile inflammation’ via TLRs. This kind of sterile inflammation may also 
contribute to the alveolar destruction and the pathology seen in COPD. This may also 
explain why the lung function of patients with COPD tends to stabilise after smoking 
cessation. DAMPs are found in abundance in cigarette smoke and play a significant role 
in cigarette smoke-induced lung inflammation [64]. Cigarette smoke has been shown to 
decrease the expression of TLR4 and TLR9 on the lining of epithelial cells of human lung 
[122] [110]. To investigate the role of TLRs in the immune response of COPD patients, we 
examined cytokine release in whole blood after stimulation with TLR, NOD1 and IL-1R 
ligands and compared these results to those obtained using blood of aged-matched 
controls. Our results showed that after TLR4 stimulation with LPS, CXCL8 levels were 
significantly higher in the blood of COPD patients suggesting the importance of this 
cytokine in disease pathogenesis. We found no effect on IL-1β secretion. Although the 
relative expression of TLR4 on blood cell components was not assessed in this study, the 
difference in effects observed in CXCL8 and IL-1β suggest that the sensitivity to LPS is 
probably not at the levels of the receptor. In contrast, we observed that there was an 
increase in IL-1β release after LPS treatment in patients with PAH. IL-1β release requires 
inflammasome activation to cleave pro-ILβ to the mature, active form. Inflammasomes 
have been implicated in a number of inflammatory and heritable disorders. Increased 
levels of IL-1β in PAH patients after LPS stimulation may suggest that IL-1β-mediated 
inflammation plays a significant role in the pathogenesis of PAH but not COPD. 
Stimulation with NOD1 and a TLR2/6 agonist did not show any increase in cytokine 
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production but activation of TLR2/1 with Pam3CSK4 significantly increased IL-1β and 
CXCL8 levels in COPD patients. We obtained interesting results after stimulation with the 
viral ligand, Poly I:C where both cytokines were significantly increased in COPD patients 
compared with controls suggesting the importance of viral induced exacerbations in 
pathogenesis of this disease. CXCL8 levels were also significantly increased in PAH 
patients. The major causes of exacerbations in COPD are respiratory infections caused by 
bacteria and viruses. TLR activation could contribute to the inflammation observed during 
exacerbations and may be partially responsible for the deterioration of lung function [188] 
Our results showing that COPD patients released more cytokines than controls after 
treatment with Gram-negative bacteria and viral ligands can explain why these patients 
are more sensitive to infections and that these exaggerated responses contribute even 
further to the pathogenesis of COPD. Although excessive mucus secretion and an 
increase in its viscosity are directly involved in the clearance of bacteria and viruses from 
the airways. 
Looking at the association of cytokines levels with disease severity, we found a negative 
correlation between CXCL8 levels after TLR4 activation and COPD GOLD stage. It is 
consistent with the results from MacRedmont et al. where it was shown that severe COPD 
was associated with reduced TLR4 expression compared to less severe disease, with 
good correlation between nasal and tracheal expression [122]. These findings can 
contribute in the future to developing a novel biomarker tool in COPD to divide patients 
into different phenotypic groups to identify those patients who are at a higher risk of 
repeated exacerbations and therefore may suffer a more rapid deterioration in lung 
function [189]. Because COPD is a complex disease with pulmonary and extra-pulmonary 
manifestations, the identification and prospective validation of specific clinical phenotypes 
is a key for the development of novel and more effective therapies. Although lung function 
remains a useful guide in assessing disease severity in COPD, there is considerable 
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patient ‘quality of life’ variability within a given GOLD Stage. For example, there are 
patients with a low FEV1 and fewer exacerbations and a better quality of life than those 
with a higher FEV1 and more frequent exacerbations. Therefore, COPD patients should 
be categorised by FEV1, QOL (symptom scores) and exacerbation frequency because 
there might be more systemic inflammation in the high symptom group patients with 
preserved lung function and more exacerbations. Patients who demonstrate a higher level 
of inflammation may therefore constitute a novel distinct phenotype within the larger group 
of patients with COPD and could be the target of novel therapeutic strategies [190]. Our 
results showing that COPD patients are more sensitive to some bacterial and viral ligands 
may give us insight into why some individuals exacerbate more frequently. 
It is also worth noting that white blood cell counts were in the normal range in all of the 
COPD patients but unfortunately we did not obtain these data for healthy controls and so 
were unable to make comparisons. Only selective agonists affected CXCL8 and IL-1β 
levels in the blood suggesting that small differences in the overall cellular composition of 
the blood had little effect on the overall responses to PAMPs. Analysing COPD study 
results may be limited because of the effect of inhaled corticosteroids and long-acting β2 
agonists which are commonly prescribed for COPD. This type of therapy can control the 
symptoms of COPD and lower mortality risk [121]. These drugs together affect a broad 
range of physiological processes which are central to inflammation. They can inhibit 
proliferation of airway smooth muscle cells [191],  abolish TNF-α-induced eotaxin release 
[192], inhibit NF-κB –regulated gene expression [193] and TNF-α-induced CXCL8 release 
[194]. All our patients were on different combinations of therapies, however an 
inflammatory response was still observed after TLR or NLR activation. Another limitation 
is the number of patients used in this study. Since this is a pilot study, more subjects are 
required to draw concrete conclusions from the data. However, our results are promising 
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and may lead to a tool for stratification of COPD patients and subsequent improvements 
in their clinical management.  
Chapter summary 
To summarize our results, we demonstrated that (i) levels of CXCL8 are higher in COPD 
patients than controls, (ii) COPD patients showed increased response in CXCL8 
production after TLR4 stimulation with LPS and TLR2 stimulation with Pam3CSK4 (iii) after 
stimulation with a viral ligand, COPD patients had significantly increased release of 
CXCL8 and IL-1β in plasma. These findings suggest that CXCL8 is an important cytokine 
in COPD pathogenesis and can contribute to disease progression by recruitment, 
activation and survival of inflammatory cells, and can increase susceptibility to bacterial 
and viral infections of COPD patients. Together our results may give us an insight into 
why patients with COPD experience repeated infective exacerbations and help us to 
understand why numerous exacerbations lead to worsening lung function. 
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The Role of TLRs in lung cancer cell proliferation and survival. 
Rationale 
Toll-like receptors (TLRs) are type I transmembrane receptors that recognize structurally 
conserved pathogen associated molecular patterns (PAMPs) and non-pathogenic self-
danger molecules. They participate in the first line of defence and play a significant role in 
inflammation, immune cell regulation, survival and proliferation [195]. Most of the evidence 
for TLRs and proliferation in noncancerous cells has been shown in vascular smooth 
muscle cells (VSMC) and cardiovascular models [196] [127] but the mechanisms 
responsible for the control of these outcomes are poorly defined. Chronic infection and 
inflammation are widely known as risk factors for tumorigenesis. Immune system cells are 
present at tumor sites and in the supporting stroma. Damage caused by invading 
pathogens and danger molecules can result in excessive tissue remodeling, loss of tissue 
and DNA mutations [197]. Activated TLRs on cancer cells may promote cancer 
progression, anti-apoptotic activity and resistance to host immune response. Ligation of 
TLRs increases production of pro-inflammatory cytokines and chemokines	  These TLR-
dependent mechanisms maintain the tumor microenvironment and promote cancer 
progression [128] [129]. Cigarette smoke-induced oxidative stress has been shown to 
cause DNA damage in the form of strand breaks and oxidative modifications. Through the 
activation of survival signaling cascades like EGFR/NF-κB/Akt, oxidative stress causes 
uncontrolled cell proliferation and cell transformation [198]. Also the airway epithelium in 
chronic bronchitis and COPD often shows squamous metaplasia, which may result from 
increased proliferation of airway epithelial cells. Proliferation in basal airway epithelial 
cells, measured by proliferative cell nuclear antigen, is increased in some normal smokers 
but is markedly increased in patients with chronic bronchitis and correlates with the 
degree of squamous metaplasia [199]. 
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Recently, the expression or up-regulation of TLRs has been detected in many tumor cell 
lines or tumors, especially epithelial derived cancers. NF-κB activation leads to the 
transcription of many anti-apoptotic genes such as BCL2A1 [83]. Because TLRs are 
potent activators of NF-κB pathway there is growing evidence that they provide a signal to 
promote the survival of epithelial cells under stress conditions [22]. Recent studies 
showed that activation of TLRs resulted in resistance to apoptosis [136] [200] [119] and 
better understanding of function and regulation of TLRs is essential for developing TLR-
based therapies inhibiting cell proliferation, tumor growth and progression. Therefore in 
this chapter we hypothesised that activation of TLRs on lung cancer cells will induce cell 
proliferation and resistance to apoptosis. In the present study, we stimulated the epithelial 
lung cancer cell line (A549) with TLR ligands and measured cytokine release to 
demonstrate that TLRs were active in these cells. To assess apoptosis in A549 cells, cell 
viability/respiration was measured by AlamarBlue and expression of annexin V was 
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A549 cells were cultured in 96 well or 6 well plates as described in chapter 2. Cells were 
treated with TLR agonists for 24, 48 and 72h. Proliferation was assessed by a few 
different methods described in the results section. A549 cells cycle profile was analyzed 
by Cellomics. CXCL8 and CXCL10 levels were measured by ELISA. For cell viability 
experiments A549 were treated with apoptotic agents 4h prior to TLRs activation. 
Apoptosis resistance was measured by AlamarBlue assay and FACS after 24h. More 
details about methods can be found in chapter 2 and in the figure legends. 
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5.1. Stimulation of A549 cells with TLR ligands.  
TLR ligation can stimulate immune cells to secrete many kinds of proinflammatory 
cytokines such as CXCL8, TNF-α and IL-1β. CXCL8 is a proangiogenic chemokine that 
has anti-apoptotic properties and is secreted by tumor cells [136]. Hence, CXCL8 can 
promote cancer metastasis and apoptosis resistance in malignant cells. To investigate 
whether TLRs expressed on lung cancer cells are functionally active, we performed ELISA 
assays to measure secreted CXCL8 levels after TLR stimulation. Thus, A549 cells were 
cultured in either 0 or 10% FCS and stimulated with bacterial (Fig. 40) or viral (Fig. 41) 
ligands for 24, 48 and 72h.  
Stimulation of TLR2/1 with Pam3CSK4 or TLR2/6 with FSL-1 or TLR4 with LPS resulted in 
a concentration dependent increase in CXCL8 production after 24, 48 and 72h. This was 
true regardless of the presence or absence of serum. FSL-1 in all cases caused a greater 
increase in CXCL8 levels than Pam3CSK4 and LPS. Our results demonstrated that TLR2 
heterodimers and TLR4 homodimers are functionally active on this cancer cell line. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  





















































































































































Figure 40. The effect of bacterial ligands on the activation of A549 cells. A549 cells 
were seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS and 
allowed to equilibrate for 12h. After this time period, media was replaced with DMEM 
containing either 0 (A-C) or 10% FCS (D-F). Cells were treated with the ligands and 
incubated for 24 (A,D), 48 (B,E), 72h (C,F) after which CXCL8 levels were measured in the 
supernatants by specific ELISA. Data represented are the mean ± SEM of n=9 replicates 
measured over 3 separate experimental days. *denotes p≤ 0.05 as assessed using a one-
way ANOVA followed by a Dunnett’s multiple comparison post-hoc test. 
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Production of CXCL8 after viral ligand stimulation was less clear (Fig. 41). We observed 
significant increase after TLR8 stimulation with ssRNA40/Lyovec in all condition we used 
but only the highest concentration of this ligand induced a significant release. Poly I:C 
which activates TLR3 also caused CXCL8 production in all conditions we used except 48h 
time point in the absence of serum (Fig. 41B). The TLR7 agonist (Imiquimod) was not a 
potent inducer of CXCL8 as we only observed significant release after 72h treatment. 
Generally, levels of CXCL8 were much lower after viral ligand stimulation, but they usually 
require an additional activation with IFNs to produce greater levels of this chemokine. We 
also measured CXCL10 release, which is a more appropriate cytokine to measure viral 
driven host immune responses, but levels of this cytokine were below the detection limit of 
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Figure 41. The effect of viral ligands on the activation of A549 cells. A549 cells were 
seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS and allowed to 
equilibrate for 12h. After this time period, media was replaced with DMEM containing 
either 0 (A-C) or 10% FCS (D-F). Cells were treated with the ligands and incubated for 24 
(A,D), 48 (B,E), 72h (C,F) after which CXCL8 levels were measured in the supernatants 
by specific ELISA. Data represented are the mean ± SEM of n=9 replicates measured 
over 3 separate experimental days. *denotes p≤ 0.05 as assessed using a one-way 
ANOVA followed by a Dunnett’s multiple comparison post-hoc test. 
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CXCL10 Release (0%FCS) 
 Ctr 
Poly I:C (µg/ml) Imiquimod (µg/ml) ssRNA40 (µg/ml) 
0.1 1 10 0.1 1 10 0.1 1 10 
24h nd nd nd nd nd nd nd nd nd nd 
48h nd nd nd nd nd nd nd nd nd nd 
72h nd nd nd nd nd nd nd nd nd nd 
 
CXCL10 Release (10%FCS) 
 Ctr 
Poly I:C (µg/ml) Imiquimod (µg/ml) ssRNA40 (µg/ml) 
0.1 1 10 0.1 1 10 0.1 1 10 
24h nd nd nd nd nd nd nd nd nd nd 
48h nd nd nd nd nd nd nd nd nd nd 






5.2. Effect of seeding density on A549 proliferation.  
It has been previously described that ligation of TLR2, TLR4, TLR5 and TLR9 can induce 
proliferation of tumor cells, which include ovarian, breast, prostate, and gastric cancers 
[119, 136, 179, 180, 201, 202]. To test what seeding density would be best to study A549 
cell proliferation over a 72h period, we seeded cells at 1x104 and 2.5x104cells/well. A549 
cells were grown with either 0 or 10% FCS and treated with 0.1µg/ml and 1µg/ml of 
Pam3CSK4 or FSL-1. We harvested cells 24, 48, 72h after stimulation and counted them 
using the haemocytometer. 
After Pam3CSK4 stimulation we observed a significant increase in proliferation at the 72h 
time point with or without serum and at the lowest seeding density (Tab. 10A,C). Similarly, 
Table 9. The effect of viral ligands on the activation of A549 cells. A549 cells were 
seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS and allowed to 
equilibrate for 12h. After this time period, media was replaced with DMEM containing 
either 0 (A) or 10% FCS (B). Cells were treated with the ligands and incubated for 24, 48, 
72h an after which CXCL10 levels were measured in the supernatants by specific ELISA. 
Data represented are the mean ± SEM of n=9 replicates measured over 3 separate 
experimental days. *denotes p≤ 0.05 as assessed using a one-way ANOVA followed by a 
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FSL-1 caused an increase in proliferation at 72h in the absence of serum. When we 
seeded A549 cells at density 2.5X104 cells/well there was an increase in proliferation after 
Pam3CSK4 and FSL-1 stimulation in the presence of serum at 48h (Tab. 10D).  
A549 cells are a cancerous cell line and proliferate rapidly. We observed that these cells 
seeded at a density of 2.5x104 cells/well became fully confluent after 48h. When we 
seeded A549 cells at this density and stimulated them with Pam3CSK4 and FSL-1 in the 
presence of serum, an increase in proliferation was observed after 48h (Tab. 10D). For 
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0% FCS        Seeding Density – 1x104 cells/well 
 Control 
Pam3CSK4 FSL-1 
0.1 µg/ml 1µg/ml 0.1 µg/ml 1µg/ml 
24h 10.8±2.5 7.0±1.4 ns 8.6±1.4 ns 10.1±2.2 ns 10.3±1.6 ns 
48h 27.5±5.9 25.9±6.4 ns 27.0±5.3 ns 28.9±5.7 ns 25.6±5.6 ns 
72h 26.6±4.6 41.3±5.7 ns 33.9±4.0 * 36.0±5.7 ns 31.8±6.0 * 
 
0% FCS        Seeding Density – 2.5x104 cells/well 
 Control 
Pam3CSK4 FSL-1 
0.1 µg/ml 1µg/ml 0.1 µg/ml 1µg/ml 
24h 29.6±4.8 29.5±3.6 ns 24.2±3.0 ns 32.2±5.9 ns 29.1±4.4 ns 
48h 61.3±13.3 68.6±11.7 ns 67.0±8.9 ns 56.2±8.9 ns 51.5±13.1 ns 
72h 65.3±7.8 72.7±7.0 ns 77.0±7.7 ns 66.2±9.4 ns 68.6±7.2 ns 
 
10% FCS        Seeding Density – 1x104 cells/well 
 Control 
Pam3CSK4 FSL-1 
0.1 µg/ml 1µg/ml 0.1 µg/ml 1µg/ml 
24h 14.5±1.0 13.5±1.0 ns 13.1±0.5 ns 13±1.4 ns 12.8±1.8 ns 
48h 40.9±5.6 47.4±6.9 ns 46.0±6.9 ns 48.8±6.9 ns 47.1±5.8 ns 
72h 53.1±12.8 71.6±7.5 * 55.6±13.8 ns 64.2±11.0 ns 58.4±9.3 ns 
 
10% FCS        Seeding Density – 2.5x104 cells/well 
 Control 
Pam3CSK4 FSL-1 
0.1 µg/ml 1µg/ml 0.1 µg/ml 1µg/ml 
24h 43.3±4.4 39.6±2.1 ns 44.5±3.9 ns 43.5±4.5 ns 35.0±4.7 ns 
48h 71.0±9.8 84.0±8.0 * 84.3±8.7 * 88.4±9.2 ns 90.6±8.1 * 






Table 10. Effect of seeding density on A549 proliferation. A549 cells were seeded in 
a 96 well plates at 1 x 104 (A,C) or 2.5 x 104 (B,D) cells per well in DMEM with 10% FCS 
and allowed to equilibrate for 12h. After this time period media was replaced with DMEM 
containing either 0 (A,B) or 10 % FCS (C,D). Cells were treated with the ligands and 
incubated for 24, 48 and 72h after which proliferation was assessed by direct cell 
counting. Data represented are the mean ± SEM of n=9 replicates measured over 3 
separate experimental days. *denotes p≤ 0.05 as assessed using one-way ANOVA 
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5.3. Concentration-dependent effect of Pam3CSK4 on the proliferation of A549 cells. 
The previous experiment, using direct cell counting, indicated that Pam3CSK4 activated 
TLR2/1 heterodimer and stimulated the proliferation of A549 cells; although this appeared 
to be inversely related to concentration. It was therefore important to perform additional 
experiments using a more extensive range of concentrations of the agonist. To determine 
whether these cells proliferated to Pam3CSK4 in a concentration dependent manner the 
experiment was repeated using a range of concentrations from 0.001µg/ml to 3µg/ml. We 
chose a 72h time point, as this was where we observed the significant increase in cell 
number. Cells were seeded at the density 1x104 cell/well and counted using the 
haemocytometer.  
Figure 42 shows that activation of TLR2 increased A549 proliferation in the presence of 
10% serum.  All doses of the ligand significantly increased cell growth, however the 
biggest effect was observed with the lowest concentration of Pam3CSK4, where there was 
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Figure 42. Effect of Pam3CSK4 concentration on the proliferation of A549 cells after 
72h. A549 cells were seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% 
FCS and allowed to equilibrate for 12h. After this time period media was replaced with 
DMEM containing either 0% FCS (A) or 10% FCS (B). Cells were treated with the ligands 
and incubated for 72h after which proliferation was assessed by direct cell counting. Data 
represented are the mean ± SEM of n=9 replicates measured over 3 separate 
experimental days. *denotes p≤ 0.05 as assessed using column statistics followed by one 
sample t-test of normalised data. 
 
5.4. TLR2/1 stimulation and cell cycle profile. 
The increase in cellular proliferation in response to the TLR2/1 agonist, Pam3CSK4, may 
be a result of a change in the cell cycle profile induced in A549 cells. Therefore, to test 
this cell cycle profile was assessed using a Cell Cycle BioApplication protocol (Cellomics). 
Fluorescent images of A549 cells stained with DAPI were captured by a high-resolution 
camera. Image analysis was performed on DAPI positive cellular bodies, which allowed 
identification of chromatin staining within individual cells and subsequent characterisation 
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of the cell cycle stage. Briefly, A549 cells were seeded in 96-well plates either with 1 or 
10% FCS and stimulated with Pam3CSK4 for 6, 24, 48 and 72h.  
Looking at 6 at 24h time points more closely (Fig. 43A-D) we observed that a reduction in 
cell number in the G0/G1 phase corresponded to an increase in the S phase. The results 
showed significant changes in the G0/G1 and S phase only after 6 and 48h in cells grown 
with 1% FCS, but not in the G2/M phase. All three concentration of Pam3CSK4 induced 
small modification of DNA profile compared with the control. We were not able to analyse 
cells stimulated for 72h as A549 cells were too confluent therefore making it impossible for 
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Figure 43. Effect of TLR2/1 stimulation on A549 cell cycle profile. A549 cells were 
seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS and allowed to 
equilibrate for 12h. After this time period media was replaced with DMEM containing 1  or 
10% FCS. Cells were treated with the ligands and incubated for 6 (A,B), 24 (C,D), 48 
(E,F) after which DNA profile was assessed by Cell Cycle BioApplication (Cellomics). 
Data represented are the mean ± SEM of n=3 replicates. * denotes p≤ 0.05 as assessed 
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5.5. Effect of TLRs stimulation on A549 proliferation/viability.  
TLR2/1 activation induced a small increase in A549 proliferation. Thus, we decided to 
check whether this is true for other TLR ligands. Again we stimulated cells with bacterial 
and viral ligands and measured cell proliferation using AlamarBlue assay. AlamarBlue is a 
permeable and non-toxic cell health indicator. It uses the reducing power of living cells to 
convert resazurin (blue and non-fluorescent) to resorufin (red in color and highly 
fluorescent). Viable cells continuously convert resazurin to resorufin, increasing the overall 
fluorescence and color of the media surrounding cells, thereby making it easy to 
quantitatively measure proliferation, using the assumption that more cells produce a 
greater colour over the same period of time. Direct cell counting using the 
haemocytometer is time-consuming and can be affected by human bias and sampling 
error. Thus, the AlamarBlue assay was used to measure A549 proliferation/viability. 
Although, we saw an increase in cell proliferation of A549 cells using direct cell counting 
after Pam3CSK4 treatment, using the AlamarBlue assay we did not observe any 
significant difference in cellular proliferation after stimulation of TLR2/1, TLR2/6, TLR4 
(Fig. 44) and TLR3 (Fig. 45). TLR7 and TLR8 agonist induced cell death at 24h, 48h and 
72h in the presence and absence of serum (Fig. 45).    
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Figure 44. Effect of bacterial ligands on the proliferation of A549 cells over 72 hours. 
A549 cells were seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS 
and allowed to equilibrate for 12h. After this time period media was replaced with DMEM 
containing 0 (A-C) or 10% FCS (D-F). Cells were treated with increasing concentrations of 
agonists. Cells were then incubated for 24 (A,D), 48 (B,E) and 72h (C,F) after which 
proliferation was assessed using the AlamarBlue assay. Data represented are the mean ± 
SEM of n=6 replicates measured over 3 separate experimental days. *denotes p≤ 0.05 as 
assessed using a one-way ANOVA followed by a Dunnett’s multiple comparison post-hoc 
test.  
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5.6. A549 proliferation in response to serum 
AlamarBlue monitors cellular respiration as indicator of cell viability and as such is an 
indirect measure of proliferation. In order to validate observations using AlamarBlue, DNA 
was quantified using the CyQuant assay. This assay is a fluorescence-based method that 
utilises ‘GR-CyQuant’ dye, which binds to the nucleic acid within the cell. The DNA 
content of a cell is constant therefore; measuring cell number using DNA provides an 
24h
10% FCS














































































































































Figure 45. The effect of viral ligands on the proliferation of A549 cells over 72 hours. 
A549 cells were seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS 
and allowed to equilibrate for 12h. After this time period media was replaced with DMEM 
containing 0 (A-C) or 10% FCS (D-F). Cells were treated with increasing concentrations of 
agonists. Cells were then incubated for 24 (A,D), 48 (B,E) and 72h (C,F) after which 
proliferation was assessed using the AlamarBlue assay. Data represented are the mean ± 
SEM of n=6 replicates measured over 3 separate experimental days. *denotes p≤ 0.05 as 
assessed using a one-way ANOVA followed by a Dunnett’s multiple comparison post-hoc 
test.  
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accurate indication of relative cell number. Firstly, we assessed the proliferation potential 
of A549 cells and the suitability of the CyQuant assay as readout for proliferation. This 
was achieved by growing A549 cells in different concentrations of FCS (0-10%) over a 
72h time period. For each experiment, a DNA standard curve was prepared from different 
dilutions of bacteriophage λ DNA that was provided with the kit. The DNA content of 
samples was calculated using the standard curve generated each time. Increased DNA 
content in our experiments represented an increase in a relative number of cells. 
Serum caused a concentration-dependent increase in A549 cells at 24, 48 and 72h (Fig. 
46). It is also worth noting that A549 cells can still proliferate after serum withdrawal. This 
is a property that is common in nontransformed cancer cell lines and distinguish them 
from primary cells [203]. After 24h DNA content in the 0% FCS was 581ng/ml, this was 
also similar at 48h (551ng/ml) and increased to 868ng/ml after 72h. However, in the 
presence of 10% FCS the level of DNA present in A549 cells was 913ng/ml at 24h and 
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5.7. A549 proliferation after TLRs stimulation assessed using the the CyQuant 
assay.    
In order to perform the CyQuant assay, we chose TLR agonists, which were the most 
potent inducers of CXCL8 release. We also used ssRNA40/Lyovec as we saw a decrease 
in cell survival after TRL8 stimulation. Briefly, A549 cells were treated for 24, 48 and 72h 
with the TLR2/1, TLR2/6, TLR4 and TLR8 agonists and subjected to CyQuant assay. 	  	  
After 24 hours Pam3CSK4 at 0.1µg/ml and 1 µg/ml significantly induced proliferation (Fig. 
47A). By contrast, we observed small decrease in DNA content after 48h in 0.3% FCS 
(Fig. 47B). After 72h there was increase in A549 cell number when media with 10% of 
FCS was used (Fig. 47C). 
Serum Curve 24h


































































Figure 46. Effect of serum on the proliferation of A549 cells over 72 hours. A549 cells 
were seeded in a 96 well plates at 1 x 104 cells per ml in DMEM with 10% FCS and allowed 
to equilibrate for 12h. After this time period media was replaced with DMEM containing 0, 
0.3, 1, 3 and 10% FCS. Cells were then incubated for 24 (A), 48 (B) and 72h (C) after which 
proliferation was assessed by DNA content using the CyQuant assay. Data represented are 
the mean ± SEM of n=9 replicates measured over 3 separate experimental days. *denotes 
p≤ 0.05 as assessed using a one-way ANOVA followed by a Dunnett’s multiple comparison 
post-hoc test.  
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Figure 47. Effect of TLR2/1 stimulation on A549 proliferation grown in different 
concentration of FCS over 72h. A549 cells were seeded in a 96 well plates at 1 x 
104 cells per ml in DMEM with 10% FCS and allowed to equilibrate for 12h. After this 
time period media was replaced with DMEM containing 0, 0.3, 1, 3 and 10% FCS. 
Cells were treated with Pam3CSK4 and incubated for 24h (A), 48h (B) and 72h (C) 
after which proliferation was assessed by DNA content using the CyQuant assay. 
Data represented are the mean ± SEM of n=6 replicates measured over 3 separate 
experimental days. *denotes p≤ 0.05 as assessed using a one-way ANOVA followed 
by one sample t-test of normalised data. 
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After FSL-1 treatment we observed significant increase in cell number when media with 
10% FCS was used (Fig. 48A), but there was a decrease after 48h (0.3% and 1% FCS) 
(Fig. 48B). At 72h time point again we observed a small increase with 3% FCS (Fig. 48C). 
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Figure 48. Effect of TLR2/6 stimulation on A549 proliferation grown in different 
concentration of FCS over 72h. A549 cells were seeded in a 96 well plates at 1 x 104 
cells per ml in DMEM with 10% FCS and allowed to equilibrate for 12h. After this time 
period media was replaced with DMEM containing 0, 0.3, 1, 3 and 10% FCS. Cells were 
treated with FSL-1 and incubated for 24h (A), 48h (B) and 72h (C) after which proliferation 
was assessed by DNA content using the CyQuant assay. Data represented are the mean 
± SEM of n=6 replicates measured over 3 separate experimental days. *denotes p≤ 0.05 

















































































































A                                                    
B                                                    
C                                                    
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  




Our results after activation of TLR4 with LPS were not consistent. It induced a decrease in 
DNA content (Fig. 49) as well as an increase, suggesting that the effect of TLR agonism 
on cellular proliferation may be more complex than first envisaged. 
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Figure 49. Effect of TLR4 stimulation on A549 proliferation grown in different 
concentration of FCS over 72h. A549 cells were seeded in a 96 well plates at 1 x 104 
cells per ml in DMEM with 10% FCS and allowed to equilibrate for 12h. After this time 
period media was replaced with DMEM containing 0, 0.3, 1, 3 and 10% FCS. Cells were 
treated with LPS and incubated for 24h (A), 48h (B) and 72h (C) after which proliferation 
was assessed by DNA content using the CyQuant assay. Data represented are the mean 
± SEM of n=6 replicates measured over 3 separate experimental days. *denotes p≤ 0.05 
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The most interesting results were obtained after TLR8 stimulation. Our results showed 
that the lowest concentration of this ligand (0.1µg/ml) induced increase in DNA content but 
at the highest concentration (10µg/ml) induced cell death (Fig. 50). 
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Figure 50. Effect of TLR8 stimulation on A549 proliferation grown in different 
concentration of FCS over 72h. A549 cells were seeded in a 96 well plates at 1 x 104 
cells per ml in DMEM with 10% FCS and allowed to equilibrate for 12h. After this time 
period media was replaced with DMEM containing 0, 0.3, 1, 3 and 10% FCS. Cells were 
treated with ssRNA40/Lyovec and incubated for 24h (A), 48h (B) and 72h (C) after which 
proliferation was assessed by DNA content using the CyQuant assay. Data represented 
are the mean ± SEM of n=6 replicates measured over 3 separate experimental days. 
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5.8. Effect of apoptotic agents on A549 cell survival. 
Previous results by other groups showed that activation of TLR4 can induce resistance to 
apoptosis [11]. To determine whether it is true for our cell line and other TLRs, we 
performed AlamarBlue assay after treatment with apoptotic agents. Firstly, to choose the 
best apoptotic agent, we stimulated A549 cells with TNF-α+cycloheximide, cycloheximide 
alone, TNF-α alone and H2O2 alone. 
Figure 51 shows that all agents except TNF-α induced cell death. The death rate for TNF-
α+ cycloheximide was 25% and 24% for cells grown with 1% and 10% FCS respectively, 
25% and 40% for cycloheximide, and 24% and 32% for H2O2.  
 
Figure 51. Effect of apoptotic agents on A549 survival. A549 cells were seeded in a 
96 well plates at 1 x 104 cells well in DMEM with 10% FCS and allowed to equilibrate for 
12h. After this time period media was replaced with DMEM containing 1 (A) or 10% FCS 
(B). Cells were treated with TNF-α (3ng/ml)+CHX (3µg/ml), CHX (3µg/ml), TNF-α (3ng/ml) 
and H2O2 (0.6mM). After 24h incubation cell viability was measured by the AlamarBlue 
assay. Data represented are the mean ± SEM of n=8 replicates measured over 4 separate 
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To ascertain whether activation of TLRs can induce apoptosis resistance, we treated 
A549 cells with increasing concentrations of Pam3CSK4 in 96 well plates. These 
conditions were chosen based on our preliminary data. After 4h, the cell death agents 
were added and cells were incubated for a further 24h.  
Our results showed that when A549 cells were stimulated with Pam3CSK4 (1µg/ml) in 
10% FCS prior to treatment with cycloheximide, cell viability was increased from 62% to 
77%, and appeared to be dose dependent (Fig. 52D). These findings did not hold true for 
treatment with TNF-α+cycloheximide and H2O2 (Fig. 52A,B,E,F).  
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Figure 52. Effect of TLR2/1 stimulation on A549 survival. A549 cells were seeded in a 
96 well plates at 1 x 104 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period media was replaced with DMEM containing 1 (A,C,E) or 
10% FCS (B,D,F). 4h after adding Pam3CSK4 cells were treated with TNF-α+CHX (A,B), 
CHX alone (C,D) and H2O2 (E,F). After 24h incubation cell viability was measured by the 
AlamarBlue assay. Data represented is the mean ± SEM of n=8 replicates measured over 
4 separate experimental days. * denotes p≤0.05 as assessed using one-way ANOVA 
followed by one-sample t-test of normalized data. 
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5.9. Flow cytometric analysis of apoptosis in A549 cells after TLR stimulation.  
For analysis of apoptosis in the A549 cell line we used annexin V and propidium iodide 
(PI) staining. FITC annexin V staining precedes the loss of membrane integrity which 
accompanies the latest stages of cell death resulting from either apoptotic or necrotic 
processes. Therefore, staining with FITC annexin V is typically used in conjunction with a 
vital dye such as propidium iodide (PI) to allow the investigator to identify early apoptotic 
cells.  We used four different apoptotic agents: cycloheximide, TRAIL, and cycloheximide 
combined with TNF-α. Firstly, we analysed cells health status by looking at them under 
the microscope. Thus, we seeded A549 cells in 6 well plates at 3x103 cell/well and treated 
them with apoptotic agents. After 24h we took the pictures of these cells using Cannon 
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Figure 53. Effect of cycloheximide on A549 cells. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with increasing concentration of cycloheximide. 




Figure 54. Effect TRAIL on A549 cells. A549 cells were seeded in a 6 well plates at 3 x 
105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. After this 
time period cells were treated with increasing concentration of TRAIL. After 24h pictures 
were taken with Cannon CoolpixTM digital camera (5 mega pixels) with 100x magnification. 
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Figure 55. Effect of cycloheximide and TNF-α on A549 cells. A549 cells were seeded 
in a 6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to 
equilibrate for 12h. After this time period cells were treated with increasing concentration 
of cycloheximide and TNF-α (15ng/ml). After 24h pictures were taken with Cannon 
CoolpixTM digital camera (5 mega pixels) with 100x magnification. 
 
 
Figure 56. Effect of TNF-α and cycloheximide on A549 cells. A549 cells were seeded 
in a 6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to 
equilibrate for 12h. After this time period cells were treated with increasing concentration 
of TNF-α and cycloheximide (1µg/ml). After 24h pictures were taken with Cannon 
CoolpixTM digital camera (5 mega pixels) with 100x magnification.  
 
To analyse apoptosis in more detail using FACS, A549 cells were harvested after 
treatment and stained with annexin V-FITC and PI. Cell were analysed within an hour.  
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TRAIL (TNF-related apoptosis-inducing ligand) is a type II transmembrane protein with 
homology to other members of the TNF family. It binds to the death receptors, DR4 and 
DR5. The process of apoptosis is caspase-8-dependent. This protein preferentially 
induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells 
although it is expressed at a significant level in most normal tissues. Our results showed 
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Figure 57. Effect of TRAIL on A549 cells viability. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with increasing concentration of TRAIL and 
incubated for 24h at 37°C. Cells were harvested and stained with annexin V and PI and 
analysed by FACS. Representative scatter plot of PI and annexin V staining (A). The % of 
dead cells from the scatter plot Q1, Q2 and Q4 (B). Data represented are the mean ± 
SEM of n=3 replicates measured over 3 separate experimental days. *denotes p≤0.05 as 
assessed using one-way ANOVA followed by Dunnett’s multiple comparison test. Q1 – 
dead cells (annexin V negative, PI positive), Q2- late apoptotic cells (annexin V and PI 
positive), Q3- live cells (annexin V and PI negative), Q4- early apoptotic cells (annexin V 
positive, PI negative). 
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Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity is 
translation inhibition in eukaryotes resulting in cell growth arrest and cell death. It induced 
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Figure 58. Effect of TRAIL on A549 cells viability. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with increasing concentration of CHX and 
incubated for 24h at 37°C. Cells were harvested and stained with annexin V and PI and 
analysed by FACS assay. Representative scatter plot of PI and annexin V staining (A). 
The % of dead cells from the scatter plot Q1, Q2 and Q4 (B). Data represented are the 
mean ± SEM of n=3 replicates measured over 3 separate experimental days. *denotes 
p≤0.05 as assessed using one-way ANOVA followed by Dunnett’s multiple comparison 
test. Q1 – dead cells (annexin V negative, PI positive), Q2- late apoptotic cells (annexin V 
and PI positive), Q3- live cells (annexin V and PI negative), Q4- early apoptotic cells 
(annexin V positive, PI negative). 
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TNF-α alone did not cause apoptosis of A549 cells in our model. CHX has been 
previously shown to sensitize cells to TNF-α-induced cell death by lowering FLICE-like 
inhibitory protein (FLIP) levels. Thus, we modified our approach by combining TNF-α and 
CHX [2]. Therefore, we used one concentration of TNF-α (15ng/ml) and increasing 
concentration of CHX. Figure 59 shows that cells were very sensitive for these agents and 
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Figure 59. Effect of TRAIL on A549 cells viability. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with increasing concentration of CHX + TNF-α 
(15ng/ml) and incubated for 24h at 37°C. Cells were harvested and stained with annexin V 
and PI and analysed by FACS. Representative scatter plot of PI and annexin V staining 
(A). The % of dead cells from the scatter plot Q1, Q2 and Q4 (B). Data represented are 
the mean ± SEM of n=3 replicates measured over 3 separate experimental days. *denotes 
p≤0.05 as assessed using one-way ANOVA followed by Dunnett’s multiple comparison 
test. Q1 – dead cells (annexin V negative, PI positive), Q2- late apoptotic cells (annexin V 
and PI positive), Q3- live cells (annexin V and PI negative), Q4- early apoptotic cells 
(annexin V positive, PI negative). 
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The effects of combining increasing concentrations of TNF-α with CHX (1µg/ml) had no 
significant effect on the amount of apoptosis seen. In all conditions used, we observed a 
concentration dependent apoptosis of A549 cells (Fig. 60).  
For future experiments, we decided to use TRAIL at a concentration of 1µg/ml and TNF-
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Figure 60. Effect of TRAIL on A549 cells viability. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with increasing concentration of TNF-α + CHX 
(1µg/ml) and incubated for 24h at 37°C. Cells were harvested and stained with annexin V 
and PI and analysed by FACS. Representative scatter plot of PI and annexin V staining 
(A). The % of dead cells from the scatter plot Q1, Q2 and Q4 (B). Data represented are 
the mean ± SEM of n=3 replicates measured over 3 separate experimental days. *denotes 
p≤0.05 as assessed using one-way ANOVA followed by Dunnett’s multiple comparison 
test. Q1 – dead cells (annexin V negative, PI positive), Q2- late apoptotic cells (annexin V 
and PI positive), Q3- live cells (annexin V and PI negative), Q4- early apoptotic cells 
(annexin V positive, PI negative). 
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A549 is an adherent cell line and specific membrane damage may occur during cell 
detachment or harvesting. Thus, we tried three different methods of harvesting to avoid 
cell damage. We used (i) standard trypsin detachment, (ii) dissociation buffer (DB) which 
is designed for gentle dissociation of mammalian cells from each other and the culture 
plate, and (iii) a scraping method. Our results showed that using trypsin was the best way 
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Figure 61. Effect of TRAIL on A549 cells viability. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with TRAIL (1µg/ml) and incubated for 24h at 
37°C. Cells were harvested and stained with annexin V and PI and analysed by FACS. 
Representative scatter plot of PI and annexin V staining (A). The % of dead cells from the 
scatter plot Q1, Q2 and Q4 (B). Data represented are the mean ± SEM of n=3 replicates 
measured over 3 separate experimental days. *denotes p≤0.05 as assessed using one-
way ANOVA followed by Dunnett’s multiple comparison test. Q1 – dead cells (annexin V 
negative, PI positive), Q2- late apoptotic cells (annexin V and PI positive), Q3- live cells 
(annexin V and PI negative), Q4- early apoptotic cells (annexin V positive, PI negative). 
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The amount of purified recombinant annexin V required to saturate binding sites may vary 
according to cell type and stage of apoptosis so titration of annexin V and PI is required to 
obtain optimal results. Figure 62 shows that all concentrations of annexin V and PI that we 
used were equally effective at detecting apoptosis of the cells. We therefore used a 
concentration of 2.5µl for future experiments as this was the lowest concentration that 
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Figure 62.  Effect of TRAIL on A549 cells viability. A549 cells were seeded in a 6 well 
plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate for 12h. 
After this time period cells were treated with TRAIL (1µg/ml) and incubated for 24h at 
37°C. Cells were harvested and stained with annexin V and PI and analysed by FACS. 
Representative scatter plot of PI and annexin V staining (A). The % of dead cells from the 
scatter plot Q1, Q2 and Q4 (B). Data represented are the mean ± SEM of n=3 replicates 
measured over 3 separate experimental days. *denotes p≤0.05 as assessed using one-
way ANOVA followed by Dunnett’s multiple comparison test. Q1 – dead cells (annexin V 
negative, PI positive), Q2- late apoptotic cells (annexin V and PI positive), Q3- live cells 
(annexin V and PI negative), Q4- early apoptotic cells (annexin V positive, PI negative). 
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After optimization of the FACS protocol we performed further experiments to determine 
whether activation of TLRs on A549 cells could induce apoptosis resistance. We seeded 
cells in 6 well plates and treated them with TLR agonists 4 hours prior to TNF-α+CHX and 
TRAIL treatment. We measured apoptosis 24h later. TRAIL was not a good agent to 
induce apoptosis. It worked in the first experiment but was not effective later on. 
TNFα+CHX worked better and induce around 20% of cell death.  
Figures 63, 64 and 65 show that stimulation of TLR2/1, TLR2/6 and TLR4 with 
Pam3CSK4, FSL-1 and LPS respectively did not have any effect on apoptosis resistance 
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Figure 63. Effect of TLR2/1 agonist on A549 cells viability. A549 cells were seeded in 
a 6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period cells were treated with TNF-α (15ng/ml)+CHX (1µg/ml) or 
TRAIL (1µg/ml) 4h prior Pam3CSK4 treatment. After 24h cells were harvested and stained 
with annexin V and PI and analysed by FACS. Representative scatter plot of PI and 
annexin V staining (A). The % of dead cells from the scatter plot from Q1, Q2 and Q4 (B). 
Data represented are the mean ± SEM of n=3 replicates measured over 3 separate 
experimental days. *denotes p≤0.05 as assessed using one-way ANOVA followed by 
Dunnett’s multiple comparison test. Q1 – dead cells (annexin V negative, PI positive), Q2- 
late apoptotic cells (annexin V and PI positive), Q3- live cells (annexin V and PI negative), 
Q4- early apoptotic cells (annexin V positive, PI negative). 
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Figure 64. Effect of TLR2/6 agonist on A549 cells viability. A549 cells were seeded in 
a 6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period cells were treated with TNF-α (15ng/ml)+CHX (1µg/ml) or 
TRAIL (1µg/ml) 4h prior FSL-1 treatment. After 24h cells were harvested and stained with 
annexin V and PI and analysed by FACS. Representative scatter plot of PI and annexin V 
staining (A). The % of dead cells from the scatter plot from Q1, Q2 and Q4 (B). Data 
represented are the mean ± SEM of n=3 replicates measured over 3 separate 
experimental days. *denotes p≤0.05 as assessed using one-way ANOVA followed by 
Dunnett’s multiple comparison test. Q1 – dead cells (annexin V negative, PI positive), Q2- 
late apoptotic cells (annexin V and PI positive), Q3- live cells (annexin V and PI negative), 
Q4- early apoptotic cells (annexin V positive, PI negative). 
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Figure 65. Effect of TLR4 agonist on A549 cells viability. A549 cells were seeded in a 
6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period cells were treated with TNF-α (15ng/ml)+CHX (1µg/ml) or 
TRAIL (1µg/ml) 4h prior LPS treatment. After 24h cells were harvested and stained with 
annexin V and PI and analysed by FACS. Representative scatter plot of PI and annexin V 
staining (A). The % of dead cells from the scatter plot from Q1, Q2 and Q4 (B). Data 
represented are the mean ± SEM of n=3 replicates measured over 3 separate 
experimental days. *denotes p≤0.05 as assessed using one-way ANOVA followed by 
Dunnett’s multiple comparison test. Q1 – dead cells (annexin V negative, PI positive), Q2- 
late apoptotic cells (annexin V and PI positive), Q3- live cells (annexin V and PI negative), 
Q4- early apoptotic cells (annexin V positive, PI negative). 
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Figure 66. Effect of TLR3 agonist on A549 cells viability. A549 cells were seeded in a 
6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period cells were treated with TNF-α (15ng/ml)+CHX (1µg/ml) or 
TRAIL (1µg/ml) 4h prior Poly I:C treatment. After 24h cells were harvested and stained 
with annexin V and PI and analysed by FACS. Representative scatter plot of PI and 
annexin V staining (A). The % of dead cells from the scatter plot from Q1, Q2 and Q4 (B). 
Data represented are the mean ± SEM of n=3 replicates measured over 3 separate 
experimental days. *denotes p≤0.05 as assessed using one-way ANOVA followed by 
Dunnett’s multiple comparison test. Q1 – dead cells (annexin V negative, PI positive), Q2- 
late apoptotic cells (annexin V and PI positive), Q3- live cells (annexin V and PI negative), 
Q4- early apoptotic cells (annexin V positive, PI negative). 
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Imiquimod, an agonist of TLR7, caused an increase in apoptosis when it was used 
together with TNF-α+CHX (Fig. 67A,D). Similar effects were observed with the TLR8 
agonist, ssRNA40 (Fig. 68). This agonist alone was able to induce A549 apoptosis. This 
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Figure 67. Effect of TLR7 agonist on A549 cells viability. A549 cells were seeded in a 
6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period cells were treated with TNF-α (15ng/ml)+CHX (1µg/ml) or 
TRAIL (1µg/ml) 4h prior Imiquimod treatment. After 24h cells were harvested and stained 
with annexin V and PI and analysed by FACS. Representative scatter plot of PI and 
annexin V staining (A). The % of dead cells from the scatter plot from Q1, Q2 and Q4 (B). 
Data represented are the mean ± SEM of n=3 replicates measured over 3 separate 
experimental days. *denotes p≤0.05 as assessed using one-way ANOVA followed by 
Dunnett’s multiple comparison test. Q1 – dead cells (annexin V negative, PI positive), Q2- 
late apoptotic cells (annexin V and PI positive), Q3- live cells (annexin V and PI negative), 
Q4- early apoptotic cells (annexin V positive, PI negative). 
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Figure 68. Effect of TLR8 agonist on A549 cells viability. A549 cells were seeded in a 
6 well plates at 3 x 105 cells per well in DMEM with 10% FCS and allowed to equilibrate 
for 12h. After this time period cells were treated with TNF-α (15ng/ml)+CHX (1µg/ml) or 
TRAIL (1µg/ml) 4h prior ssRNA/Lyovec treatment. After 24h cells were harvested and 
stained with annexin V and PI and analysed by FACS. Representative scatter plot of PI 
and annexin V staining (A). The % of dead cells from the scatter plot from Q1, Q2 and Q4 
(B). Data represented are the mean ± SEM of n=3 replicates measured over 3 separate 
experimental days. *denotes p≤0.05 as assessed using one-way ANOVA followed by 
Dunnett’s multiple comparison test. Q1 – dead cells (annexin V negative, PI positive), Q2- 
late apoptotic cells (annexin V and PI positive), Q3- live cells (annexin V and PI negative), 
Q4- early apoptotic cells (annexin V positive, PI negative). 
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Cigarette smoking is responsible for 90% of all lung cancers, which are the leading cause 
of cancer deaths in the world. It is also the major cause of COPD, the fourth leading cause 
of death worldwide. Cigarette smoke-induced chronic lung inflammatory 
microenvironment, oxidative stress and cell structural alterations such as the increase of 
cell proliferation, angiogenesis and apoptosis arrest are irreversible processes that are 
associated with lung tumor cell growth.  
Our department has previously shown that TLRs are involved in the perception of 
inflammation in immune cells after acute cigarette smoke exposure and therefore may 
play a part in cellular processes such as increased cell proliferation and resistance to 
apoptosis found in lung cancer cells. To test this hypothesis we firstly looked to see if 
TLRs were functionally active on A549 cells. Agonists of TLRs resulted in a robust 
production of CXCL8, suggesting that TLRs are present and are functionally active. It is 
interesting to note that bacterial ligands were more potent in the release of CXCL8 
compared with viral ligands. The secretion of CXCL8 in A549 cells was concentration 
dependent regardless of the presence or absence of serum.  
We also demonstrated that TLRs were active on A549 cells, therefore we performed 
experiments to determine whether activation of these receptors could induce cell 
proliferation. It is suggested that carcinogenesis is an abnormal form of tissue repair, 
which requires proliferation. Molecules released during this process are important stimuli 
for TLR-induced cell proliferation [204]. In several types of cancer TLR stimulation led to 
increased cell proliferation and tumor metastasis. Three multiple myeloma cell lines, 
ANBL-6, RPMI-8226 and OH-2, also increased proliferation after Pam3Cys and MALP-2 
stimulation [205]. In addition, TLR2 also promoted migration and growth of cancer cells 
including U1810, HeLa and NCI-H292 [206]. However, two other studies on A549 cell line 
showed no increase in cell proliferation after TLR4, TLR7 and TLR8 stimulation [136, 
200]. Activation of TLR2 on the oral squamous cell carcinoma cell line, YD-10B, also had 
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no effect on tumor progression [136]. In the present study we demonstrated that serum 
caused a concentration-dependent proliferation of A549 cells and that stimulation of TLRs 
with bacterial ligands induced a small increase in A549 proliferation under certain 
condition. However, the CyQuant assay which measures DNA content in the cell also 
showed some decrease in cell number suggesting that this effect was not biologically 
relevant. The The AlamarBlue assay showed that TLR7 and TLR8 ligands induced a 
decrease in cell viability/respiration, this was confirmed for a TLR8 agonist using the 
CyQuant assay, where we found decreased DNA content in A549 cells stimulated with 
ssRNA40/Lyovec. Our data from the cellomics assay showed that there was a small but 
significant increase in cellular proliferation at 48h after TLR2 activation. This was 
represented by a decrease in total cells in G0/G1 phase and a corresponding increase in 
cells in S phase. Although this data did not match the timings seen with the CyQuant 
assay, where a maximal effect was observed at 72h post TLR2 activation. Unfortunately 
the density of the cells as a monolayer was prohibitive for this technique to distinguish 
individual cells at 72h time point.  
Since cancer cell survival and inflammation-induced chemoresistance have been linked to 
activation of NF-κB, upregulation of antiapoptotic proteins and inhibition of proapoptotic 
proteins [22], we wanted to verify whether TLR activation can induce apoptosis resistance 
in the A549 cell line. The AlamarBlue assay results showed that when A549 cells were 
stimulated with Pam3CSK4 prior to treatment with CHX cell viability was increased, with 
these effects being concentration dependent. Our results are similar to those obtained by 
He and colleagues where stimulation of TLR4 on A549 cells induced resistance to TRAIL-
induced apoptosis [136]. Another study on a human lung cancer cell line showed that 
TLR7 and TLR8 agonism led to the activation of NF-κB and upregulation of the anti-
apoptotic protein Bcl-2. This resulted in increased tumor survival and chemoresistance 
[200]. However, this was not an overall class effect of TLRs on cancer cells, as a TLR3 
agonist, in combination with a type I IFN or a protein synthesis inhibitor, reduced cell 
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proliferation and induced tumor cell death in melanoma cells. This effect was found to be 
caspase dependent. Moreover, it was demonstrated that TLR3-mediated cell death 
involved the activation of caspases and engaged both extrinsic and intrinsic apoptotic 
pathways [207]. Our results from FACS analysis showed that activation of TLR2, TLR3 
and TLR4 did not have any effect on resistance to apoptosis. However, again we 
observed increased cell death after TLR7 and TLR8 activation. The biggest effect was 
seen after TLR8 stimulation with ssRNA40/Lyovec, where we demonstrated that this 
agonist could induce A549 cell death. Taking all our findings into account, it is unlikely that 
bacterial ligands activating TLRs can induce cell proliferation and resistance to apoptosis. 
However CXCL8 released by these cells can contribute to cancer development and 
progression.  
Both, cancer development and tissue repair processes, are characterized by high 
numbers of infiltrating immune cells. These cells produce high level of cytokines, growth 
factors and prostaglandins [22].  CXCL8 is a proangiogenic chemokine which has anti-
apoptotic properties that promote tumor metastasis and death resistance. CXCL8 is found 
in high levels within the tumor microenvironment [208]. In addition to its chemotactic 
function, CXCL8 has been shown to promote tumor cell proliferation in breast cancer, 
melanoma and bronchogenic carcinoma [209-211]. Furthermore, levels of CXCL8 
production correlated directly with the metastatic potential of tumors [122, 208, 212, 213]. 
Our data showed that secretion of CXCL8 in A549 cells was increased significantly by 
TLR ligation and may contribute to lung cancer cell escape from immune control but it 
does not affect cell proliferation. Our findings also showed that it is implausible that 
activation of TLR2, TLR3 and TLR4 can promote resistance to apoptosis. We found that 
only ligands for TLR7 and TLR8 induced cell death in A549 cells. Similar results were 
obtained by other groups where Ahn et al. demonstrated that Imiquimod inhibited 
effectively the growth of OSCC cells by inducing apoptosis and necrosis [214]. Moreover, 
TLR7/8 activation by imidazoquinolines also enhanced antitumor effects through inhibition 
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of angiogenesis, NK-mediated cytotoxicity and direct apoptosis of tumor cells [215-217]. 
Imiquimod formulated as imiquimod 5% cream (Aldara™) is indicated for the treatment of 
a variety of diseases ranging from human papillomavirus (HPV)-related external genital 
and perianal warts to primary skin malignancies or premalignant conditions (actinic 
keratosis). Treatment of superficial basal cell carcinoma (sBCC) with imiquimod 5% cream 
resulted in histological clearance rates of 79–82% in Phase III studies [218]. VTX-2337 
(VentiRx Pharmaceuticals), a new TLR8 ligand is in phase I/II clinical trials in combination 
with current regimens for the treatment of lymphoma and various other solid tumors [219]. 
The antitumoral activities of TLR7/8 agonists have been associated with their ability to 
induce IL12p70 secretion by DC, enhancement of NK cell activation, as well as a 
decrease in Tregs. Their ability to induce a potent Th1-type immune response and 
decrease the number of Tregs could lead to a tumor microenvironment more favourable 
for the host immune system to respond strongly against the tumor [160]. 
The last remaining question is whether the cell death observed in A549 cells occurred 
because of a real TLR-mediated effect or whether the concentrations of the drugs we 
used were too high, resulting in cell death. When considering the use of these ligands in 
tumor therapy, it is important to consider the potential effect of these agonists on the 
entire organism as well. To answer this question a few additional experiments are 
required. It will be useful to extend the concentration range of these compounds, and also 
to try other TLR7 and TLR8 agonists to verify if this was a TLR class effect rather than a 
specific agonist effect. It would also be of use to try different approaches to capture 
apoptosis e.g. confocal microscopy with annexin V staining. 
Some studies suggest that TLR activation can promote tumor growth and the escape of 
tumor cells from the host immune system while others claim the opposite effect.  Thus, the 
choice between either agonist or antagonist for TLRs in cancer therapy may be very 
difficult. As TLR research is still in its infancy, more functional studies are required in 
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human diseases using both agonists and antagonists to give us definitive answers 
regarding the role of TLRs in inflammation and cancer. 
 
Chapter summary 
Our data showed that secretion of CXCL8 in A549 cells increased significantly after TLR 
ligation and may contribute to lung cancer cell escape from immune control, but it does 
not affect cell proliferation. Activation of TLR2, TLR3 and TLR4 did not promote resistance 
to apoptosis. Only the viral ligands, TLR7 and TLR8, had effects on A549 viability where 
we demonstrated that these agonists induced cell death. 
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Cigarette smoke causes inflammation and is a major risk factor in the pathogenesis of 
many diseases including COPD, lung cancer and atherosclerosis. Oxidants, of which 
there are many in cigarette smoke, activate monocytes/macrophages and airway cells to 
release cytokines such as CXCL8 and IL-1β. Production of these cytokines can contribute 
to inflammatory responses observed in the lung and can result in chronic bronchitis, 
emphysema, airway wall remodelling, fibrosis and chronic inflammation. These chronic 
lung pathologies are known to be contributory risk factors for cancer. Work from our group 
has shown that when cells were stimulated with smoke in vitro there was an increase in 
the expression of some of the pro-inflammatory genes such as CXCL8, TNF-α as well as 
the anti-oxidant gene, HMOX1. Whilst we know that smoke is the causative agent in 
COPD we still don’t know too much about how it induces inflammation. There are a great 
number of publications showing that TLRs mediate cigarette smoke-induced cytokine 
production and pro-inflammatory responses [64, 101, 106, 220] so the aim of this thesis 
was to study the role of TLRs in smoking related disease. The basic aims of my PhD have 
fallen into three areas. Firstly, I analysed the role of TLRs in inflammasome activation and 
cytokine release. Since TLRs and the inflammasome are now implicated in respiratory 
diseases such as COPD, I performed a mechanistic part to my PhD where I directly 
compared the signalling pathways between TLR4 and TLR2-induced release of IL-1β and 
CXCL8. Secondly, I have performed a clinical study to investigate how whole blood from 
patients with COPD, and later patients with PAH, respond to stimulation with specific TLR 
agonists. Thirdly, I analysed lung cancer cell proliferation and viability characteristics in 
response to TLR agonists. 
Since inflammasome signalling in airway cells may play an important role in the 
pathogenesis of diseases like COPD [110], we wanted to investigate the contribution of 
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TLRs to inflammasome activation and cytokine release. In Chapter 3, we found that the 
activation of TLR4 and TLR2 resulted in the release of CXCL8 and IL-1β. ATP further 
enhanced IL-1β production. We found no difference between TLR2 and TLR4 mediated 
CXCL8 secretion. However, there were clear differences in the release of mature IL-1β 
after TLR2 versus TLR4 stimulation. In these experiments we found evidence to suggest 
that TLR2 and TLR4 induced IL-1β release proceeds via different signalling pathways 
where the TLR4-induced release did not involve pannexin-1, a hemichannel protein. We 
think that the TLR4 pathway, which activates TRIF, also activates inflammasome 
assembly. This was demonstrated in a paper by Rathinam et al. who showed that this 
TRIF-dependent activation of TLR4 was able to activate the inflammasome without the 
need for a second stimulus [170]. This is verified by the results that I obtained showing 
that TLR2, which doesn’t activate TRIF pathway, required pannexin-1. Pannexin-1 is 
necessary in this process, it forms large pores in the cell membrane, which allows the 
passage of large molecules such as ATP, which can then stimulate inflammasome 
assembly by an undefined mechanism. Our data suggest an important dissociation in 
inflammasome activation induced by TLR4 versus TLR2 which could be important in our 
understanding of both bacterial and sterile inflammation in man. This is important as it 
may help us target diseases where TLR2 or TLR4-induced IL-1β release may be the 
underlying cause of pathology.  
As it was mentioned before, cigarette smoke is the major cause in the development of 
COPD. TLRs play a role in oxidant sensing and there is growing evidence that activation 
of TLRs can contribute to disease pathogenesis and progression. COPD describes a 
heterogeneous group of disorders whereby some individuals suffer with frequent infective 
exacerbations, despite smoking cessation. These exacerbations are known to accelerate 
the destructive process and manifest in a more rapid decline in lung function. The 
“frequent exacerbator” phenotype has recently been elucidated [221] and is reflected in 
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the updated GOLD staging of COPD. However, little is known about what defines this 
group of individuals on a genetic or immunological basis. It is well established that 
patients with COPD are more susceptible to viral and bacterial airway infection, with a 
number of mechanisms proposed. We hypothesised that the systemic inflammation 
observed in patients with COPD may be regulated by TLRs and that TLR stimulation (by 
bacteria, viruses or DAMPs) will result in the release of inflammatory cytokines that play a 
role in alveolar destruction and systemic inflammation. This is important as it may help us 
target diseases where TLR2 or TLR4-induced IL-1β release may be the underlying cause 
of pathology. In Chapter 4, we tested this hypothesis using an in vitro system to model the 
effect of TLR stimulation of blood from COPD patients and measured the important 
inflammatory cytokines, CXCL8 and IL-1β. Among the mediators of neutrophil recruitment 
into the lung, the chemokine CXCL8 is considered to be a major player in COPD. We 
found that COPD patients had higher levels of CXCL8 in unstimulated blood. It was also 
demonstrated that the blood of COPD patients was more sensitive to some of the Gram-
positive and Gram-negative bacterial ligands. In addition, elevated levels of CXCL8 and 
IL-1β were found in COPD subjects in response to the viral ligand, Poly I:C, compared to 
age-matched controls. Our data might help to understand better the relationship between 
responses to TLR activation in COPD and give us an insight into why patients with COPD 
experience repeated infective exacerbations leading to worsening lung function. A similar 
approach was taken when investigating the effects of TLRs in the blood of patients with 
PAH. Our results showed that LPS stimulation resulted in increases in levels of IL-1β 
suggesting an increased sensitivity to TLR4 activation in the blood of PAH patients.  This 
very much fits into the hypothesis that patients with inflammatory lung disease are more 
susceptible to pathogen activation in immune cells. 
In Chapter 5, we wanted to investigate the role of TLRs in a different disease associated 
with cigarette smoking, namely lung cancer. TLRs have been shown to regulate cancer 
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cell proliferation and survival, thus expanding the role of these immune cell receptors into 
the cancer field. The original idea that stimulation of TLRs has a positive role in 
tumorigenesis came from reports demonstrating that TLR ligands augment the growth of 
adoptively transferred tumors [222-224]. In our study, we wanted to investigate whether 
activation of TLRs on cancerous lung epithelial cell line A549 can contribute to increased 
cell proliferation and lung cancer progression. Firstly, we performed some preliminary 
experiments to choose appropriate conditions for our cell line. Then, we used different 
methods to establish proliferation characteristics of our cells and the effect of TLR 
agonism on this process. Our results showed that it is unlikely that TLR activation induces 
increased cell proliferation, however a decrease in cell viability was observed after 
stimulation of TLR8 with single-stranded RNA. To take our study further, we also wanted 
to verify whether activation of TLRs can induce apoptosis resistance rather than 
proliferation. Our FACS data indicated that activation of TLRs with bacterial ligands did 
not have any effect on cell survival. However, stimulation with the TLR8 agonist again 
caused an increase in A549 cell death and therefore TLR8 may act as a potential useful 
target in cancer therapy. 
Since first being described in the fruit fly, Drosophila melanogaster, TLRs are seen as an 
attractive target to immunologists and investigators interested in the molecular basis of 
inflammation, as they directly sense PAMPs and DAMPs, and cause a robust 
inflammatory response [225]. There have been many attempts to use TLR manipulation 
for the treatment of infectious, allergic and autoimmune diseases, as well as cancer. 
These studies are in the early clinical phases, and results have not always been positive. 
TLRs recognize viral and bacterial PAMPs as well as DAMPs but the pathways they 
activate are complex and involve multiple genes and molecules. In addition, during the 
process of inflammation, there is a release of host breakdown products from the 
extracellular matrix, which are able to further stimulate TLRs. TLR activation occurs early 
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in the cascade of events that gives rise to inflammation, there might be an advantage in 
blocking them as they might be close to the initiating events that give rise to chronic 
inflammation. As it was mentioned before (Chapter 5) single stranded RNA-based TLR7 
and TLR8 agonists are being developed for the treatment of cancer [225]. Early studies 
showed that the activation of TLR7 or TLR8 can reverse the suppressive function 
of Tregs. When combined with the ability of TLR7 and TLR8 to activate dendritic cells, this 
effect results in a strong antitumor response. However, some studies suggest that TLR 
activation can promote tumor growth, and tumor cell evasion of the host immune system. 
We therefore need more research on the functional aspects of TLRs in different cell types 
to establish whether an agonist or antagonist approach would be beneficial in specific 
clinical settings. Synthetic TLR activators are currently under clinical development for the 
treatment of asthma and allergies; these include; TLR3, TLR4, TLR5, TLR7, and TLR9 
agonists [226]. TLR agonist or adjuvant therapy could be useful in the treatment of COPD 
exacerbations induced by bacteria or viruses.  Effective defence mechanisms during 
infection together with a fast recovery will minimize the duration of disease worsening. 
Triggering of TLRs by using agonists may boost the protective inflammatory response that 
destroys pathogens and protects the host. On the other hand, antagonist therapy may be 
beneficial in chronic inflammation. Antagonist therapy could be achieved by blocking the 
interaction between the TLR and the disease-related ligand or by blocking downstream 
signalling molecules [116].  In a healthy person, there is a balance between the protective 
inflammatory host response and inhibition of an excessive inflammatory or autoimmune 
response. This balance might be disturbed during disease and is another reason for 
having a good understanding of the molecular mechanisms regarding TLR activation 
[227]. Disease may result from overactive TLR signalling triggered by harmless molecules 
or may result from insufficient TLR signalling during viral or bacterial infections leading to 
poor defence mechanisms and resolution. Both ways could contribute to disease 
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pathology, and for therapeutic implications, it is of huge importance to understand the 
causal relationships underlying disease symptoms [116].  
TLRs offer promising therapeutic strategies for inflammatory diseases, which are caused 
by dysregulation of the immune system. However, targeting such a fundamental and 
complex pathway has to be carefully assessed [139]. There is a lot of data indicating that 
in the future TLRs will act as validated targets for inflammatory disorders. The aim of my 
thesis was to investigate role of TLRs in smoking-related disease. It is clear from my 
results that activation of these receptors has important effect on immune responses to 
their ligands. These findings could provide useful information about therapeutic potential 
of TLRs in clinical settings. 
In conclusion, the work in my thesis shows that there is a distinct difference in the 
activation of the inflammasome and subsequent release of IL-1β by TLR2 and TLR4 
pathways. This difference was identified to be at the level of pannexin-1 activation. 
Pannexin-1 makes large pores in the membrane, which allows the passive trafficking of 
molecules such as ATP, ROS and MSU into the cytoplasm of the cell. However, the 
specific function of this pore in the activation of the inflammasome is unclear. Further 
experiments are required in order to clarify how pannexin-1 specifically affects individual 
steps in the NLRP3 inflammasome assembly. Nevertheless, we can conclude that 
pannexin-1 is essential for the secretion of mature IL-1β after TLR2, but not TLR4, 
activation in human monocytes.  
Using our whole blood assay we observed that blood of COPD patients was more 
sensitive to activation with LPS, Pam3CSK4 and Poly I:C. It is known clinically that COPD 
patients have a greater susceptibility to common colds and flu. One causative factor is 
that these patients suffer from excessive mucus secretion that is thicker, thereby reducing 
pathogen clearance in the airways leading to higher infection rates. Therefore the 
increased sensitivity to viral and bacterial PAMPs observed in the blood of patients, might 
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manifest itself in an overactive response to what would normally be considered threshold 
concentrations of PAMPs in healthy volunteers. Interestingly, our study highlighted a 
possible new biomarker for COPD, as we observed a negative correlation between TLR4-
induced CXCL8 levels and GOLD stage of COPD severity. This observation may have 
therapeutic potential, although a larger patient cohort is required to make a definitive 
conclusion.  
Considering the role of TLRs in lung cancer cell proliferation, our data showed that TLR8 
caused an inhibition of proliferation by inducing apoptosis in A549 cells. These data 
identify TLR8 as a potential therapeutic target in lung cancer. Lung cancer has the poorest 
prognosis of all cancers; therefore the addition of TLR8 ligands to established 
chemotherapeutic regimes may increase the effectiveness of these agents thereby 
improving the prognosis. In this regard, a TLR7 agonist has been successfully used for 
the treatment of basal cell carcinoma in the skin. The specificity of these agents may also 
be improved with the use of nano-cages, which are reported to target chemotherapeutic 
agents to cancer cells [228] 
My thesis therefore shows that TLRs contribute to the inflammation and pathology of 
respiratory diseases and may be useful as a biomarker or therapeutic target for their 






	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Katarzyna	  Parzych	  





There are several directions in which this project could be extended: for the 
inflammasome study, it would be interesting to measure pro-IL-1β levels from the cell 
lysates after TLR2 and TLR4 stimulation to show that pro-IL-1β release was not affected 
by the inhibitors used, and hence that pannexin-1 was more associated with 
inflammasome assembly than pro-IL-1β cleavage. As a control, I could also measure IL-
18 secretion, as IL-18 synthesis does not depend on TLR signalling. Measuring ATP 
levels in cell supernatants and lysates would indicate that endogenous levels of ATP are 
sufficient for inflammasome activation and caspase-1 cleavage. It would also be 
interesting to elucidate the role of TRIF in inflammasome assembly after TLR4 activation 
using a gene knock-down approach. This would verify what was observed with the 
signalling inhibitors used in my thesis. I would also characterise specific pathways in 
human cells that lead to pro-IL-1β cleavage after TLR4 stimulation. It is known that 
caspase 11 in mice is responsible for inflammasome activation, however caspase 11 was 
not found in human monocytes. I could verify the role of potential alternative caspases in 
human cells, for example caspase 4 and 5 to investigate their role in inflammasome 
assembly and IL-1β secretion. Finally, it would be useful to measure pannexin-1 and 
P2XR protein expression by western blot after siRNA knock-down.  
One of the major limitations of the COPD study was the number of subjects we used. This 
would be greatly improved by performing a bigger study using at least n=20 for each 
group and also to include age-matched smokers as an additional control group. This 
would allow me to determine whether any changes in responses to PAMPs are due to the 
smoking status or as a consequence of the disease process. Finally, I would measure the 
expression of TLRs on blood cells to see whether any differences in the sensitivity to 
PAMPs were due to differences in levels of TLR expression.  
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To investigate further the role of TLRs activation on cell proliferation and apoptosis I would 
use other TLR8 agonists to investigate whether cell death observed in my study was 
TLR8 mediated or due to non-specific toxicity of the drug.  It would be also interesting to 
use another technique capturing the cell death e.g. Cellomics or confocal microscopy. I 
could also combine TLR8 agonists with other chemotherapeutic agents and extend this 
work to in vivo studies; the mouse Lewis lung model would be appropriate for this work. 
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